

PRE CONCEPTION SCREENING

GENE PANEL DG 3.7.0 (2337 GENES)

Releasedate: 31-08-2023

| Gene | TWIST X2 covered >10x | TWIST X2 covered >20x | srWGS GRCh38 covered >10x | srWGS GRCh38 covered >20x | Associated Phenotype description and OMIM disease ID |
|--------|-----------------------|-----------------------|---------------------------|---------------------------|---|
| AAAS | 100.0% | 100.0% | 100.0% | 99.6% | Achalasia-addisonianism-alacrimia syndrome, 231550 |
| AARS1 | 100.0% | 100.0% | 100.0% | 99.5% | Developmental and epileptic encephalopathy 29, 616339 Charcot-Marie-Tooth disease, axonal, type 2N, 613287 ?Leukoencephalopathy, hereditary diffuse, with spheroids 2, 619661 Trichothiodystrophy 8, nonphotosensitive, 619691 |
| AARS2 | 100.0% | 100.0% | 100.0% | 99.9% | Leukoencephalopathy, progressive, with ovarian failure, 615889 Combined oxidative phosphorylation deficiency 8, 614096 |
| AASS | 100.0% | 100.0% | 100.0% | 98.9% | Hyperlysinemia, 238700 |
| ABAT | 100.0% | 100.0% | 100.0% | 99.5% | GABA-transaminase deficiency, 613163 |
| ABCA1 | 100.0% | 100.0% | 100.0% | 99.6% | Tangier disease, 205400 HDL deficiency, familial, 1, 604091 |
| ABCA3 | 100.0% | 100.0% | 100.0% | 99.8% | Surfactant metabolism dysfunction, pulmonary, 3, 610921 |
| ABCA4 | 100.0% | 100.0% | 100.0% | 99.7% | Retinal dystrophy, early-onset severe, 248200 Retinitis pigmentosa 19, 601718 Cone-rod dystrophy 3, 604116 Fundus flavimaculatus, 248200 Stargardt disease 1, 248200 |
| ABCB11 | 100.0% | 99.7% | 100.0% | 99.3% | Cholestasis, benign recurrent intrahepatic, 2, 605479 Cholestasis, progressive familial intrahepatic 2, 601847 |
| ABCB4 | 100.0% | 100.0% | 100.0% | 99.4% | Gallbladder disease 1, 600803 Cholestasis, intrahepatic, of pregnancy, 3, 614972 Cholestasis, progressive familial intrahepatic 3, 602347 |
| ABCC2 | 100.0% | 100.0% | 100.0% | 99.4% | Dubin-Johnson syndrome, 237500 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| | | | | | Pseudoxanthoma elasticum, 264800 Arterial calcification, generalized, of infancy, 2, 614473 Pseudoxanthoma elasticum, forme fruste, 177850 |
| ABCC6 | 100.0% | 100.0% | 100.0% | 99.7% | |
| | | | | | Diabetes mellitus, permanent neonatal 3, w/wo neurologic features, 618857 Diabetes mellitus, transient neonatal 2, 610374 Diabetes mellitus, noninsulin-dependent, 125853 Hypoglycemia of infancy, leucine-sensitive, 240800 Hyperinsulinemic hypoglycemia, familial, 1, 256450 |
| ABCC8 | 100.0% | 100.0% | 100.0% | 99.7% | |
| ABCD4 | 100.0% | 100.0% | 100.0% | 99.6% | Methylmalonic aciduria and homocystinuria, cblJ type, 614857 |
| ABCG5 | 100.0% | 100.0% | 100.0% | 99.4% | Sitosterolemia 2, 618666 |
| ABCG8 | 100.0% | 100.0% | 100.0% | 99.6% | Sitosterolemia 1, 210250 |
| ABHD12 | 100.0% | 100.0% | 100.0% | 99.2% | Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 |
| ABHD16A | 100.0% | 100.0% | 100.0% | 99.5% | Spastic paraplegia 86, autosomal recessive, 619735 |
| ABHD5 | 100.0% | 100.0% | 100.0% | 99.7% | Chanarin-Dorfman syndrome, 275630 |
| ACACA | 100.0% | 100.0% | 100.0% | 99.6% | No OMIM disease ID |
| ACAD8 | 100.0% | 100.0% | 100.0% | 99.4% | Isobutyryl-CoA dehydrogenase deficiency, 611283 |
| ACAD9 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex I deficiency, nuclear type 20, 611126 |
| ACADM | 100.0% | 100.0% | 99.9% | 98.1% | Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 |
| ACADS | 100.0% | 100.0% | 100.0% | 100.0% | Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 |
| ACADSB | 100.0% | 100.0% | 100.0% | 99.5% | 2-methylbutyrylglycinuria, 610006 |
| ACADVL | 100.0% | 100.0% | 99.9% | 98.3% | VLCAD deficiency, 201475 |
| | | | | | ?Spondyloepiphyseal dysplasia, Kimberley type, 608361 Short stature and advanced bone age, w/wo early-onset osteoarthritis and/or osteochondritis dissecans, 165800 Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 |
| ACAN | 99.1% | 99.0% | 97.7% | 94.2% | |
| ACAT1 | 100.0% | 100.0% | 99.8% | 97.1% | Alpha-methylacetoacetic aciduria, 203750 |
| ACE | 100.0% | 100.0% | 99.9% | 99.2% | Renal tubular dysgenesis, 267430 |
| ACER3 | 100.0% | 100.0% | 100.0% | 99.4% | ?Leukodystrophy, progressive, early childhood-onset, 617762 |
| | | | | | Optic atrophy 9, 616289 Infantile cerebellar-retinal degeneration, 614559 |
| ACO2 | 100.0% | 100.0% | 100.0% | 99.7% | |
| | | | | | Mitchell syndrome, 618960 Peroxisomal acyl-CoA oxidase deficiency, 264470 |
| ACOX1 | 100.0% | 100.0% | 100.0% | 99.3% | |
| ACOX2 | 100.0% | 100.0% | 100.0% | 99.3% | Bile acid synthesis defect, congenital, 6, 617308 |
| ACP5 | 100.0% | 100.0% | 100.0% | 99.9% | Spondyloenchondrodysplasia with immune dysregulation, 607944 |
| ACSF3 | 100.0% | 100.0% | 100.0% | 99.5% | Combined malonic and methylmalonic aciduria, 614265 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| ACTA1 | 100.0% | 100.0% | 100.0% | 99.0% | Congenital myopathy 2B, severe infantile, autosomal recessive, 620265 ?Myopathy, scapulohumeroperoneal, 616852 Congenital myopathy 2C, severe infantile, autosomal dominant, 620278 Congenital myopathy 2A, typical, autosomal dominant, 161800 |
| ACTL6B | 100.0% | 100.0% | 100.0% | 99.7% | Developmental and epileptic encephalopathy 76, 618468 Intellectual developmental disorder with severe speech and ambulation defects, 618470 |
| ACY1 | 100.0% | 100.0% | 100.0% | 99.8% | Aminoacylase 1 deficiency, 609924 |
| ADA | 100.0% | 100.0% | 100.0% | 99.8% | Adenosine deaminase deficiency, partial, 102700 Severe combined immunodeficiency due to ADA deficiency, 102700 |
| ADA2 | 100.0% | 100.0% | 100.0% | 99.6% | Sneddon syndrome, 182410 Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome, 615688 |
| ADAM17 | 100.0% | 100.0% | 100.0% | 99.3% | ?Inflammatory skin and bowel disease, neonatal, 1, 614328 |
| ADAM22 | 100.0% | 100.0% | 100.0% | 99.2% | Developmental and epileptic encephalopathy 61, 617933 |
| ADAM9 | 100.0% | 100.0% | 100.0% | 99.4% | Cone-rod dystrophy 9, 612775 |
| ADAMTS10 | 100.0% | 100.0% | 100.0% | 99.8% | Weill-Marchesani syndrome 1, recessive, 277600 |
| ADAMTS13 | 100.0% | 100.0% | 100.0% | 99.4% | Thrombotic thrombocytopenic purpura, hereditary, 274150 |
| ADAMTS17 | 100.0% | 100.0% | 100.0% | 99.4% | Weill-Marchesani 4 syndrome, recessive, 613195 |
| ADAMTS18 | 100.0% | 100.0% | 100.0% | 99.4% | Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 |
| ADAMTS2 | 97.9% | 97.9% | 100.0% | 99.6% | Ehlers-Danlos syndrome, dermatosparaxis type, 225410 |
| ADAMTS3 | 99.3% | 98.7% | 100.0% | 99.5% | Hennekam lymphangiectasia-lymphedema syndrome 3, 618154 |
| ADAMTSL2 | 100.0% | 99.7% | 100.0% | 99.9% | Geleophysic dysplasia 1, 231050 |
| ADAMTSL4 | 100.0% | 100.0% | 100.0% | 99.6% | Ectopia lentis et pupillae, 225200 Ectopia lentis, isolated, autosomal recessive, 225100 |
| ADAR | 100.0% | 100.0% | 100.0% | 99.1% | Dyschromatosis symmetrica hereditaria, 127400 Aicardi-Goutieres syndrome 6, 615010 |
| ADARB1 | 95.0% | 94.8% | 100.0% | 99.8% | Neurodevelopmental disorder with hypotonia, microcephaly, and seizures, 618862 |
| ADAT3 | 100.0% | 100.0% | 100.0% | 100.0% | Neurodevelopmental disorder with brain abnormalities, poor growth, and dysmorphic facies, 615286 |
| ADCY6 | 100.0% | 100.0% | 100.0% | 99.8% | Lethal congenital contracture syndrome 8, 616287 |
| ADD3 | 100.0% | 100.0% | 100.0% | 99.3% | Cerebral palsy, spastic quadriplegic, 3, 617008 |
| ADGRG1 | 100.0% | 100.0% | 100.0% | 99.8% | Polymicrogyria, bilateral frontoparietal, 606854 Polymicrogyria, bilateral perisylvian, 615752 |
| ADGRG6 | 100.0% | 99.8% | 100.0% | 99.2% | Lethal congenital contracture syndrome 9, 616503 |
| ADGRV1 | 100.0% | 100.0% | 100.0% | 99.3% | Usher syndrome, type 2C, 605472 Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 ?Febrile seizures, familial, 4, 604352 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| ADK | 90.9% | 90.9% | 100.0% | 99.5% | Hypermethioninemia due to adenosine kinase deficiency, 614300 |
| ADPRS | 100.0% | 100.0% | 100.0% | 99.8% | Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170 |
| ADSL | 100.0% | 100.0% | 100.0% | 99.4% | Adenylosuccinase deficiency, 103050 |
| ADSS1 | 100.0% | 100.0% | 100.0% | 99.6% | Myopathy, distal, 5, 617030 |
| AEBP1 | 100.0% | 100.0% | 100.0% | 99.6% | Ehlers-Danlos syndrome, classic-like, 2, 618000 |
| | | | | | Spastic ataxia 5, autosomal recessive, 614487 |
| | | | | | Optic atrophy 12, 618977 |
| AFG3L2 | 100.0% | 100.0% | 100.0% | 99.1% | Spinocerebellar ataxia 28, 610246 |
| AGA | 100.0% | 100.0% | 100.0% | 99.6% | Aspartylglucosaminuria, 208400 |
| AGBL5 | 100.0% | 100.0% | 100.0% | 99.7% | Retinitis pigmentosa 75, 617023 |
| | | | | | Cataract 38, autosomal recessive, 614691 |
| AGK | 91.7% | 91.7% | 100.0% | 99.6% | Sengers syndrome, 212350 |
| | | | | | Glycogen storage disease IIIa, 232400 |
| AGL | 100.0% | 100.0% | 100.0% | 99.2% | Glycogen storage disease IIIb, 232400 |
| AGPAT2 | 100.0% | 100.0% | 100.0% | 99.9% | Lipodystrophy, congenital generalized, type 1, 608594 |
| AGPS | 100.0% | 100.0% | 100.0% | 99.0% | Rhizomelic chondrodysplasia punctata, type 3, 600121 |
| AGRN | 100.0% | 100.0% | 100.0% | 99.8% | Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 |
| AGT | 100.0% | 100.0% | 100.0% | 99.6% | Renal tubular dysgenesis, 267430 |
| AGTPBP1 | 100.0% | 100.0% | 100.0% | 99.1% | Neurodegeneration, childhood-onset, with cerebellar atrophy, 618276 |
| AGTR1 | 100.0% | 100.0% | 100.0% | 99.2% | Renal tubular dysgenesis, 267430 |
| AGXT | 100.0% | 100.0% | 100.0% | 99.9% | Hyperoxaluria, primary, type 1, 259900 |
| AHCY | 100.0% | 100.0% | 100.0% | 99.9% | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 |
| AHI1 | 100.0% | 100.0% | 100.0% | 99.1% | Joubert syndrome 3, 608629 |
| AHR | 100.0% | 100.0% | 100.0% | 99.5% | ?Retinitis pigmentosa 85, 618345 |
| AICDA | 100.0% | 100.0% | 100.0% | 99.2% | Immunodeficiency with hyper-IgM, type 2, 605258 |
| AIMP1 | 100.0% | 100.0% | 100.0% | 98.8% | Leukodystrophy, hypomyelinating, 3, 260600 |
| AIMP2 | 100.0% | 100.0% | 100.0% | 99.7% | Leukodystrophy, hypomyelinating, 17, 618006 |
| | | | | | Leber congenital amaurosis 4, 604393 |
| | | | | | Retinitis pigmentosa, juvenile, 604393 |
| AIPL1 | 100.0% | 100.0% | 100.0% | 100.0% | Cone-rod dystrophy, 604393 |
| AIRE | 100.0% | 100.0% | 100.0% | 99.9% | Autoimmune polyendocrinopathy syndrome , type I, w/wo reversible metaphyseal dysplasia, 240300 |
| AK1 | 100.0% | 100.0% | 100.0% | 99.9% | Hemolytic anemia due to adenylate kinase deficiency, 612631 |
| AK2 | 100.0% | 100.0% | 100.0% | 99.3% | Reticular dysgenesis, 267500 |
| AKR1D1 | 100.0% | 100.0% | 100.0% | 99.5% | Bile acid synthesis defect, congenital, 2, 235555 |
| ALAD | 100.0% | 100.0% | 100.0% | 99.8% | Porphyria, acute hepatic, 612740 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| ALB | 100.0% | 100.0% | 100.0% | 98.8% | Analbuminemia, 616000 |
| | | | | | Spastic paraplegia 9A, autosomal dominant, 601162 Cutis laxa, autosomal recessive, type IIIA, 219150 Spastic paraplegia 9B, autosomal recessive, 616586 |
| ALDH18A1 | 100.0% | 100.0% | 100.0% | 99.6% | Cutis laxa, autosomal dominant 3, 616603 |
| ALDH1A3 | 100.0% | 100.0% | 100.0% | 99.4% | Microphthalmia, isolated 8, 615113 |
| ALDH3A2 | 93.5% | 93.5% | 100.0% | 99.5% | Sjogren-Larsson syndrome, 270200 |
| ALDH4A1 | 100.0% | 100.0% | 100.0% | 99.5% | Hyperprolinemia, type II, 239510 |
| ALDH5A1 | 100.0% | 100.0% | 100.0% | 99.6% | Succinic semialdehyde dehydrogenase deficiency, 271980 |
| ALDH6A1 | 100.0% | 100.0% | 100.0% | 98.5% | Methylmalonate semialdehyde dehydrogenase deficiency, 614105 |
| ALDH7A1 | 100.0% | 100.0% | 100.0% | 99.6% | Epilepsy, pyridoxine-dependent, 266100 |
| ALDOA | 100.0% | 100.0% | 100.0% | 99.9% | Glycogen storage disease XII, 611881 |
| ALDOB | 100.0% | 100.0% | 100.0% | 99.7% | Fructose intolerance, hereditary, 229600 |
| ALG1 | 100.0% | 100.0% | 100.0% | 99.9% | Congenital disorder of glycosylation, type Ik, 608540 |
| ALG11 | 96.0% | 96.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type Ip, 613661 |
| ALG12 | 100.0% | 100.0% | 100.0% | 99.9% | Congenital disorder of glycosylation, type Ig, 607143 |
| | | | | | Intellectual developmental disorder with epilepsy, behavioral abnormalities, and coarse facies, 619031 Myopathy, epilepsy, and progressive cerebral atrophy, 619036 ?Myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 |
| ALG14 | 100.0% | 100.0% | 100.0% | 99.0% | |
| | | | | | Congenital disorder of glycosylation, type Ii, 607906 Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 |
| ALG2 | 100.0% | 100.0% | 100.0% | 99.8% | |
| ALG3 | 100.0% | 100.0% | 100.0% | 99.7% | Congenital disorder of glycosylation, type Id, 601110 |
| ALG6 | 100.0% | 100.0% | 100.0% | 98.8% | Congenital disorder of glycosylation, type Ic, 603147 |
| | | | | | Congenital disorder of glycosylation, type Ih, 608104 Polycystic liver disease 3 w/wo kidney cysts, 617874 |
| ALG8 | 96.1% | 96.1% | 100.0% | 99.1% | |
| | | | | | Gillessen-Kaesbach-Nishimura syndrome, 263210 Congenital disorder of glycosylation, type II, 608776 |
| ALG9 | 100.0% | 100.0% | 100.0% | 99.3% | |
| ALKBH8 | 100.0% | 100.0% | 100.0% | 99.7% | Intellectual developmental disorder, autosomal recessive 71, 618504 |
| ALMS1 | 100.0% | 100.0% | 100.0% | 99.2% | Alstrom syndrome, 203800 |
| ALOX12B | 100.0% | 100.0% | 100.0% | 99.9% | Ichthyosis, congenital, autosomal recessive 2, 242100 |
| ALOXE3 | 100.0% | 100.0% | 100.0% | 99.3% | Ichthyosis, congenital, autosomal recessive 3, 606545 |
| ALPK3 | 100.0% | 100.0% | 100.0% | 99.6% | Cardiomyopathy, familial hypertrophic 27, 618052 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| ALPL | 100.0% | 100.0% | 100.0% | 99.7% | Odontohypophosphatasia, 146300 Hypophosphatasia, infantile, 241500 Hypophosphatasia, childhood, 241510 Hypophosphatasia, adult, 146300 |
| ALS2 | 100.0% | 100.0% | 100.0% | 99.2% | Primary lateral sclerosis, juvenile, 606353 Spastic paralysis, infantile onset ascending, 607225 Amyotrophic lateral sclerosis 2, juvenile, 205100 |
| ALX1 | 100.0% | 100.0% | 100.0% | 99.0% | Frontonasal dysplasia 3, 613456 |
| ALX3 | 100.0% | 100.0% | 100.0% | 99.3% | Frontonasal dysplasia 1, 136760 |
| ALX4 | 100.0% | 100.0% | 100.0% | 99.3% | Parietal foramina 2, 609597 Frontonasal dysplasia 2, 613451 |
| AMACR | 100.0% | 100.0% | 100.0% | 99.1% | Alpha-methylacyl-CoA racemase deficiency, 614307 Bile acid synthesis defect, congenital, 4, 214950 |
| AMBN | 100.0% | 99.5% | 100.0% | 99.1% | Amelogenesis imperfecta, type IF, 616270 |
| AMN | 100.0% | 100.0% | 100.0% | 100.0% | Imerslund-Grasbeck syndrome 2, 618882 |
| AMPD1 | 100.0% | 100.0% | 100.0% | 99.4% | Myopathy due to myoadenylate deaminase deficiency, 615511 |
| AMPD2 | 100.0% | 100.0% | 100.0% | 99.4% | ?Spastic paraplegia 63, 615686 Pontocerebellar hypoplasia, type 9, 615809 |
| AMT | 100.0% | 100.0% | 100.0% | 99.8% | Glycine encephalopathy 2, 620398 |
| ANAPC1 | 100.0% | 100.0% | 100.0% | 99.1% | Rothmund-Thomson syndrome, type 1, 618625 |
| ANGPTL3 | 100.0% | 100.0% | 100.0% | 99.0% | Hypobetalipoproteinemia, familial, 2, 605019 |
| ANK1 | 100.0% | 100.0% | 100.0% | 99.9% | Spherocytosis, type 1, 182900 |
| ANK3 | 100.0% | 99.9% | 100.0% | 99.2% | Intellectual developmental disorder, autosomal recessive 37, 615493 |
| ANKH | 100.0% | 100.0% | 100.0% | 99.9% | Chondrocalcinosis 2, 118600 Craniometaphyseal dysplasia, 123000 |
| ANKLE2 | 100.0% | 100.0% | 100.0% | 98.1% | Microcephaly 16, primary, autosomal recessive, 616681 |
| ANKS6 | 99.9% | 99.4% | 100.0% | 99.5% | Nephronophthisis 16, 615382 |
| ANO10 | 100.0% | 100.0% | 100.0% | 99.6% | Spinocerebellar ataxia, autosomal recessive 10, 613728 |
| ANO5 | 100.0% | 100.0% | 100.0% | 99.4% | Muscular dystrophy, limb-girdle, autosomal recessive 12, 611307 Miyoshi muscular dystrophy 3, 613319 Gnathodiaphyseal dysplasia, 166260 |
| ANO6 | 100.0% | 100.0% | 100.0% | 99.4% | Scott syndrome, 262890 |
| ANTXR1 | 100.0% | 99.8% | 99.4% | 94.8% | GAPO syndrome, 230740 |
| ANTXR2 | 100.0% | 100.0% | 100.0% | 99.2% | Hyaline fibromatosis syndrome, 228600 |
| AP1B1 | 100.0% | 100.0% | 100.0% | 99.7% | Keratitis-ichthyosis-deafness syndrome, autosomal recessive, 242150 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| AP1S1 | 100.0% | 100.0% | 100.0% | 99.5% | MEDNIK syndrome, 609313 |
| AP3B1 | 100.0% | 100.0% | 100.0% | 99.7% | Hermansky-Pudlak syndrome 2, 608233 |
| AP3B2 | 100.0% | 100.0% | 100.0% | 99.6% | Developmental and epileptic encephalopathy 48, 617276 |
| AP3D1 | 100.0% | 100.0% | 100.0% | 99.7% | ?Hermansky-Pudlak syndrome 10, 617050 |
| AP4B1 | 100.0% | 100.0% | 100.0% | 99.7% | Spastic paraplegia 47, autosomal recessive, 614066 |
| AP4E1 | 100.0% | 100.0% | 100.0% | 99.4% | Stuttering, familial persistent, 1, 184450 Spastic paraplegia 51, autosomal recessive, 613744 |
| AP4M1 | 100.0% | 100.0% | 100.0% | 99.7% | Spastic paraplegia 50, autosomal recessive, 612936 |
| AP4S1 | 87.4% | 87.4% | 100.0% | 99.2% | Spastic paraplegia 52, autosomal recessive, 614067 |
| AP5Z1 | 100.0% | 100.0% | 100.0% | 99.9% | Spastic paraplegia 48, autosomal recessive, 613647 |
| APC2 | 100.0% | 100.0% | 100.0% | 99.7% | Cortical dysplasia, complex, with other brain malformations 10, 618677 Intellectual developmental disorder, autosomal recessive 74, 617169 |
| APOC2 | 100.0% | 100.0% | 100.0% | 99.5% | Hyperlipoproteinemia, type Ib, 207750 |
| APOE | 100.0% | 100.0% | 100.0% | 99.8% | Alzheimer disease 2, 104310 Sea-blue histiocyte disease, 269600 Lipoprotein glomerulopathy, 611771 Hyperlipoproteinemia, type III, 617347 |
| APRT | 100.0% | 100.0% | 100.0% | 99.9% | Adenine phosphoribosyltransferase deficiency, 614723 |
| APTX | 100.0% | 100.0% | 100.0% | 99.5% | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 |
| AQP2 | 100.0% | 100.0% | 100.0% | 99.8% | Diabetes insipidus, nephrogenic, 2, 125800 |
| ARFGEF2 | 100.0% | 100.0% | 100.0% | 99.5% | Periventricular heterotopia with microcephaly, 608097 |
| ARG1 | 93.0% | 93.0% | 100.0% | 99.7% | Argininemia, 207800 |
| ARHGDI1 | 100.0% | 100.0% | 100.0% | 100.0% | Nephrotic syndrome, type 8, 615244 |
| ARHGEF18 | 100.0% | 100.0% | 100.0% | 99.5% | Retinitis pigmentosa 78, 617433 |
| ARHGEF2 | 100.0% | 100.0% | 100.0% | 99.7% | ?Neurodevelopmental disorder with midbrain and hindbrain malformations, 617523 |
| ARL13B | 100.0% | 100.0% | 100.0% | 98.5% | Joubert syndrome 8, 612291 |
| ARL2BP | 100.0% | 100.0% | 100.0% | 98.6% | Retinitis pigmentosa w/wo situs inversus, 615434 |
| ARL3 | 100.0% | 100.0% | 100.0% | 99.5% | Retinitis pigmentosa 83, 618173 Joubert syndrome 35, 618161 |
| ARL6 | 100.0% | 100.0% | 100.0% | 98.1% | Retinitis pigmentosa 55, 613575 Bardet-Biedl syndrome 3, 600151 |
| ARL6IP1 | 100.0% | 100.0% | 100.0% | 99.7% | ?Spastic paraplegia 61, autosomal recessive, 615685 |
| ARMC4 | 95.9% | 95.6% | 100.0% | 99.1% | Ciliary dyskinesia, primary, 23, 615451 |
| ARMC9 | 100.0% | 100.0% | 100.0% | 99.6% | Joubert syndrome 30, 617622 |
| ARNT2 | 100.0% | 100.0% | 100.0% | 99.5% | ?Webb-Dattani syndrome, 615926 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| ARPC1B | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia, 617718 |
| ARSA | 100.0% | 100.0% | 100.0% | 100.0% | Metachromatic leukodystrophy, 250100 |
| ARSB | 100.0% | 100.0% | 100.0% | 99.7% | Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 |
| ARSG | 100.0% | 100.0% | 100.0% | 99.1% | Usher syndrome, type IV, 618144 |
| ARV1 | 100.0% | 100.0% | 100.0% | 99.3% | Developmental and epileptic encephalopathy 38, 617020 |
| ASAH1 | 100.0% | 100.0% | 100.0% | 99.3% | Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 Farber lipogranulomatosis, 228000 |
| ASCC1 | 86.7% | 86.6% | 100.0% | 98.8% | Spinal muscular atrophy with congenital bone fractures 2, 616867 Barrett esophagus/esophageal adenocarcinoma, 614266 |
| ASL | 100.0% | 100.0% | 100.0% | 99.9% | Argininosuccinic aciduria, 207900 |
| ASNS | 100.0% | 100.0% | 100.0% | 99.4% | Asparagine synthetase deficiency, 615574 |
| ASPA | 100.0% | 100.0% | 100.0% | 99.0% | Canavan disease, 271900 |
| ASPH | 99.9% | 99.5% | 100.0% | 99.2% | Traboulsi syndrome, 601552 |
| ASPM | 100.0% | 99.8% | 100.0% | 99.1% | Microcephaly 5, primary, autosomal recessive, 608716 |
| ASS1 | 100.0% | 100.0% | 100.0% | 99.9% | Citrullinemia, 215700 |
| ATAD1 | 100.0% | 99.7% | 100.0% | 98.9% | Hyperekplexia 4, 618011 |
| ATAD3A | 100.0% | 100.0% | 100.0% | 99.1% | Harel-Yoon syndrome, 617183 Pontocerebellar hypoplasia, hypotonia, and respiratory insufficiency syndrome, neonatal lethal, 618810 |
| ATCAY | 100.0% | 100.0% | 100.0% | 99.6% | Ataxia, cerebellar, Cayman type, 601238 |
| ATF6 | 100.0% | 100.0% | 100.0% | 99.6% | Achromatopsia 7, 616517 |
| ATG5 | 100.0% | 100.0% | 100.0% | 98.9% | ?Spinocerebellar ataxia, autosomal recessive 25, 617584 |
| ATIC | 100.0% | 100.0% | 100.0% | 99.2% | AICA-ribosiduria due to ATIC deficiency, 608688 |
| ATM | 100.0% | 100.0% | 100.0% | 99.0% | Ataxia-telangiectasia, 208900 Lymphoma, B-cell non-Hodgkin, somatic, T-cell prolymphocytic leukemia, somatic, Lymphoma, mantle cell, somatic, |
| ATOH7 | 100.0% | 100.0% | 100.0% | 99.8% | Persistent hyperplastic primary vitreous, autosomal recessive, 221900 |
| ATP13A2 | 100.0% | 100.0% | 100.0% | 99.8% | Spastic paraplegia 78, autosomal recessive, 617225 Kufor-Rakeb syndrome, 606693 |
| ATP2A1 | 100.0% | 100.0% | 100.0% | 99.5% | Brody myopathy, 601003 |
| ATP5F1A | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4A, 620358 ?Combined oxidative phosphorylation deficiency 22, 616045 ?Mitochondrial complex V (ATP synthase) deficiency, nuclear type 4B, encephalopathic type, 615228 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| ATP5F1D | 100.0% | 100.0% | 100.0% | 99.9% | Mitochondrial complex V (ATP synthase) deficiency, 618120 |
| ATP5F1E | 100.0% | 100.0% | 100.0% | 97.8% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 3, 614053 |
| ATP6VOA2 | 100.0% | 100.0% | 100.0% | 98.9% | Wrinkly skin syndrome, 278250 Cutis laxa, autosomal recessive, type IIA, 219200 |
| ATP6VOA4 | 100.0% | 100.0% | 100.0% | 99.1% | Distal renal tubular acidosis 3, w/wo sensorineural hearing loss, 602722 |
| ATP6V1A | 100.0% | 100.0% | 100.0% | 99.3% | Cutis laxa, autosomal recessive, type IID, 617403 Developmental and epileptic encephalopathy 93, 618012 |
| ATP6V1B1 | 100.0% | 100.0% | 100.0% | 99.7% | Distal renal tubular acidosis 2 with progressive sensorineural hearing loss, 267300 |
| ATP6V1E1 | 100.0% | 100.0% | 100.0% | 99.1% | Cutis laxa, autosomal recessive, type IIC, 617402 |
| ATP7B | 100.0% | 100.0% | 100.0% | 99.7% | Wilson disease, 277900 |
| ATP8A2 | 100.0% | 100.0% | 100.0% | 99.5% | ?Cerebellar ataxia, impaired intellectual development, and dysequilibrium syndrome 4, 615268 |
| ATP8B1 | 100.0% | 100.0% | 100.0% | 98.7% | Cholestasis, progressive familial intrahepatic 1, 211600 Cholestasis, intrahepatic, of pregnancy, 1, 147480 Cholestasis, benign recurrent intrahepatic, 243300 |
| ATPAF2 | 100.0% | 100.0% | 100.0% | 99.4% | ?Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 |
| ATR | 100.0% | 100.0% | 100.0% | 99.2% | Seckel syndrome 1, 210600 ?Cutaneous telangiectasia and cancer syndrome, familial, 614564 |
| AUH | 100.0% | 100.0% | 100.0% | 99.5% | 3-methylglutaconic aciduria, type I, 250950 |
| AURKC | 100.0% | 100.0% | 100.0% | 99.6% | Spermatogenic failure 5, 243060 |
| B2M | 100.0% | 100.0% | 100.0% | 99.5% | ?Amyloidosis, familial visceral, 105200 Immunodeficiency 43, 241600 |
| B3GALNT2 | 92.4% | 92.4% | 100.0% | 99.1% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 11, 615181 |
| B3GALT6 | 99.9% | 98.0% | 100.0% | 99.8% | Ehlers-Danlos syndrome, spondylodysplastic type, 2, 615349 Spondyloepimetaphyseal dysplasia with joint laxity, type 1, w/wo fractures, 271640 Al-Gazali syndrome, 609465 |
| B3GAT3 | 94.5% | 93.8% | 100.0% | 99.7% | Multiple joint dislocations, short stature, craniofacial dysmorphism, w/wo congenital heart defects, 245600 |
| B3GLCT | 100.0% | 100.0% | 100.0% | 99.1% | Peters-plus syndrome, 261540 |
| B4GALNT1 | 100.0% | 100.0% | 100.0% | 99.7% | Spastic paraplegia 26, autosomal recessive, 609195 |
| B4GALT1 | 100.0% | 100.0% | 100.0% | 99.6% | Combined low LDL and fibrinogen, 620364 Congenital disorder of glycosylation, type IId, 607091 |
| B4GALT7 | 100.0% | 100.0% | 100.0% | 99.7% | Ehlers-Danlos syndrome, spondylodysplastic type, 1, 130070 |
| B4GAT1 | 100.0% | 100.0% | 100.0% | 99.8% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 |
| B9D1 | 100.0% | 100.0% | 100.0% | 99.8% | ?Meckel syndrome 9, 614209 Joubert syndrome 27, 617120 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| B9D2 | 100.0% | 100.0% | 100.0% | 99.8% | ?Meckel syndrome 10, 614175 Joubert syndrome 34, 614175 |
| BAAT | 100.0% | 100.0% | 100.0% | 99.4% | Bile acid conjugation defect 1, 619232 |
| BANF1 | 100.0% | 100.0% | 100.0% | 99.7% | Nestor-Guillermo progeria syndrome, 614008 |
| BBS1 | 100.0% | 100.0% | 100.0% | 99.8% | Bardet-Biedl syndrome 1, 209900 |
| BBS10 | 100.0% | 100.0% | 100.0% | 99.7% | Bardet-Biedl syndrome 10, 615987 |
| BBS12 | 100.0% | 100.0% | 100.0% | 99.6% | Bardet-Biedl syndrome 12, 615989 |
| BBS2 | 100.0% | 100.0% | 100.0% | 99.3% | Retinitis pigmentosa 74, 616562 Bardet-Biedl syndrome 2, 615981 |
| BBS4 | 100.0% | 100.0% | 100.0% | 99.5% | Bardet-Biedl syndrome 4, 615982 |
| BBS5 | 100.0% | 100.0% | 100.0% | 99.2% | Bardet-Biedl syndrome 5, 615983 |
| BBS7 | 100.0% | 100.0% | 100.0% | 99.3% | Bardet-Biedl syndrome 7, 615984 |
| BBS9 | 95.8% | 95.8% | 100.0% | 99.1% | Bardet-Biedl syndrome 9, 615986 |
| BCAS3 | 100.0% | 100.0% | 100.0% | 99.6% | Hengel-Marooofian-Schols syndrome, 619641 |
| BCKDHA | 100.0% | 100.0% | 100.0% | 99.6% | Maple syrup urine disease, type Ia, 248600 |
| BCKDHB | 100.0% | 99.8% | 100.0% | 99.4% | Maple syrup urine disease, type Ib, 248600 |
| BCKDK | 100.0% | 100.0% | 100.0% | 99.8% | Branched-chain keto acid dehydrogenase kinase deficiency, 614923 |
| BCL10 | 100.0% | 100.0% | 100.0% | 99.6% | ?Immunodeficiency 37, 616098 Lymphoma, MALT, somatic, 137245 |
| BCS1L | 100.0% | 100.0% | 100.0% | 99.9% | GRACILE syndrome, 603358 Mitochondrial complex III deficiency, nuclear type 1, 124000 Bjornstad syndrome, 262000 |
| BFSP1 | 100.0% | 100.0% | 100.0% | 99.2% | Cataract 33, multiple types, 611391 |
| BFSP2 | 100.0% | 100.0% | 100.0% | 99.5% | Cataract 12, multiple types, 611597 |
| BHLHA9 | 100.0% | 100.0% | 100.0% | 99.0% | ?Camptosynpolydactyly, complex, 607539 Syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 |
| BIN1 | 100.0% | 100.0% | 100.0% | 99.6% | Centronuclear myopathy 2, 255200 |
| BLM | 100.0% | 100.0% | 100.0% | 99.2% | Bloom syndrome, 210900 |
| BLOC1S3 | 100.0% | 100.0% | 100.0% | 99.6% | Hermansky-Pudlak syndrome 8, 614077 |
| BLOC1S6 | 100.0% | 100.0% | 100.0% | 99.1% | ?Hermansky-Pudlak syndrome 9, 614171 |
| BLVRA | 100.0% | 99.9% | 100.0% | 99.7% | Hyperbiliverdinemia, 614156 |
| BMP1 | 100.0% | 100.0% | 100.0% | 99.7% | Osteogenesis imperfecta, type XIII, 614856 |
| BMPER | 100.0% | 100.0% | 100.0% | 99.5% | Diaphanospondylodysostosis, 608022 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| | | | | | Acromesomelic dysplasia 3, 609441 |
| BMPR1B | 100.0% | 100.0% | 100.0% | 99.5% | Brachydactyly, type A2, 112600 Brachydactyly, type A1, D, 616849 |
| BOLA3 | 100.0% | 100.0% | 100.0% | 99.4% | Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299 |
| BPGM | 100.0% | 100.0% | 100.0% | 99.1% | Erythrocytosis, familial, 8, 222800 |
| BRAT1 | 100.0% | 100.0% | 100.0% | 99.9% | Neurodevelopmental disorder with cerebellar atrophy and w/wo seizures, 618056 Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 |
| BRCA1 | 100.0% | 100.0% | 100.0% | 99.1% | Fanconi anemia, complementation group S, 617883 |
| BRCA2 | 100.0% | 100.0% | 100.0% | 98.6% | Fanconi anemia, complementation group D1, 605724 Wilms tumor, 194070 |
| BRF1 | 100.0% | 100.0% | 100.0% | 99.9% | Cerebellofaciodental syndrome, 616202 |
| BRIP1 | 100.0% | 100.0% | 100.0% | 99.1% | Fanconi anemia, complementation group J, 609054 |
| BSCL2 | 100.0% | 100.0% | 100.0% | 99.6% | Lipodystrophy, congenital generalized, type 2, 269700 Neuropathy, distal hereditary motor, type VC, 619112 Silver spastic paraplegia syndrome, 270685 Encephalopathy, progressive, w/wo lipodystrophy, 615924 |
| BSND | 100.0% | 100.0% | 100.0% | 99.5% | Sensorineural deafness with mild renal dysfunction, 602522 Bartter syndrome, type 4a, 602522 |
| BTD | 94.4% | 94.3% | 100.0% | 99.5% | Biotinidase deficiency, 253260 |
| BUB1B | 100.0% | 100.0% | 100.0% | 99.5% | Colorectal cancer, somatic, 114500 Mosaic variegated aneuploidy syndrome 1, 257300 |
| BVES | 100.0% | 100.0% | 100.0% | 99.2% | Muscular dystrophy, limb-girdle, autosomal recessive 25, 616812 |
| C12orf4 | 100.0% | 100.0% | 100.0% | 99.0% | Intellectual developmental disorder, autosomal recessive 66, 618221 |
| C12orf57 | 100.0% | 100.0% | 100.0% | 99.5% | Temtamy syndrome, 218340 |
| C12orf65 | 100.0% | 100.0% | 100.0% | 98.6% | Spastic paraplegia 55, autosomal recessive, 615035 Combined oxidative phosphorylation deficiency 7, 613559 |
| C15orf41 | 100.0% | 99.9% | 100.0% | 99.9% | Dyserythropoietic anemia, congenital, type Ib, 615631 |
| C19orf12 | 100.0% | 99.9% | 100.0% | 98.8% | Neurodegeneration with brain iron accumulation 4, 614298 ?Spastic paraplegia 43, autosomal recessive, 615043 |
| C1QA | 100.0% | 100.0% | 100.0% | 99.9% | C1q deficiency 1, 613652 |
| C1QB | 100.0% | 100.0% | 100.0% | 98.8% | C1q deficiency 2, 620321 |
| C1QBP | 100.0% | 100.0% | 100.0% | 99.1% | Combined oxidative phosphorylation deficiency 33, 617713 |
| C1QC | 100.0% | 100.0% | 100.0% | 99.3% | C1q deficiency 3, 620322 |
| C1S | 99.9% | 99.3% | 100.0% | 99.6% | C1s deficiency, 613783 Ehlers-Danlos syndrome, periodontal type, 2, 617174 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| C2CD3 | 96.0% | 96.0% | 100.0% | 99.4% | Orofaciodigital syndrome XIV, 615948 |
| C2orf69 | 100.0% | 100.0% | 100.0% | 99.3% | Combined oxidative phosphorylation deficiency 53, 619423 |
| C3 | 100.0% | 100.0% | 100.0% | 99.4% | C3 deficiency, 613779 |
| C4A | 99.7% | 99.3% | 99.4% | 96.0% | C4a deficiency, 614380 |
| C4B | 100.0% | 99.8% | 99.1% | 95.1% | C4B deficiency, 614379 |
| C5 | 100.0% | 100.0% | 100.0% | 99.2% | C5 deficiency, 609536 |
| C8A | 100.0% | 100.0% | 100.0% | 99.7% | C8 deficiency, type I, 613790 |
| C8B | 100.0% | 100.0% | 100.0% | 99.7% | C8 deficiency, type II, 613789 |
| C8orf37 | 100.0% | 100.0% | 100.0% | 99.8% | Retinitis pigmentosa 64, 614500 Cone-rod dystrophy 16, 614500 Bardet-Biedl syndrome 21, 617406 |
| C9 | 100.0% | 100.0% | 100.0% | 99.3% | C9 deficiency, 613825 |
| CA12 | 100.0% | 100.0% | 100.0% | 99.6% | Hyperchlorhidrosis, isolated, 143860 |
| CA2 | 100.0% | 100.0% | 100.0% | 99.5% | Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 |
| CA5A | 100.0% | 100.0% | 100.0% | 99.1% | Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 |
| CA8 | 100.0% | 100.0% | 100.0% | 99.6% | Cerebellar ataxia, impaired intellectual development and dysequilibrium syndrome 3, 613227 |
| CABP2 | 100.0% | 100.0% | 100.0% | 98.9% | Deafness, autosomal recessive 93, 614899 |
| CABP4 | 100.0% | 100.0% | 100.0% | 99.9% | Cone-rod synaptic disorder, congenital nonprogressive, 610427 |
| CACNA1B | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497 |
| CACNA1D | 100.0% | 100.0% | 100.0% | 99.3% | Primary aldosteronism, seizures, and neurologic abnormalities, 615474 Sinoatrial node dysfunction and deafness, 614896 |
| CACNA2D2 | 100.0% | 100.0% | 100.0% | 99.5% | Cerebellar atrophy with seizures and variable developmental delay, 618501 |
| CAD | 100.0% | 100.0% | 100.0% | 99.8% | Developmental and epileptic encephalopathy 50, 616457 |
| CAMK2A | 100.0% | 100.0% | 100.0% | 99.4% | Intellectual developmental disorder, autosomal dominant 53, 617798 ?Intellectual developmental disorder, autosomal recessive 63, 618095 |
| CANT1 | 100.0% | 100.0% | 100.0% | 99.9% | Desbuquois dysplasia 1, 251450 Epiphyseal dysplasia, multiple, 7, 617719 |
| CAPN1 | 100.0% | 100.0% | 100.0% | 99.8% | Spastic paraplegia 76, autosomal recessive, 616907 |
| CAPN10 | 100.0% | 100.0% | 100.0% | 99.8% | No OMIM disease ID |
| CAPN3 | 100.0% | 100.0% | 100.0% | 99.3% | Muscular dystrophy, limb-girdle, autosomal recessive 1, 253600 Muscular dystrophy, limb-girdle, autosomal dominant 4, 618129 |
| CARD11 | 100.0% | 100.0% | 100.0% | 99.7% | B-cell expansion with NFKB and T-cell anergy, 616452 Immunodeficiency 11B with atopic dermatitis, 617638 Immunodeficiency 11A, 615206 |
| CARD9 | 100.0% | 100.0% | 100.0% | 100.0% | Immunodeficiency 103, susceptibility to fungal infection, 212050 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| CARS2 | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 27, 616672 |
| CASP14 | 100.0% | 100.0% | 100.0% | 98.7% | Ichthyosis, congenital, autosomal recessive 12, 617320 |
| CASP8 | 95.1% | 95.1% | 100.0% | 99.5% | ?Caspase 8 lymphadenopathy syndrome, 607271 Hepatocellular carcinoma, somatic, 114550 |
| CASQ2 | 100.0% | 100.0% | 100.0% | 99.1% | Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 |
| CASR | 100.0% | 100.0% | 100.0% | 99.7% | Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 Hyperparathyroidism, neonatal, 239200 Hypocalcemia, autosomal dominant, 601198 Hypocalciuric hypercalcemia, type I, 145980 |
| CAST | 100.0% | 100.0% | 100.0% | 99.3% | Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 |
| CAT | 100.0% | 100.0% | 100.0% | 99.4% | Acatlasemia, 614097 |
| CATSPER1 | 100.0% | 100.0% | 100.0% | 98.4% | Spermatogenic failure 7, 612997 |
| CAV1 | 100.0% | 100.0% | 100.0% | 99.8% | Lipodystrophy, congenital generalized, type 3, 612526 Pulmonary hypertension, primary, 3, 615343 Lipodystrophy, familial partial, type 7, 606721 |
| CAVIN1 | 100.0% | 100.0% | 100.0% | 100.0% | Lipodystrophy, congenital generalized, type 4, 613327 |
| CBLIF | 100.0% | 100.0% | 100.0% | 99.8% | Intrinsic factor deficiency, 261000 |
| CBS | 100.0% | 100.0% | 100.0% | 100.0% | Thrombosis, hyperhomocysteinemic, 236200 Homocystinuria, B6-responsive and nonresponsive types, 236200 |
| CC2D1A | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 3, 608443 |
| CC2D2A | 98.2% | 98.2% | 100.0% | 99.4% | COACH syndrome 2, 619111 Retinitis pigmentosa 93, 619845 Meckel syndrome 6, 612284 Joubert syndrome 9, 612285 |
| CCBE1 | 100.0% | 100.0% | 100.0% | 99.9% | Hennekam lymphangiectasia-lymphedema syndrome 1, 235510 |
| CCDC103 | 100.0% | 100.0% | 100.0% | 99.6% | Ciliary dyskinesia, primary, 17, 614679 |
| CCDC114 | 100.0% | 100.0% | 100.0% | 99.4% | Ciliary dyskinesia, primary, 20, 615067 |
| CCDC115 | 100.0% | 100.0% | 100.0% | 98.7% | Congenital disorder of glycosylation, type IIo, 616828 |
| CCDC151 | 100.0% | 100.0% | 100.0% | 99.9% | Ciliary dyskinesia, primary, 30, 616037 |
| CCDC174 | 100.0% | 100.0% | 100.0% | 98.5% | Hypotonia, infantile, with psychomotor retardation, 616816 |
| CCDC39 | 100.0% | 100.0% | 100.0% | 98.4% | Ciliary dyskinesia, primary, 14, 613807 |
| CCDC40 | 100.0% | 100.0% | 100.0% | 99.3% | Ciliary dyskinesia, primary, 15, 613808 |
| CCDC47 | 100.0% | 100.0% | 100.0% | 98.9% | Trichohepatoneurodevelopmental syndrome, 618268 |
| CCDC65 | 100.0% | 100.0% | 100.0% | 99.0% | Ciliary dyskinesia, primary, 27, 615504 |
| CCDC8 | 100.0% | 100.0% | 100.0% | 99.5% | 3-M syndrome 3, 614205 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| CCDC88A | 97.4% | 97.4% | 100.0% | 97.7% | ?PEHO syndrome-like, 617507 |
| | | | | | ?Spinocerebellar ataxia 40, 616053 |
| CCDC88C | 100.0% | 100.0% | 100.0% | 99.7% | Hydrocephalus, congenital, 1, 236600 |
| CCN6 | 100.0% | 100.0% | 100.0% | 99.4% | Progressive pseudorheumatoid dysplasia, 208230 |
| CCNO | 100.0% | 100.0% | 100.0% | 99.9% | Ciliary dyskinesia, primary, 29, 615872 |
| CCT5 | 100.0% | 100.0% | 100.0% | 99.7% | Neuropathy, hereditary sensory, with spastic paraplegia, 256840 |
| CD151 | 100.0% | 100.0% | 100.0% | 100.0% | Epidermolysis bullosa simplex 7, with nephropathy and deafness, 609057 |
| CD19 | 100.0% | 100.0% | 100.0% | 99.3% | Immunodeficiency, common variable, 3, 613493 |
| CD247 | 100.0% | 100.0% | 100.0% | 99.9% | ?Immunodeficiency 25, 610163 |
| CD27 | 100.0% | 100.0% | 100.0% | 99.7% | Lymphoproliferative syndrome 2, 615122 |
| CD2AP | 100.0% | 100.0% | 100.0% | 98.7% | Glomerulosclerosis, focal segmental, 3, 607832 |
| CD320 | 100.0% | 100.0% | 100.0% | 100.0% | Methylmalonic aciduria, transient, due to transcobalamin receptor defect, 613646 |
| CD3D | 100.0% | 100.0% | 100.0% | 99.9% | Immunodeficiency 19, severe combined, 615617 |
| | | | | | Immunodeficiency 18, 615615 |
| CD3E | 100.0% | 100.0% | 100.0% | 99.4% | Immunodeficiency 18, SCID variant, 615615 |
| CD3G | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 17, CD3 gamma deficient, 615607 |
| CD40 | 100.0% | 100.0% | 100.0% | 99.3% | Immunodeficiency with hyper-IgM, type 3, 606843 |
| CD55 | 95.8% | 92.9% | 100.0% | 99.7% | Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, 226300 |
| CD59 | 100.0% | 100.0% | 100.0% | 99.6% | Hemolytic anemia, CD59-mediated, w/wo immune-mediated polyneuropathy, 612300 |
| CD79A | 100.0% | 99.5% | 99.9% | 93.2% | Agammaglobulinemia 3, 613501 |
| CD79B | 100.0% | 100.0% | 100.0% | 99.8% | Agammaglobulinemia 6, 612692 |
| CD81 | 100.0% | 99.9% | 100.0% | 100.0% | Immunodeficiency, common variable, 6, 613496 |
| CD8A | 100.0% | 100.0% | 100.0% | 99.9% | CD8 deficiency, familial, 608957 |
| CDAN1 | 100.0% | 100.0% | 100.0% | 99.4% | Dyserythropoietic anemia, congenital, type Ia, 224120 |
| CDC14A | 100.0% | 100.0% | 100.0% | 98.6% | Deafness, autosomal recessive 32, w/wo immotile sperm, 608653 |
| CDC45 | 100.0% | 100.0% | 100.0% | 99.8% | Meier-Gorlin syndrome 7, 617063 |
| CDC6 | 100.0% | 100.0% | 100.0% | 99.3% | ?Meier-Gorlin syndrome 5, 613805 |
| CDCA7 | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency-centromeric instability-facial anomalies syndrome 3, 616910 |
| | | | | | Teebi hypertelorism syndrome 2, 619736 |
| CDH11 | 100.0% | 100.0% | 100.0% | 99.7% | Elsahy-Waters syndrome, 211380 |
| | | | | | Usher syndrome, type 1D, 601067 |
| | | | | | Usher syndrome, type 1D/F digenic, 601067 |
| CDH23 | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal recessive 12, 601386 |
| | | | | | Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 |
| CDH3 | 100.0% | 100.0% | 100.0% | 99.7% | Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| CDHR1 | 100.0% | 100.0% | 100.0% | 99.7% | Macular dystrophy, retinal, 613660 Cone-rod dystrophy 15, 613660 Retinitis pigmentosa 65, 613660 |
| CDK10 | 100.0% | 100.0% | 100.0% | 99.9% | Al Kaissi syndrome, 617694 |
| CDK5 | 100.0% | 100.0% | 100.0% | 99.9% | ?Lissencephaly 7 with cerebellar hypoplasia, 616342 |
| CDK5RAP2 | 100.0% | 100.0% | 100.0% | 99.3% | Microcephaly 3, primary, autosomal recessive, 604804 |
| CDK6 | 100.0% | 100.0% | 100.0% | 99.4% | ?Microcephaly 12, primary, autosomal recessive, 616080 |
| CDSN | 100.0% | 100.0% | 100.0% | 99.8% | Hypotrichosis 2, 146520 Peeling skin syndrome 1, 270300 |
| CDT1 | 100.0% | 100.0% | 100.0% | 99.7% | Meier-Gorlin syndrome 4, 613804 |
| CEACAM16 | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal dominant 4B, 614614 Deafness, autosomal recessive 113, 618410 |
| CEBPE | 100.0% | 100.0% | 100.0% | 99.1% | ?Immunodeficiency 108 with autoinflammation, 260570 Specific granule deficiency, 245480 |
| CENPE | 100.0% | 100.0% | 100.0% | 98.2% | ?Microcephaly 13, primary, autosomal recessive, 616051 |
| CENPF | 100.0% | 100.0% | 100.0% | 98.8% | Stromme syndrome, 243605 |
| CENPJ | 100.0% | 100.0% | 100.0% | 99.2% | Microcephaly 6, primary, autosomal recessive, 608393 ?Seckel syndrome 4, 613676 |
| CEP104 | 100.0% | 100.0% | 100.0% | 98.9% | Joubert syndrome 25, 616781 Intellectual developmental disorder, autosomal recessive 77, 619988 |
| CEP120 | 100.0% | 100.0% | 100.0% | 99.6% | Short-rib thoracic dysplasia 13 w/wo polydactyly, 616300 Joubert syndrome 31, 617761 |
| CEP135 | 100.0% | 100.0% | 100.0% | 98.8% | Microcephaly 8, primary, autosomal recessive, 614673 |
| CEP152 | 100.0% | 100.0% | 100.0% | 99.1% | Microcephaly 9, primary, autosomal recessive, 614852 Seckel syndrome 5, 613823 |
| CEP164 | 100.0% | 100.0% | 100.0% | 98.7% | Nephronophthisis 15, 614845 |
| CEP19 | 100.0% | 100.0% | 100.0% | 99.3% | Morbid obesity and spermatogenic failure, 615703 |
| CEP290 | 100.0% | 100.0% | 100.0% | 98.5% | Leber congenital amaurosis 10, 611755 Joubert syndrome 5, 610188 Senior-Loken syndrome 6, 610189 ?Bardet-Biedl syndrome 14, 615991 Meckel syndrome 4, 611134 |
| CEP41 | 100.0% | 100.0% | 100.0% | 99.0% | Joubert syndrome 15, 614464 |
| CEP55 | 100.0% | 100.0% | 100.0% | 99.4% | Multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly, 236500 |
| CEP57 | 100.0% | 100.0% | 99.9% | 98.4% | Mosaic variegated aneuploidy syndrome 2, 614114 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| CEP63 | 100.0% | 100.0% | 100.0% | 98.9% | ?Seckel syndrome 6, 614728 |
| CEP78 | 100.0% | 100.0% | 100.0% | 99.5% | Cone-rod dystrophy and hearing loss, 617236 |
| CEP83 | 100.0% | 100.0% | 100.0% | 98.0% | Nephronophthisis 18, 615862 |
| CERKL | 98.8% | 98.4% | 100.0% | 99.3% | Retinitis pigmentosa 26, 608380 |
| CERS1 | 99.9% | 99.5% | 100.0% | 99.8% | Epilepsy, progressive myoclonic, 8, 616230 |
| CERS3 | 100.0% | 100.0% | 100.0% | 99.5% | Ichthyosis, congenital, autosomal recessive 9, 615023 |
| CFAP298 | 100.0% | 100.0% | 100.0% | 99.3% | Ciliary dyskinesia, primary, 26, 615500 |
| CFAP410 | 100.0% | 100.0% | 100.0% | 99.9% | Retinal dystrophy with macular staphyloma, 617547 Spondylometaphyseal dysplasia, axial, 602271 |
| CFAP53 | 100.0% | 100.0% | 99.9% | 98.3% | Heterotaxy, visceral, 6, autosomal recessive, 614779 |
| CFD | 100.0% | 100.0% | 100.0% | 99.0% | Complement factor D deficiency, 613912 |
| CFH | 100.0% | 100.0% | 100.0% | 99.6% | Basal laminar drusen, 126700 Complement factor H deficiency, 609814 |
| CFI | 100.0% | 100.0% | 100.0% | 99.0% | Complement factor I deficiency, 610984 |
| CFL2 | 100.0% | 100.0% | 100.0% | 99.3% | Nemaline myopathy 7, autosomal recessive, 610687 |
| CFTR | 100.0% | 100.0% | 100.0% | 99.4% | Cystic fibrosis, 219700 Congenital bilateral absence of vas deferens, 277180 Sweat chloride elevation without CF, |
| CHAT | 100.0% | 100.0% | 100.0% | 99.3% | Myasthenic syndrome, congenital, 6, presynaptic, 254210 |
| CHKB | 100.0% | 100.0% | 100.0% | 99.2% | Muscular dystrophy, congenital, megaconial type, 602541 |
| CHMP1A | 100.0% | 100.0% | 100.0% | 99.9% | Pontocerebellar hypoplasia, type 8, 614961 |
| CHP1 | 100.0% | 100.0% | 100.0% | 99.1% | ?Spastic ataxia 9, autosomal recessive, 618438 |
| CHRM3 | 100.0% | 100.0% | 100.0% | 99.6% | Prune belly syndrome, 100100 |
| CHRNA1 | 100.0% | 100.0% | 100.0% | 98.9% | Myasthenic syndrome, congenital, 1B, fast-channel, 608930 Myasthenic syndrome, congenital, 1A, slow-channel, 601462 Multiple pterygium syndrome, lethal type, 253290 |
| CHRNB1 | 100.0% | 100.0% | 100.0% | 99.0% | ?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency, 616314 Myasthenic syndrome, congenital, 2A, slow-channel, 616313 |
| CHRND | 100.0% | 100.0% | 100.0% | 99.4% | ?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency, 616323 Multiple pterygium syndrome, lethal type, 253290 Myasthenic syndrome, congenital, 3B, fast-channel, 616322 ?Myasthenic syndrome, congenital, 3A, slow-channel, 616321 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| CHRNE | 100.0% | 100.0% | 100.0% | 99.6% | Myasthenic syndrome, congenital, 4A, slow-channel, 605809 Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931 Myasthenic syndrome, congenital, 4B, fast-channel, 616324 |
| CHRNG | 100.0% | 100.0% | 100.0% | 99.9% | Multiple pterygium syndrome, lethal type, 253290 Escobar syndrome, 265000 |
| CHST11 | 100.0% | 100.0% | 100.0% | 99.6% | ?Osteochondrodysplasia, brachydactyly, and overlapping malformed digits, 618167 |
| CHST14 | 100.0% | 100.0% | 100.0% | 98.6% | Ehlers-Danlos syndrome, musculocontractural type 1, 601776 |
| CHST3 | 100.0% | 100.0% | 100.0% | 99.9% | Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 |
| CHST6 | 100.0% | 100.0% | 100.0% | 100.0% | Macular corneal dystrophy, 217800 |
| CHST8 | 100.0% | 100.0% | 100.0% | 99.8% | ?Peeling skin syndrome 3, 616265 |
| CHSY1 | 99.9% | 99.7% | 100.0% | 99.6% | Temtamy preaxial brachydactyly syndrome, 605282 |
| CIB2 | 100.0% | 99.9% | 99.9% | 98.8% | Deafness, autosomal recessive 48, 609439 Usher syndrome, type IJ, 614869 |
| CIDEC | 100.0% | 100.0% | 100.0% | 99.6% | ?Lipodystrophy, familial partial, type 5, 615238 |
| CIITA | 100.0% | 100.0% | 100.0% | 99.6% | Bare lymphocyte syndrome, type II, complementation group A, 209920 |
| CILK1 | 100.0% | 100.0% | 100.0% | 99.7% | Endocrine-cerebroosteodysplasia, 612651 |
| CISD2 | 100.0% | 100.0% | 100.0% | 99.2% | Wolfram syndrome 2, 604928 |
| CIT | 100.0% | 100.0% | 100.0% | 99.3% | Microcephaly 17, primary, autosomal recessive, 617090 |
| CKAP2L | 100.0% | 100.0% | 100.0% | 99.1% | Filippi syndrome, 272440 |
| CLCF1 | 100.0% | 100.0% | 100.0% | 99.6% | Cold-induced sweating syndrome 2, 610313 |
| CLCN1 | 100.0% | 100.0% | 100.0% | 99.5% | Myotonia congenita, recessive, 255700 Myotonia congenita, dominant, 160800 Myotonia levior, 160800 |
| CLCN2 | 100.0% | 100.0% | 100.0% | 99.4% | Leukoencephalopathy with ataxia, 615651 Hyperaldosteronism, familial, type II, 605635 |
| CLCN7 | 100.0% | 100.0% | 100.0% | 99.9% | Hypopigmentation, organomegaly, and delayed myelination and development, 618541 Osteopetrosis, autosomal recessive 4, 611490 Osteopetrosis, autosomal dominant 2, 166600 |
| CLCNKB | 100.0% | 100.0% | 100.0% | 99.4% | Bartter syndrome, type 3, 607364 Bartter syndrome, type 4b, digenic, 613090 |
| CLDN1 | 100.0% | 100.0% | 100.0% | 99.8% | Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 |
| CLDN10 | 100.0% | 100.0% | 100.0% | 100.0% | HELIX syndrome, 617671 |
| CLDN14 | 100.0% | 100.0% | 100.0% | 99.9% | Deafness, autosomal recessive 29, 614035 |
| CLDN16 | 100.0% | 100.0% | 100.0% | 99.2% | Hypomagnesemia 3, renal, 248250 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| CLDN19 | 100.0% | 100.0% | 100.0% | 99.8% | Hypomagnesemia 5, renal, with ocular involvement, 248190 |
| CLIP1 | 100.0% | 100.0% | 100.0% | 98.8% | No OMIM disease ID |
| CLMP | 100.0% | 100.0% | 100.0% | 99.5% | Congenital short bowel syndrome, 615237 |
| CLN3 | 93.2% | 93.1% | 100.0% | 99.3% | Ceroid lipofuscinosis, neuronal, 3, 204200 |
| CLN5 | 83.1% | 83.0% | 100.0% | 98.6% | Ceroid lipofuscinosis, neuronal, 5, 256731 |
| CLN6 | 100.0% | 100.0% | 100.0% | 99.6% | Ceroid lipofuscinosis, neuronal, 6B (Kufs type), 204300 Ceroid lipofuscinosis, neuronal, 6A, 601780 |
| CLN8 | 100.0% | 100.0% | 100.0% | 99.5% | Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 Ceroid lipofuscinosis, neuronal, 8, 600143 |
| CLP1 | 100.0% | 100.0% | 100.0% | 99.8% | Pontocerebellar hypoplasia, type 10, 615803 |
| CLPB | 100.0% | 100.0% | 100.0% | 98.9% | Neutropenia, severe congenital, 9, autosomal dominant, 619813 3-methylglutaconic aciduria, type VIIB, autosomal recessive, 616271 3-methylglutaconic aciduria, type VIIA, autosomal dominant, 619835 |
| CLPP | 100.0% | 100.0% | 100.0% | 99.3% | Perrault syndrome 3, 614129 |
| CLRN1 | 100.0% | 100.0% | 100.0% | 99.2% | Usher syndrome, type 3A, 276902 Retinitis pigmentosa 61, 614180 |
| CNGA1 | 91.2% | 91.2% | 100.0% | 98.1% | Retinitis pigmentosa 49, 613756 |
| CNGA3 | 100.0% | 100.0% | 100.0% | 99.9% | Achromatopsia 2, 216900 |
| CNGB1 | 100.0% | 100.0% | 100.0% | 99.4% | Retinitis pigmentosa 45, 613767 |
| CNGB3 | 100.0% | 100.0% | 100.0% | 99.5% | Achromatopsia 3, 262300 |
| CNNM2 | 100.0% | 100.0% | 100.0% | 99.6% | Hypomagnesemia 6, renal, 613882 Hypomagnesemia, seizures, and impaired intellectual development 1, 616418 |
| CNNM4 | 100.0% | 100.0% | 100.0% | 99.8% | Jalili syndrome, 217080 |
| CNPY3 | 100.0% | 100.0% | 100.0% | 99.6% | Developmental and epileptic encephalopathy 60, 617929 |
| CNTN1 | 100.0% | 100.0% | 100.0% | 99.2% | ?Congenital myopathy 12, 612540 |
| CNTN2 | 100.0% | 100.0% | 100.0% | 99.6% | ?Epilepsy, myoclonic, familial adult, 5, 615400 |
| CNTNAP1 | 100.0% | 100.0% | 100.0% | 99.4% | Lethal congenital contracture syndrome 7, 616286 Hypomyelinating neuropathy, congenital, 3, 618186 |
| CNTNAP2 | 100.0% | 100.0% | 100.0% | 99.4% | Pitt-Hopkins like syndrome 1, 610042 |
| COA5 | 82.4% | 82.4% | 100.0% | 99.4% | ?Mitochondrial complex IV, deficiency, nuclear type 9, 616500 |
| COA6 | 100.0% | 100.0% | 100.0% | 99.4% | Mitochondrial complex IV deficiency, nuclear type 13, 616501 |
| COA7 | 100.0% | 100.0% | 100.0% | 99.6% | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 3, 618387 |
| COA8 | 100.0% | 99.9% | 100.0% | 98.9% | Mitochondrial complex IV deficiency, nuclear type 17, 619061 |
| COASY | 100.0% | 100.0% | 100.0% | 99.5% | Pontocerebellar hypoplasia, type 12, 618266 Neurodegeneration with brain iron accumulation 6, 615643 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| COCH | 100.0% | 100.0% | 100.0% | 99.7% | Deafness, autosomal dominant 9, 601369 ?Deafness, autosomal recessive 110, 618094 |
| COG1 | 100.0% | 100.0% | 100.0% | 99.7% | Congenital disorder of glycosylation, type IIg, 611209 |
| COG4 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type IIj, 613489 Saul-Wilson syndrome, 618150 |
| COG5 | 100.0% | 100.0% | 100.0% | 99.2% | Congenital disorder of glycosylation, type IIi, 613612 |
| COG6 | 100.0% | 100.0% | 100.0% | 99.3% | Shaheen syndrome, 615328 Congenital disorder of glycosylation, type III, 614576 |
| COG7 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type IIe, 608779 |
| COG8 | 100.0% | 100.0% | 100.0% | 99.7% | Congenital disorder of glycosylation, type IIh, 611182 |
| COL11A1 | 100.0% | 100.0% | 100.0% | 99.2% | Fibrochondrogenesis 1, 228520 Stickler syndrome, type II, 604841 Marshall syndrome, 154780 Deafness, autosomal dominant 37, 618533 |
| COL11A2 | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal dominant 13, 601868 Otospondylomegapiphyseal dysplasia, autosomal recessive, 215150 Fibrochondrogenesis 2, 614524 Deafness, autosomal recessive 53, 609706 Otospondylomegapiphyseal dysplasia, autosomal dominant, 184840 |
| COL12A1 | 100.0% | 100.0% | 100.0% | 99.4% | Bethlem myopathy 2, 616471 ?Ullrich congenital muscular dystrophy 2, 616470 |
| COL13A1 | 100.0% | 100.0% | 100.0% | 99.7% | Myasthenic syndrome, congenital, 19, 616720 |
| COL17A1 | 100.0% | 100.0% | 100.0% | 99.7% | Epithelial recurrent erosion dystrophy, 122400 Epidermolysis bullosa, junctional 4, intermediate, 619787 |
| COL18A1 | 100.0% | 100.0% | 100.0% | 99.8% | Knobloch syndrome, type 1, 267750 Glaucoma, primary closed-angle, 618880 |
| COL1A2 | 100.0% | 100.0% | 100.0% | 99.5% | Osteogenesis imperfecta, type III, 259420 Ehlers-Danlos syndrome, arthrochalasia type, 2, 617821 Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2, 619120 Ehlers-Danlos syndrome, cardiac valvular type, 225320 Osteogenesis imperfecta, type IV, 166220 Osteogenesis imperfecta, type II, 166210 |
| COL25A1 | 99.4% | 99.4% | 100.0% | 99.2% | Fibrosis of extraocular muscles, congenital, 5, 616219 |
| COL27A1 | 100.0% | 100.0% | 100.0% | 99.4% | Steel syndrome, 615155 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| COL3A1 | 100.0% | 100.0% | 100.0% | 99.2% | Ehlers-Danlos syndrome, vascular type, 130050 Polymicrogyria w/wo vascular-type EDS, 618343 |
| COL4A3 | 100.0% | 100.0% | 100.0% | 99.3% | Hematuria, benign familial, 2, 620320 Alport syndrome 3, autosomal dominant, 104200 Alport syndrome 2, autosomal recessive, 203780 |
| COL4A4 | 100.0% | 100.0% | 100.0% | 99.4% | Hematuria, familial benign, 1, 141200 Alport syndrome 2, autosomal recessive, 203780 |
| COL6A1 | 100.0% | 100.0% | 100.0% | 99.8% | Bethlem myopathy 1, 158810 Ullrich congenital muscular dystrophy 1, 254090 |
| COL6A2 | 100.0% | 100.0% | 100.0% | 99.9% | Bethlem myopathy 1, 158810 ?Myosclerosis, congenital, 255600 Ullrich congenital muscular dystrophy 1, 254090 |
| COL6A3 | 100.0% | 100.0% | 100.0% | 99.5% | Ullrich congenital muscular dystrophy 1, 254090 Dystonia 27, 616411 Bethlem myopathy 1, 158810 |
| COL7A1 | 100.0% | 100.0% | 100.0% | 99.7% | Nail disorder, nonsyndromic congenital, 8, 607523 Epidermolysis bullosa dystrophica, Bart type, 132000 Epidermolysis bullosa dystrophica inversa, 226600 Epidermolysis bullosa dystrophica, autosomal recessive, 226600 Epidermolysis bullosa, pretibial, 131850 Epidermolysis bullosa dystrophica, autosomal dominant, 131750 Transient bullous of the newborn, 131705 Epidermolysis bullosa pruriginosa, 604129 Epidermolysis bullosa dystrophica, localisata variant, 226600 |
| COL9A1 | 100.0% | 100.0% | 100.0% | 99.0% | Stickler syndrome, type IV, 614134 ?Epiphyseal dysplasia, multiple, 6, 614135 |
| COL9A2 | 100.0% | 100.0% | 100.0% | 99.5% | Epiphyseal dysplasia, multiple, 2, 600204 ?Stickler syndrome, type V, 614284 |
| COLEC10 | 100.0% | 100.0% | 100.0% | 98.3% | 3MC syndrome 3, 248340 |
| COLEC11 | 100.0% | 100.0% | 100.0% | 100.0% | 3MC syndrome 2, 265050 |
| COLGALT1 | 100.0% | 100.0% | 100.0% | 98.9% | Brain small vessel disease 3, 618360 |
| COLQ | 100.0% | 100.0% | 100.0% | 99.5% | Myasthenic syndrome, congenital, 5, 603034 |
| COPB2 | 100.0% | 100.0% | 100.0% | 99.6% | Osteoporosis, childhood- or juvenile-onset, with developmental delay, 619884 ?Microcephaly 19, primary, autosomal recessive, 617800 |
| COQ2 | 96.3% | 96.3% | 100.0% | 99.7% | Coenzyme Q10 deficiency, primary, 1, 607426 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| COQ4 | 100.0% | 100.0% | 100.0% | 99.9% | Coenzyme Q10 deficiency, primary, 7, 616276 |
| COQ6 | 100.0% | 100.0% | 100.0% | 99.5% | Coenzyme Q10 deficiency, primary, 6, 614650 |
| COQ8A | 100.0% | 100.0% | 100.0% | 100.0% | Coenzyme Q10 deficiency, primary, 4, 612016 |
| COQ8B | 100.0% | 100.0% | 100.0% | 99.8% | Nephrotic syndrome, type 9, 615573 |
| COQ9 | 100.0% | 100.0% | 100.0% | 99.6% | Coenzyme Q10 deficiency, primary, 5, 614654 |
| CORO1A | 100.0% | 100.0% | 100.0% | 98.7% | Immunodeficiency 8, 615401 |
| COX10 | 100.0% | 100.0% | 99.9% | 98.3% | Mitochondrial complex IV deficiency, nuclear type 3, 619046 |
| COX14 | 100.0% | 100.0% | 100.0% | 100.0% | ?Mitochondrial complex IV deficiency, nuclear type 10, 619053 |
| COX15 | 100.0% | 100.0% | 100.0% | 99.2% | Mitochondrial complex IV deficiency, nuclear type 6, 615119 |
| COX20 | 100.0% | 100.0% | 100.0% | 99.4% | Mitochondrial complex IV deficiency, nuclear type 11, 619054 |
| COX4I2 | 100.0% | 100.0% | 100.0% | 98.8% | Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 |
| COX6A1 | 100.0% | 100.0% | 100.0% | 99.4% | Charcot-Marie-Tooth disease, recessive intermediate D, 616039 |
| COX6A2 | 100.0% | 99.6% | 100.0% | 98.8% | Mitochondrial complex IV deficiency, nuclear type 18, 619062 |
| COX6B1 | 100.0% | 100.0% | 100.0% | 99.9% | Mitochondrial complex IV deficiency, nuclear type 7, 619051 |
| COX8A | 100.0% | 100.0% | 100.0% | 100.0% | ?Mitochondrial complex IV deficiency, nuclear type 15, 619059 |
| CP | 100.0% | 100.0% | 100.0% | 99.0% | Cerebellar ataxia, 604290 Hemosiderosis, systemic, due to aceruloplasminemia, 604290 |
| CPA6 | 100.0% | 100.0% | 100.0% | 99.6% | Febrile seizures, familial, 11, 614418 Epilepsy, familial temporal lobe, 5, 614417 |
| CPAMD8 | 100.0% | 100.0% | 100.0% | 99.6% | Anterior segment dysgenesis 8, 617319 |
| CPLANE1 | 100.0% | 100.0% | 100.0% | 99.2% | Orofaciodigital syndrome VI, 277170 Joubert syndrome 17, 614615 |
| CPLX1 | 100.0% | 100.0% | 100.0% | 99.5% | Developmental and epileptic encephalopathy 63, 617976 |
| CPN1 | 100.0% | 100.0% | 100.0% | 99.1% | Carboxypeptidase N deficiency, 212070 |
| CPOX | 100.0% | 100.0% | 100.0% | 99.4% | Coproporphyrinuria, 121300 Harderoporphyria, 618892 |
| CPS1 | 100.0% | 100.0% | 100.0% | 99.4% | Carbamoylphosphate synthetase I deficiency, 237300 |
| CPT1A | 100.0% | 100.0% | 100.0% | 99.3% | CPT deficiency, hepatic, type IA, 255120 |
| CPT2 | 100.0% | 100.0% | 100.0% | 99.7% | CPT II deficiency, infantile, 600649 CPT II deficiency, lethal neonatal, 608836 CPT II deficiency, myopathic, stress-induced, 255110 |
| CR2 | 100.0% | 100.0% | 100.0% | 99.5% | ?Immunodeficiency, common variable, 7, 614699 |
| CRADD | 100.0% | 100.0% | 100.0% | 99.3% | Intellectual developmental disorder, autosomal recessive 34, with variant lissencephaly, 614499 |
| CRAT | 100.0% | 100.0% | 100.0% | 99.8% | ?Neurodegeneration with brain iron accumulation 8, 617917 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| CRB1 | 100.0% | 100.0% | 100.0% | 99.5% | Leber congenital amaurosis 8, 613835 Retinitis pigmentosa-12, 600105 Pigmented paravenous chorioretinal atrophy, 172870 |
| CRB2 | 100.0% | 100.0% | 100.0% | 99.8% | Focal segmental glomerulosclerosis 9, 616220 Ventriculomegaly with cystic kidney disease, 219730 |
| CRBN | 100.0% | 99.1% | 100.0% | 99.1% | Intellectual developmental disorder, autosomal recessive 2, 607417 |
| CREB3L1 | 100.0% | 100.0% | 100.0% | 99.7% | Osteogenesis imperfecta, type XVI, 616229 |
| CRIPT | 100.0% | 100.0% | 100.0% | 99.0% | Short stature with microcephaly and distinctive facies, 615789 |
| CRLF1 | 99.7% | 98.6% | 99.7% | 93.0% | Cold-induced sweating syndrome 1, 272430 |
| CRPPA | 100.0% | 100.0% | 100.0% | 99.0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 |
| CRTAP | 100.0% | 100.0% | 100.0% | 99.5% | Osteogenesis imperfecta, type VII, 610682 |
| CRYAA | 100.0% | 100.0% | 100.0% | 99.7% | Cataract 9, multiple types, 604219 |
| CRYAB | 100.0% | 100.0% | 100.0% | 99.5% | Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related, 613869 Myopathy, myofibrillar, 2, 608810 Cataract 16, multiple types, 613763 Cardiomyopathy, dilated, 1II, 615184 |
| CRYBB1 | 100.0% | 100.0% | 100.0% | 99.5% | Cataract 17, multiple types, 611544 |
| CRYBB3 | 100.0% | 100.0% | 100.0% | 99.6% | Cataract 22, 609741 |
| CSF1R | 100.0% | 100.0% | 100.0% | 99.4% | Brain abnormalities, neurodegeneration, and dysosteosclerosis, 618476 Leukoencephalopathy, diffuse hereditary, with spheroids 1, 221820 |
| CSF2RB | 100.0% | 100.0% | 100.0% | 99.8% | Surfactant metabolism dysfunction, pulmonary, 5, 614370 |
| CSPP1 | 100.0% | 100.0% | 100.0% | 99.2% | Joubert syndrome 21, 615636 |
| CSTA | 100.0% | 100.0% | 100.0% | 99.3% | Peeling skin syndrome 4, 607936 |
| CSTB | 100.0% | 100.0% | 100.0% | 99.7% | Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 |
| CTC1 | 100.0% | 100.0% | 100.0% | 99.6% | Cerebroretinal microangiopathy with calcifications and cysts, 612199 |
| CTDP1 | 100.0% | 100.0% | 100.0% | 99.9% | Congenital cataracts, facial dysmorphism, and neuropathy, 604168 |
| CTNNA2 | 99.8% | 99.4% | 100.0% | 99.5% | Cortical dysplasia, complex, with other brain malformations 9, 618174 |
| CTNS | 100.0% | 100.0% | 100.0% | 99.5% | Cystinosis, nephropathic, 219800 Cystinosis, ocular nonnephropathic, 219750 Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 Cystinosis, atypical nephropathic, 219800 |
| CTPS1 | 100.0% | 100.0% | 100.0% | 99.5% | Immunodeficiency 24, 615897 |
| CTSA | 100.0% | 100.0% | 100.0% | 99.2% | Galactosialidosis, 256540 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| CTSC | 100.0% | 100.0% | 100.0% | 99.4% | Periodontitis 1, juvenile, 170650 Haim-Munk syndrome, 245010 Papillon-Lefevre syndrome, 245000 |
| CTSD | 100.0% | 100.0% | 100.0% | 99.9% | Ceroid lipofuscinosis, neuronal, 10, 610127 |
| CTSF | 100.0% | 100.0% | 100.0% | 99.6% | Ceroid lipofuscinosis, neuronal, 13 (Kufs type), 615362 |
| CTSK | 100.0% | 100.0% | 100.0% | 99.8% | Pycnodysostosis, 265800 |
| CTU2 | 100.0% | 100.0% | 100.0% | 99.9% | Microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome, 618142 |
| CUBN | 100.0% | 100.0% | 100.0% | 99.5% | Imlerslund-Grasbeck syndrome 1, 261100 |
| CUL7 | 100.0% | 100.0% | 100.0% | 99.5% | 3-M syndrome 1, 273750 |
| CWC27 | 100.0% | 100.0% | 100.0% | 98.4% | Retinitis pigmentosa w/wo skeletal anomalies, 250410 |
| CWF19L1 | 100.0% | 100.0% | 100.0% | 99.3% | Spinocerebellar ataxia, autosomal recessive 17, 616127 |
| CYB5A | 100.0% | 100.0% | 100.0% | 99.8% | Methemoglobinemia and ambiguous genitalia, 250790 |
| CYB5R3 | 100.0% | 100.0% | 100.0% | 99.7% | Methemoglobinemia, type I, 250800 Methemoglobinemia, type II, 250800 |
| CYBA | 100.0% | 100.0% | 100.0% | 100.0% | Chronic granulomatous disease 4, autosomal recessive, 233690 |
| CYC1 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex III deficiency, nuclear type 6, 615453 |
| CYP11A1 | 100.0% | 100.0% | 100.0% | 99.8% | Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 |
| CYP11B1 | 100.0% | 100.0% | 100.0% | 99.9% | Aldosteronism, glucocorticoid-remediable, 103900 Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 |
| CYP11B2 | 100.0% | 100.0% | 100.0% | 99.9% | Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 Aldosterone to renin ratio raised, |
| CYP17A1 | 100.0% | 100.0% | 100.0% | 99.7% | 17,20-lyase deficiency, isolated, 202110 17-alpha-hydroxylase/17,20-lyase deficiency, 202110 |
| CYP19A1 | 100.0% | 99.9% | 100.0% | 99.4% | Aromatase deficiency, 613546 Aromatase excess syndrome, 139300 |
| CYP1B1 | 100.0% | 100.0% | 100.0% | 99.8% | Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 Anterior segment dysgenesis 6, multiple subtypes, 617315 |
| CYP21A2 | 100.0% | 99.9% | 100.0% | 99.6% | Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 |
| CYP24A1 | 100.0% | 100.0% | 100.0% | 99.7% | Hypercalcemia, infantile, 1, 143880 |
| CYP26B1 | 100.0% | 100.0% | 100.0% | 99.7% | Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 |
| CYP26C1 | 100.0% | 100.0% | 100.0% | 99.9% | Focal facial dermal dysplasia 4, 614974 |
| CYP27A1 | 100.0% | 100.0% | 100.0% | 99.8% | Cerebrotendinous xanthomatosis, 213700 |
| CYP27B1 | 100.0% | 100.0% | 100.0% | 99.6% | Vitamin D-dependent rickets, type I, 264700 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| CYP2C8 | 100.0% | 100.0% | 100.0% | 99.4% | No OMIM disease ID |
| CYP2R1 | 100.0% | 100.0% | 100.0% | 99.4% | Rickets due to defect in vitamin D 25-hydroxylation deficiency, 600081 |
| CYP2U1 | 100.0% | 100.0% | 100.0% | 99.6% | Spastic paraplegia 56, autosomal recessive, 615030 |
| CYP4F22 | 100.0% | 100.0% | 100.0% | 99.8% | Ichthyosis, congenital, autosomal recessive 5, 604777 |
| CYP4V2 | 100.0% | 100.0% | 100.0% | 99.1% | Bietti crystalline corneoretinal dystrophy, 210370 |
| CYP7B1 | 100.0% | 100.0% | 100.0% | 98.5% | Spastic paraplegia 5A, autosomal recessive, 270800 Bile acid synthesis defect, congenital, 3, 613812 |
| D2HGDH | 100.0% | 100.0% | 100.0% | 99.7% | D-2-hydroxyglutaric aciduria, 600721 |
| DAG1 | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9, 616538 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 |
| DARS1 | 100.0% | 100.0% | 100.0% | 99.1% | Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 |
| DARS2 | 100.0% | 100.0% | 100.0% | 98.5% | Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 |
| DBH | 100.0% | 100.0% | 100.0% | 99.5% | Orthostatic hypotension 1, due to DBH deficiency, 223360 |
| DBT | 100.0% | 100.0% | 100.0% | 99.2% | Maple syrup urine disease, type II, 248600 |
| DCAF17 | 100.0% | 100.0% | 100.0% | 99.8% | Woodhouse-Sakati syndrome, 241080 |
| DCC | 100.0% | 100.0% | 100.0% | 99.5% | Mirror movements 1 and/or agenesis of the corpus callosum, 157600 Esophageal carcinoma, somatic, 133239 Colorectal cancer, somatic, 114500 Gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542 |
| DCDC2 | 100.0% | 100.0% | 100.0% | 98.9% | Nephronophthisis 19, 616217 ?Deafness, autosomal recessive 66, 610212 Sclerosing cholangitis, neonatal, 617394 |
| DCHS1 | 100.0% | 100.0% | 100.0% | 99.9% | Mitral valve prolapse 2, 607829 Van Maldergem syndrome 1, 601390 |
| DCLRE1C | 100.0% | 100.0% | 100.0% | 99.1% | Severe combined immunodeficiency, Athabaskan type, 602450 Omenn syndrome, 603554 |
| DCPS | 100.0% | 100.0% | 100.0% | 98.9% | Al-Raqad syndrome, 616459 |
| DDB2 | 100.0% | 100.0% | 100.0% | 99.1% | Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 |
| DDC | 100.0% | 100.0% | 100.0% | 99.2% | Aromatic L-amino acid decarboxylase deficiency, 608643 |
| DDHD1 | 100.0% | 100.0% | 100.0% | 99.3% | Spastic paraplegia 28, autosomal recessive, 609340 |
| DDHD2 | 100.0% | 100.0% | 100.0% | 99.7% | Spastic paraplegia 54, autosomal recessive, 615033 |
| DDOST | 100.0% | 100.0% | 100.0% | 99.6% | Congenital disorder of glycosylation, type I _r , 614507 |
| DDR2 | 100.0% | 100.0% | 100.0% | 99.1% | Warburg-Cinotti syndrome, 618175 Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| DDR GK1 | 100.0% | 100.0% | 100.0% | 99.7% | Spondyloepimetaphyseal dysplasia, Shohat type, 602557 |
| DDX11 | 100.0% | 100.0% | 100.0% | 99.9% | Warsaw breakage syndrome, 613398 |
| DDX59 | 100.0% | 100.0% | 100.0% | 99.0% | Orofaciodigital syndrome V, 174300 |
| DEAF1 | 100.0% | 100.0% | 100.0% | 97.9% | Vulto-van Silfout-de Vries syndrome, 615828 Neurodevelopmental disorder with hypotonia, impaired expressive language, and w/wo seizures, 617171 |
| DEGS1 | 100.0% | 100.0% | 100.0% | 99.6% | Leukodystrophy, hypomyelinating, 18, 618404 |
| DENND5A | 100.0% | 100.0% | 100.0% | 99.0% | Developmental and epileptic encephalopathy 49, 617281 |
| DES | 100.0% | 100.0% | 100.0% | 99.8% | Scapulooperoneal syndrome, neurogenic, Kaeser type, 181400 Cardiomyopathy, dilated, 1l, 604765 Myopathy, myofibrillar, 1, 601419 |
| DGKE | 100.0% | 100.0% | 100.0% | 99.0% | Nephrotic syndrome, type 7, 615008 |
| DGUOK | 100.0% | 100.0% | 100.0% | 98.7% | Portal hypertension, noncirrhotic, 1, 617068 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4, 617070 Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 |
| DHCR24 | 100.0% | 100.0% | 100.0% | 99.8% | Desmosterolosis, 602398 |
| DHCR7 | 100.0% | 100.0% | 100.0% | 99.9% | Smith-Lemli-Opitz syndrome, 270400 |
| DHDDS | 94.4% | 94.4% | 100.0% | 99.5% | Developmental delay and seizures w/wo movement abnormalities, 617836 ?Congenital disorder of glycosylation, type 1bb, 613861 Retinitis pigmentosa 59, 613861 |
| DHFR | 100.0% | 100.0% | 100.0% | 99.6% | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 |
| DHH | 100.0% | 100.0% | 100.0% | 100.0% | 46XY gonadal dysgenesis with minifascicular neuropathy, 607080 46XY sex reversal 7, 233420 |
| DHODH | 100.0% | 100.0% | 100.0% | 100.0% | Miller syndrome, 263750 |
| DHPS | 96.7% | 93.0% | 100.0% | 99.7% | Neurodevelopmental disorder with seizures and speech and walking impairment, 618480 |
| DHTKD1 | 100.0% | 100.0% | 100.0% | 99.4% | ?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 Alpha-aminoacidic and alpha-ketoadipic aciduria, 204750 |
| DHX38 | 100.0% | 100.0% | 100.0% | 99.7% | Retinitis pigmentosa 84, 618220 |
| DIAPH1 | 100.0% | 100.0% | 100.0% | 97.4% | Deafness, autosomal dominant 1, w/wo thrombocytopenia, 124900 Seizures, cortical blindness, microcephaly syndrome, 616632 |
| DIS3L2 | 100.0% | 100.0% | 100.0% | 99.4% | Perlman syndrome, 267000 |
| DLAT | 100.0% | 100.0% | 100.0% | 99.4% | Pyruvate dehydrogenase E2 deficiency, 245348 |
| DLD | 100.0% | 100.0% | 100.0% | 99.3% | Dihydrolipoamide dehydrogenase deficiency, 246900 |
| DLL3 | 100.0% | 100.0% | 100.0% | 99.6% | Spondylocostal dysostosis 1, autosomal recessive, 277300 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| DLX5 | 100.0% | 100.0% | 100.0% | 100.0% | Split-hand/foot malformation 1, 183600 ?Split-hand/foot malformation 1 with sensorineural hearing loss, 220600 |
| DMGDH | 100.0% | 100.0% | 100.0% | 99.2% | Dimethylglycine dehydrogenase deficiency, 605850 |
| DMP1 | 100.0% | 100.0% | 100.0% | 99.5% | Hypophosphatemic rickets, AR, 241520 |
| DMXL2 | 100.0% | 100.0% | 100.0% | 99.2% | Developmental and epileptic encephalopathy 81, 618663 ?Deafness, autosomal dominant 71, 617605 ?Polyendocrine-polyneuropathy syndrome, 616113 |
| DNA2 | 100.0% | 100.0% | 100.0% | 98.9% | ?Seckel syndrome 8, 615807 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6, 615156 |
| DNAAF1 | 100.0% | 100.0% | 100.0% | 99.5% | Ciliary dyskinesia, primary, 13, 613193 |
| DNAAF2 | 100.0% | 100.0% | 100.0% | 99.7% | Ciliary dyskinesia, primary, 10, 612518 |
| DNAAF3 | 100.0% | 100.0% | 99.9% | 98.7% | Ciliary dyskinesia, primary, 2, 606763 |
| DNAAF4 | 100.0% | 100.0% | 100.0% | 98.5% | Ciliary dyskinesia, primary, 25, 615482 |
| DNAAF5 | 100.0% | 99.9% | 100.0% | 99.4% | Ciliary dyskinesia, primary, 18, 614874 |
| DNAH1 | 100.0% | 100.0% | 100.0% | 99.7% | Spermatogenic failure 18, 617576 Ciliary dyskinesia, primary, 37, 617577 |
| DNAH11 | 100.0% | 100.0% | 100.0% | 99.1% | Ciliary dyskinesia, primary, 7, w/wo situs inversus, 611884 |
| DNAH5 | 99.9% | 99.7% | 100.0% | 99.4% | Ciliary dyskinesia, primary, 3, w/wo situs inversus, 608644 |
| DNAH9 | 100.0% | 100.0% | 100.0% | 99.5% | Ciliary dyskinesia, primary, 40, 618300 |
| DNAI1 | 100.0% | 100.0% | 100.0% | 99.5% | Ciliary dyskinesia, primary, 1, w/wo situs inversus, 244400 |
| DNAI2 | 100.0% | 100.0% | 100.0% | 99.2% | Ciliary dyskinesia, primary, 9, w/wo situs inversus, 612444 |
| DNAJB2 | 100.0% | 100.0% | 100.0% | 99.5% | Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 |
| DNAJC12 | 100.0% | 100.0% | 100.0% | 99.4% | Hyperphenylalaninemia, mild, non-BH4-deficient, 617384 |
| DNAJC19 | 100.0% | 100.0% | 100.0% | 99.6% | 3-methylglutaconic aciduria, type V, 610198 |
| DNAJC21 | 100.0% | 100.0% | 100.0% | 98.5% | Bone marrow failure syndrome 3, 617052 |
| DNAJC3 | 100.0% | 100.0% | 100.0% | 98.5% | Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 |
| DNAJC6 | 100.0% | 100.0% | 100.0% | 99.3% | Parkinson disease 19a, juvenile-onset, 615528 Parkinson disease 19b, early-onset, 615528 |
| DNAL1 | 100.0% | 100.0% | 100.0% | 99.0% | Ciliary dyskinesia, primary, 16, 614017 |
| DNASE1L3 | 100.0% | 100.0% | 100.0% | 99.8% | Systemic lupus erythematosus 16, 614420 |
| DNM1L | 100.0% | 100.0% | 100.0% | 99.5% | Optic atrophy 5, 610708 Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1, 614388 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| | | | | | Centronuclear myopathy 1, 160150 Charcot-Marie-Tooth disease, axonal type 2M, 606482 Charcot-Marie-Tooth disease, dominant intermediate B, 606482 |
| DNM2 | 100.0% | 100.0% | 100.0% | 99.5% | Lethal congenital contracture syndrome 5, 615368 |
| DNMBP | 100.0% | 100.0% | 100.0% | 99.6% | Cataract 48, 618415 |
| DNMT3B | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 Faciocapulo humeral muscular dystrophy 4, digenic, 619478 |
| DOCK2 | 99.9% | 99.5% | 100.0% | 99.6% | Immunodeficiency 40, 616433 |
| DOCK3 | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292 |
| DOCK6 | 100.0% | 100.0% | 100.0% | 99.7% | Adams-Oliver syndrome 2, 614219 |
| DOCK7 | 100.0% | 100.0% | 100.0% | 99.0% | Developmental and epileptic encephalopathy 23, 615859 |
| DOCK8 | 100.0% | 100.0% | 100.0% | 99.4% | Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 |
| DOK7 | 100.0% | 100.0% | 100.0% | 99.5% | Fetal akinesia deformation sequence 3, 618389 Myasthenic syndrome, congenital, 10, 254300 |
| DOLK | 100.0% | 100.0% | 100.0% | 99.6% | Congenital disorder of glycosylation, type Im, 610768 |
| DONSON | 100.0% | 100.0% | 100.0% | 99.8% | Microcephaly, short stature, and limb abnormalities, 617604 Microcephaly-micromelia syndrome, 251230 |
| DPAGT1 | 100.0% | 100.0% | 100.0% | 99.6% | Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 Congenital disorder of glycosylation, type Ij, 608093 |
| DPH1 | 100.0% | 100.0% | 100.0% | 99.8% | Developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901 |
| DPM1 | 99.2% | 96.6% | 100.0% | 98.6% | Congenital disorder of glycosylation, type Ie, 608799 |
| DPM2 | 100.0% | 100.0% | 100.0% | 99.3% | Congenital disorder of glycosylation, type Iu, 615042 |
| DPM3 | 100.0% | 100.0% | 100.0% | 98.7% | ?Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15, 618992 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15, 612937 |
| DPY19L2 | 100.0% | 100.0% | 100.0% | 99.4% | Spermatogenic failure 9, 613958 |
| DPYD | 99.8% | 99.6% | 100.0% | 99.3% | Dihydropyrimidine dehydrogenase deficiency, 274270 5-fluorouracil toxicity, 274270 |
| DPYS | 100.0% | 100.0% | 100.0% | 99.5% | Dihydropyrimidinuria, 222748 |
| DRAM2 | 100.0% | 100.0% | 100.0% | 99.8% | Cone-rod dystrophy 21, 616502 |
| DRC1 | 100.0% | 100.0% | 100.0% | 99.5% | Spermatogenic failure 80, 620222 Ciliary dyskinesia, primary, 21, 615294 |
| DSC2 | 100.0% | 100.0% | 100.0% | 99.6% | Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 Arrhythmogenic right ventricular dysplasia 11, 610476 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| DSC3 | 100.0% | 100.0% | 100.0% | 99.2% | Hypotrichosis and recurrent skin vesicles, 613102 |
| DSE | 100.0% | 100.0% | 100.0% | 99.7% | Ehlers-Danlos syndrome, musculocontractural type 2, 615539 |
| DSG4 | 100.0% | 100.0% | 100.0% | 99.3% | Hypotrichosis 6, 607903 |
| DSP | 100.0% | 100.0% | 100.0% | 99.2% | Arrhythmogenic right ventricular dysplasia 8, 607450 Epidermolysis bullosa, lethal acantholytic, 609638 Keratosis palmoplantaris striata II, 612908 Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 Cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 |
| DST | 100.0% | 100.0% | 100.0% | 99.1% | Neuropathy, hereditary sensory and autonomic, type VI, 614653 Epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency, 615425 |
| DSTYK | 100.0% | 100.0% | 100.0% | 99.7% | Congenital anomalies of kidney and urinary tract 1, 610805 Spastic paraplegia 23, 270750 |
| DTNBP1 | 100.0% | 100.0% | 100.0% | 99.5% | Hermansky-Pudlak syndrome 7, 614076 |
| DTYMK | 100.0% | 100.0% | 100.0% | 99.9% | Neurodegeneration, childhood-onset, with progressive microcephaly, 619847 |
| DUOX2 | 100.0% | 100.0% | 100.0% | 99.6% | Thyroid dyshormonogenesis 6, 607200 |
| DUOXA2 | 100.0% | 100.0% | 100.0% | 100.0% | Thyroid dyshormonogenesis 5, 274900 |
| DYM | 100.0% | 99.9% | 100.0% | 99.0% | Smith-McCort dysplasia, 607326 Dyggve-Melchior-Clausen disease, 223800 |
| DYNC1I2 | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with microcephaly and structural brain anomalies, 618492 |
| DYNC2H1 | 99.8% | 99.4% | 100.0% | 99.1% | Short-rib thoracic dysplasia 3 w/wo polydactyly, 613091 |
| DYNC2LI1 | 100.0% | 100.0% | 100.0% | 98.5% | Short-rib thoracic dysplasia 15 with polydactyly, 617088 |
| DYSF | 100.0% | 100.0% | 100.0% | 99.6% | Muscular dystrophy, limb-girdle, autosomal recessive 2, 253601 Miyoshi muscular dystrophy 1, 254130 Myopathy, distal, with anterior tibial onset, 606768 |
| DZIP1L | 100.0% | 100.0% | 100.0% | 99.2% | Polycystic kidney disease 5, 617610 |
| EARS2 | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 12, 614924 |
| ECEL1 | 100.0% | 100.0% | 100.0% | 99.8% | Arthrogyrosis, distal, type 5D, 615065 |
| ECHS1 | 100.0% | 100.0% | 100.0% | 99.0% | Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 |
| ECM1 | 100.0% | 100.0% | 100.0% | 99.5% | Urbach-Wiethe disease, 247100 |
| EDAR | 100.0% | 100.0% | 100.0% | 99.7% | Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 |
| EDARADD | 100.0% | 100.0% | 100.0% | 99.3% | Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 |
| EDC3 | 100.0% | 100.0% | 100.0% | 99.8% | ?Intellectual developmental disorder, autosomal recessive 50, 616460 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| EDEM3 | 100.0% | 100.0% | 100.0% | 99.3% | Congenital disorder of glycosylation, type IIv, 619493 |
| | | | | | Question mark ears, isolated, 612798 |
| EDN1 | 100.0% | 100.0% | 100.0% | 99.1% | Auriculocondylar syndrome 3, 615706 |
| EDN3 | 100.0% | 100.0% | 100.0% | 100.0% | Waardenburg syndrome, type 4B, 613265 |
| | | | | | ?ABCD syndrome, 600501 |
| EDNRB | 100.0% | 100.0% | 100.0% | 99.0% | Waardenburg syndrome, type 4A, 277580 |
| EFEMP2 | 100.0% | 100.0% | 100.0% | 99.9% | Cutis laxa, autosomal recessive, type IB, 614437 |
| EFL1 | 100.0% | 100.0% | 100.0% | 99.6% | Shwachman-Diamond syndrome 2, 617941 |
| EGF | 100.0% | 100.0% | 100.0% | 99.3% | ?Hypomagnesemia 4, renal, 611718 |
| | | | | | ?Inflammatory skin and bowel disease, neonatal, 2, 616069 |
| | | | | | Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 |
| EGFR | 100.0% | 100.0% | 100.0% | 99.6% | Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 |
| | | | | | Dejerine-Sottas disease, 145900 |
| | | | | | Charcot-Marie-Tooth disease, type 1D, 607678 |
| EGR2 | 100.0% | 100.0% | 100.0% | 99.6% | Hypomyelinating neuropathy, congenital, 1, 605253 |
| EIF2AK3 | 100.0% | 100.0% | 100.0% | 99.2% | Wolcott-Rallison syndrome, 226980 |
| EIF2AK4 | 100.0% | 100.0% | 100.0% | 99.3% | Pulmonary venoocclusive disease 2, 234810 |
| EIF2B1 | 100.0% | 100.0% | 100.0% | 99.8% | Leukoencephalopathy with vanishing white matter 1, w/wo ovarian failure, 603896 |
| EIF2B2 | 100.0% | 100.0% | 100.0% | 99.5% | Leukoencephalopathy with vanishing white matter 2, w/wo ovarian failure, 620312 |
| EIF2B3 | 100.0% | 100.0% | 100.0% | 99.0% | Leukoencephalopathy with vanishing white matter 3, w/wo ovarian failure, 620313 |
| EIF2B4 | 100.0% | 100.0% | 100.0% | 99.7% | Leukoencephalopathy with vanishing white matter 4, w/wo ovarian failure, 620314 |
| EIF2B5 | 100.0% | 100.0% | 100.0% | 99.4% | Leukoencephalopathy with vanishing white matter 5, w/wo ovarian failure, 620315 |
| EIF3F | 100.0% | 100.0% | 100.0% | 99.7% | Intellectual developmental disorder, autosomal recessive 67, 618295 |
| EIF4A3 | 100.0% | 100.0% | 100.0% | 99.6% | Robin sequence with cleft mandible and limb anomalies, 268305 |
| ELAC2 | 100.0% | 100.0% | 100.0% | 99.7% | Combined oxidative phosphorylation deficiency 17, 615440 |
| ELMO2 | 100.0% | 100.0% | 100.0% | 99.0% | Vascular malformation, primary intraosseous, 606893 |
| | | | | | Spinocerebellar ataxia 34, 133190 |
| | | | | | Stargardt disease 3, 600110 |
| ELOVL4 | 100.0% | 100.0% | 100.0% | 99.0% | Ichthyosis, spastic quadriplegia, and impaired intellectual development, 614457 |
| ELP1 | 100.0% | 100.0% | 100.0% | 99.6% | Dysautonomia, familial, 223900 |
| ELP2 | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 58, 617270 |
| EMC1 | 100.0% | 100.0% | 100.0% | 99.2% | Cerebellar atrophy, visual impairment, and psychomotor retardation, 616875 |
| EMG1 | 100.0% | 100.0% | 100.0% | 99.7% | Bowen-Conradi syndrome, 211180 |
| EML1 | 100.0% | 100.0% | 100.0% | 99.4% | Band heterotopia, 600348 |
| EMP2 | 100.0% | 100.0% | 100.0% | 99.4% | Nephrotic syndrome, type 10, 615861 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| ENAM | 100.0% | 100.0% | 100.0% | 98.6% | Amelogenesis imperfecta, type IC, 204650 Amelogenesis imperfecta, type IB, 104500 |
| ENO3 | 100.0% | 100.0% | 100.0% | 99.9% | Glycogen storage disease XIII, 612932 |
| ENPP1 | 100.0% | 99.7% | 100.0% | 99.3% | Hypophosphatemic rickets, autosomal recessive, 2, 613312 Arterial calcification, generalized, of infancy, 1, 208000 Cole disease, 615522 |
| ENTPD1 | 100.0% | 100.0% | 100.0% | 99.5% | Spastic paraplegia 64, autosomal recessive, 615683 |
| EOGT | 98.1% | 94.0% | 100.0% | 99.4% | Adams-Oliver syndrome 4, 615297 |
| EPB41 | 100.0% | 100.0% | 100.0% | 99.2% | Elliptocytosis-1, 611804 |
| EPB42 | 100.0% | 100.0% | 100.0% | 99.7% | Spherocytosis, type 5, 612690 |
| EPCAM | 100.0% | 100.0% | 100.0% | 99.4% | Diarrhea 5, with tufting enteropathy, congenital, 613217 Lynch syndrome 8, 613244 |
| EPG5 | 100.0% | 100.0% | 100.0% | 99.2% | Vici syndrome, 242840 |
| EPHX1 | 100.0% | 100.0% | 100.0% | 99.7% | No OMIM disease ID |
| EPM2A | 100.0% | 100.0% | 100.0% | 97.2% | Epilepsy, progressive myoclonic 2A (Lafora), 254780 |
| EPO | 100.0% | 100.0% | 100.0% | 99.4% | Erythrocytosis, familial, 5, 617907 ?Diamond-Blackfan anemia-like, 617911 |
| EPRS1 | 100.0% | 100.0% | 100.0% | 99.2% | Leukodystrophy, hypomyelinating, 15, 617951 |
| EPS8L2 | 100.0% | 100.0% | 100.0% | 99.1% | Deafness autosomal recessive 106, 617637 |
| ERAL1 | 100.0% | 100.0% | 100.0% | 99.7% | Perrault syndrome 6, 617565 |
| ERBB3 | 100.0% | 100.0% | 100.0% | 99.6% | ?Lethal congenital contractural syndrome 2, 607598 Visceral neuropathy, familial, 1, autosomal recessive, 243180 |
| ERCC1 | 100.0% | 100.0% | 100.0% | 99.5% | Cerebrooculofacioskeletal syndrome 4, 610758 |
| ERCC2 | 100.0% | 100.0% | 100.0% | 99.7% | Xeroderma pigmentosum, group D, 278730 Trichothiodystrophy 1, photosensitive, 601675 ?Cerebrooculofacioskeletal syndrome 2, 610756 |
| ERCC3 | 100.0% | 100.0% | 100.0% | 99.5% | Trichothiodystrophy 2, photosensitive, 616390 Xeroderma pigmentosum, group B, 610651 |
| ERCC4 | 100.0% | 100.0% | 100.0% | 98.8% | Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 XFE progeroid syndrome, 610965 Xeroderma pigmentosum, group F, 278760 Fanconi anemia, complementation group Q, 615272 |
| ERCC5 | 100.0% | 100.0% | 100.0% | 99.3% | Xeroderma pigmentosum, group G, 278780 Cerebrooculofacioskeletal syndrome 3, 616570 Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| | | | | | UV-sensitive syndrome 1, 600630 Cerebrooculofacioskeletal syndrome 1, 214150 ?De Sanctis-Cacchione syndrome, 278800 Cockayne syndrome, type B, 133540 Premature ovarian failure 11, 616946 |
| ERCC6 | 100.0% | 100.0% | 100.0% | 99.4% | |
| ERCC6L2 | 100.0% | 99.9% | 100.0% | 99.1% | Bone marrow failure syndrome 2, 615715 |
| | | | | | UV-sensitive syndrome 2, 614621 Cockayne syndrome, type A, 216400 |
| ERCC8 | 100.0% | 100.0% | 100.0% | 99.4% | |
| ERLIN1 | 100.0% | 100.0% | 100.0% | 99.9% | Spastic paraplegia 62, 615681 |
| ERLIN2 | 100.0% | 100.0% | 100.0% | 99.4% | Spastic paraplegia 18, autosomal recessive, 611225 |
| | | | | | Juberg-Hayward syndrome, 216100 Roberts-SC phocomelia syndrome, 268300 |
| ESCO2 | 100.0% | 100.0% | 100.0% | 98.8% | |
| | | | | | Deafness, neurosensory, without vestibular involvement, autosomal dominant, 609006 Deafness, autosomal recessive 36, 609006 ?Usher syndrome, type 1M, 618632 |
| ESPN | 100.0% | 100.0% | 100.0% | 99.1% | |
| | | | | | Breast cancer, somatic, 114480 Estrogen resistance, 615363 |
| ESR1 | 100.0% | 99.8% | 100.0% | 99.4% | |
| ESRRB | 100.0% | 100.0% | 100.0% | 99.9% | Deafness, autosomal recessive 35, 608565 |
| ETFA | 100.0% | 100.0% | 100.0% | 99.0% | Glutaric acidemia IIA, 231680 |
| ETFB | 100.0% | 100.0% | 100.0% | 99.9% | Glutaric acidemia IIB, 231680 |
| ETFDH | 100.0% | 100.0% | 100.0% | 99.1% | Glutaric acidemia IIC, 231680 |
| ETHE1 | 100.0% | 100.0% | 100.0% | 99.3% | Ethylmalonic encephalopathy, 602473 |
| | | | | | Ellis-van Creveld syndrome, 225500 ?Weyers acrofacial dysostosis, 193530 |
| EVC | 100.0% | 99.9% | 100.0% | 99.3% | |
| | | | | | Ellis-van Creveld syndrome, 225500 Weyers acrofacial dysostosis, 193530 |
| EVC2 | 100.0% | 100.0% | 100.0% | 99.5% | |
| EXOC6B | 100.0% | 100.0% | 100.0% | 99.3% | Spondyloepimetaphyseal dysplasia with joint laxity, type 3, 618395 |
| EXOSC2 | 100.0% | 100.0% | 100.0% | 99.2% | Short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763 |
| EXOSC3 | 100.0% | 100.0% | 100.0% | 99.8% | Pontocerebellar hypoplasia, type 1B, 614678 |
| EXOSC8 | 100.0% | 100.0% | 99.9% | 98.9% | Pontocerebellar hypoplasia, type 1C, 616081 |
| EXOSC9 | 100.0% | 100.0% | 100.0% | 99.3% | Pontocerebellar hypoplasia, type 1D, 618065 |
| EXPH5 | 100.0% | 100.0% | 100.0% | 99.1% | Epidermolysis bullosa simplex 4, localized or generalized intermediate, autosomal recessive, 615028 |
| | | | | | Seizures, scoliosis, and macrocephaly syndrome, 616682 Exostoses, multiple, type 2, 133701 |
| EXT2 | 100.0% | 100.0% | 100.0% | 99.6% | |
| EXTL3 | 100.0% | 100.0% | 100.0% | 99.9% | Immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| EYS | 100.0% | 99.9% | 100.0% | 99.4% | Retinitis pigmentosa 25, 602772 |
| F10 | 100.0% | 100.0% | 100.0% | 99.5% | Factor X deficiency, 227600 |
| F11 | 100.0% | 100.0% | 100.0% | 99.2% | Factor XI deficiency, autosomal dominant, 612416 Factor XI deficiency, autosomal recessive, 612416 |
| F12 | 100.0% | 100.0% | 100.0% | 99.9% | Angioedema, hereditary, 3, 610618 Factor XII deficiency, 234000 |
| F13A1 | 100.0% | 100.0% | 100.0% | 99.8% | Factor XIII A deficiency, 613225 |
| F13B | 99.8% | 98.6% | 100.0% | 99.7% | Factor XIII B deficiency, 613235 |
| F2 | 100.0% | 100.0% | 100.0% | 99.7% | Hypoprothrombinemia, 613679 Dysprothrombinemia, 613679 Thrombophilia 1 due to thrombin defect, 188050 |
| F5 | 100.0% | 100.0% | 100.0% | 99.1% | Thrombophilia 2 due to activated protein C resistance, 188055 Factor V deficiency, 227400 |
| F7 | 100.0% | 100.0% | 100.0% | 99.7% | Factor VII deficiency, 227500 |
| FA2H | 100.0% | 100.0% | 100.0% | 99.8% | Spastic paraplegia 35, autosomal recessive, 612319 |
| FADD | 100.0% | 100.0% | 100.0% | 99.2% | Immunodeficiency 90 with encephalopathy, functional hyposplenism, and hepatic dysfunction, 613759 |
| FAH | 100.0% | 100.0% | 100.0% | 99.5% | Tyrosinemia, type I, 276700 |
| FAM126A | 100.0% | 100.0% | 100.0% | 99.7% | Leukodystrophy, hypomyelinating, 5, 610532 |
| FAM161A | 100.0% | 100.0% | 100.0% | 98.9% | Retinitis pigmentosa 28, 606068 |
| FAM20A | 100.0% | 100.0% | 100.0% | 99.5% | Amelogenesis imperfecta, type IG (enamel-renal syndrome), 204690 |
| FAM20C | 100.0% | 100.0% | 100.0% | 99.7% | Raine syndrome, 259775 |
| FAN1 | 100.0% | 100.0% | 99.8% | 98.0% | Interstitial nephritis, karyomegalic, 614817 |
| FANCA | 100.0% | 100.0% | 100.0% | 99.5% | Fanconi anemia, complementation group A, 227650 |
| FANCB | 100.0% | 100.0% | 98.0% | 71.0% | Fanconi anemia, complementation group B, 300514 |
| FANCC | 100.0% | 100.0% | 100.0% | 99.6% | Fanconi anemia, complementation group C, 227645 |
| FANCD2 | 100.0% | 100.0% | 100.0% | 99.1% | Fanconi anemia, complementation group D2, 227646 |
| FANCE | 100.0% | 100.0% | 100.0% | 99.6% | Fanconi anemia, complementation group E, 600901 |
| FANCF | 100.0% | 100.0% | 100.0% | 99.3% | Fanconi anemia, complementation group F, 603467 |
| FANCG | 100.0% | 100.0% | 100.0% | 98.4% | Fanconi anemia, complementation group G, 614082 |
| FANCI | 100.0% | 100.0% | 100.0% | 99.2% | Fanconi anemia, complementation group I, 609053 |
| FANCL | 100.0% | 100.0% | 100.0% | 99.3% | Fanconi anemia, complementation group L, 614083 |
| FAR1 | 100.0% | 100.0% | 100.0% | 99.6% | Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 Cataracts, spastic paraparesis, and speech delay, 619338 |
| FARS2 | 100.0% | 100.0% | 100.0% | 99.4% | Combined oxidative phosphorylation deficiency 14, 614946 Spastic paraplegia 77, autosomal recessive, 617046 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| FARSB | 100.0% | 100.0% | 100.0% | 99.3% | Rajab interstitial lung disease with brain calcifications 1, 613658 |
| FASTKD2 | 100.0% | 100.0% | 100.0% | 98.4% | Combined oxidative phosphorylation deficiency 44, 618855 |
| FAT4 | 99.9% | 99.8% | 100.0% | 99.5% | Van Maldergem syndrome 2, 615546 Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 |
| FBLN5 | 91.8% | 91.8% | 100.0% | 99.6% | Cutis laxa, autosomal recessive, type IA, 219100 Charcot-Marie-Tooth disease, demyelinating, type 1H, 619764 Macular degeneration, age-related, 3, 608895 Neuropathy, hereditary, w/wo age-related macular degeneration, 608895 ?Cutis laxa, autosomal dominant 2, 614434 |
| FBP1 | 100.0% | 100.0% | 100.0% | 99.7% | Fructose-1,6-bisphosphatase deficiency, 229700 |
| FBXL3 | 100.0% | 100.0% | 100.0% | 99.6% | Intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220 |
| FBXL4 | 100.0% | 100.0% | 100.0% | 99.8% | Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 |
| FBXO31 | 100.0% | 100.0% | 100.0% | 99.5% | ?Intellectual developmental disorder, autosomal recessive 45, 615979 |
| FBXO7 | 100.0% | 100.0% | 100.0% | 99.3% | Parkinson disease 15, autosomal recessive, 260300 |
| FCGR3A | 100.0% | 100.0% | 100.0% | 99.2% | Immunodeficiency 20, 615707 |
| FCN3 | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency due to ficolin 3 deficiency, 613860 |
| FCSK | 100.0% | 100.0% | 100.0% | 99.9% | Congenital disorder of glycosylation with defective fucosylation 2, 618324 |
| FDFT1 | 100.0% | 100.0% | 100.0% | 99.4% | Squalene synthase deficiency, 618156 |
| FDX2 | 100.0% | 100.0% | 100.0% | 99.2% | Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy, 251900 |
| FDXR | 100.0% | 100.0% | 100.0% | 99.8% | Auditory neuropathy and optic atrophy, 617717 |
| FECH | 100.0% | 100.0% | 100.0% | 99.6% | Protoporphyrinemia, erythropoietic, 1, 177000 |
| FERMT1 | 100.0% | 100.0% | 100.0% | 99.2% | Kindler syndrome, 173650 |
| FERMT3 | 100.0% | 100.0% | 100.0% | 99.6% | Leukocyte adhesion deficiency, type III, 612840 |
| FEZF1 | 100.0% | 100.0% | 100.0% | 99.0% | Hypogonadotropic hypogonadism 22, w/wo anosmia, 616030 |
| FGA | 100.0% | 100.0% | 100.0% | 99.0% | Hypodysfibrinogenemia, congenital, 616004 Dysfibrinogenemia, congenital, 616004 Amyloidosis, familial visceral, 105200 Afibrinogenemia, congenital, 202400 |
| FGB | 100.0% | 100.0% | 100.0% | 99.5% | Hypofibrinogenemia, congenital, 202400 Dysfibrinogenemia, congenital, 616004 Afibrinogenemia, congenital, 202400 |
| FGD4 | 100.0% | 100.0% | 100.0% | 99.0% | Charcot-Marie-Tooth disease, type 4H, 609311 |
| FGF20 | 100.0% | 100.0% | 100.0% | 99.8% | ?Renal hypodysplasia/aplasia 2, 615721 |
| FGF23 | 100.0% | 100.0% | 99.9% | 99.6% | Tumoral calcinosis, hyperphosphatemic, familial, 2, 617993 Hypophosphatemic rickets, autosomal dominant, 193100 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| FGF3 | 100.0% | 100.0% | 100.0% | 98.8% | Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 |
| | | | | | Dysfibrinogenemia, congenital, 616004 Hypodysfibrinogenemia, 616004 Hypofibrinogenemia, congenital, 202400 |
| FGG | 100.0% | 100.0% | 100.0% | 99.3% | Afibrinogenemia, congenital, 202400 |
| | | | | | Leiomyomatosis and renal cell cancer, 150800 |
| FH | 100.0% | 100.0% | 100.0% | 99.2% | Fumarase deficiency, 606812 |
| FIBP | 100.0% | 100.0% | 100.0% | 99.8% | Thauvin-Robinet-Faivre syndrome, 617107 |
| | | | | | Yunis-Varon syndrome, 216340 ?Polymicrogyria, bilateral temporooccipital, 612691 Amyotrophic lateral sclerosis 11, 612577 |
| FIG4 | 100.0% | 100.0% | 100.0% | 99.5% | Charcot-Marie-Tooth disease, type 4J, 611228 |
| FITM2 | 100.0% | 100.0% | 100.0% | 99.5% | Siddiqi syndrome, 618635 |
| | | | | | Osteogenesis imperfecta, type XI, 610968 |
| FKBP10 | 100.0% | 100.0% | 100.0% | 99.5% | Bruck syndrome 1, 259450 |
| FKBP14 | 100.0% | 100.0% | 100.0% | 99.8% | Ehlers-Danlos syndrome, kyphoscoliotic type, 2, 614557 |
| | | | | | Muscular dystrophy-dystroglycanopathy (congenital w/wo impaired intellectual development), type B, 5, 606612 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 |
| FKRP | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 |
| | | | | | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 Cardiomyopathy, dilated, 1X, 611615 |
| FKTN | 100.0% | 100.0% | 100.0% | 99.3% | Muscular dystrophy-dystroglycanopathy (congenital without impaired intellectual development), type B, 4, 613152 |
| FLAD1 | 100.0% | 100.0% | 100.0% | 99.8% | Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency, 255100 |
| | | | | | Larsen syndrome, 150250 Atelosteogenesis, type I, 108720 Atelosteogenesis, type III, 108721 Spondylocarpotarsal synostosis syndrome, 272460 |
| FLNB | 100.0% | 100.0% | 100.0% | 99.6% | Boomerang dysplasia, 112310 |
| FLVCR1 | 100.0% | 100.0% | 100.0% | 99.7% | Ataxia, posterior column, with retinitis pigmentosa, 609033 |
| FLVCR2 | 100.0% | 100.0% | 100.0% | 99.6% | Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| FMN2 | 100.0% | 99.8% | 99.4% | 93.8% | Intellectual developmental disorder, autosomal recessive 47, 616193 |
| FMO3 | 100.0% | 100.0% | 100.0% | 99.9% | Trimethylaminuria, 602079 |
| FOLR1 | 100.0% | 100.0% | 100.0% | 99.9% | Neurodegeneration due to cerebral folate transport deficiency, 613068 |
| FOXE1 | 100.0% | 100.0% | 100.0% | 99.2% | Bamforth-Lazarus syndrome, 241850 |
| FOXE3 | 100.0% | 99.4% | 100.0% | 98.8% | Anterior segment dysgenesis 2, multiple subtypes, 610256 Cataract 34, multiple types, 612968 |
| FOXI1 | 100.0% | 100.0% | 100.0% | 99.8% | Enlarged vestibular aqueduct, 600791 |
| FOXN1 | 100.0% | 100.0% | 100.0% | 99.7% | T-cell lymphopenia, infantile, w/wo nail dystrophy, autosomal dominant, 618806 T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 |
| FOXRED1 | 100.0% | 100.0% | 100.0% | 99.4% | Mitochondrial complex I deficiency, nuclear type 19, 618241 |
| FRAS1 | 100.0% | 99.9% | 100.0% | 99.6% | Fraser syndrome 1, 219000 |
| FREM1 | 100.0% | 100.0% | 100.0% | 99.6% | Manitoba oculotrichoanal syndrome, 248450 Bifid nose w/wo anorectal and renal anomalies, 608980 Trigonocephaly 2, 614485 |
| FREM2 | 99.9% | 99.7% | 100.0% | 99.6% | Fraser syndrome 2, 617666 Cryptophthalmos, unilateral or bilateral, isolated, 123570 |
| FRRS1L | 100.0% | 100.0% | 100.0% | 96.7% | Developmental and epileptic encephalopathy 37, 616981 |
| FSHB | 98.7% | 98.0% | 100.0% | 100.0% | Hypogonadotropic hypogonadism 24 without anosmia, 229070 |
| FSHR | 100.0% | 99.9% | 100.0% | 99.7% | Ovarian response to FSH stimulation, 276400 Ovarian hyperstimulation syndrome, 608115 Ovarian dysgenesis 1, 233300 |
| FTCD | 100.0% | 100.0% | 99.9% | 99.1% | Glutamate formiminotransferase deficiency, 229100 |
| FTO | 94.5% | 94.5% | 100.0% | 99.4% | Growth retardation, developmental delay, facial dysmorphism, 612938 |
| FUCA1 | 100.0% | 100.0% | 100.0% | 99.4% | Fucosidosis, 230000 |
| FUT8 | 100.0% | 99.8% | 100.0% | 99.3% | Congenital disorder of glycosylation with defective fucosylation 1, 618005 |
| FXN | 100.0% | 100.0% | 100.0% | 99.0% | Friedreich ataxia with retained reflexes, 229300 Friedreich ataxia, 229300 |
| FYCO1 | 100.0% | 100.0% | 100.0% | 99.8% | Cataract 18, autosomal recessive, 610019 |
| FZD6 | 100.0% | 100.0% | 100.0% | 99.5% | Nail disorder, nonsyndromic congenital, 1, 161050 |
| G6PC | 100.0% | 100.0% | 100.0% | 99.5% | Glycogen storage disease Ia, 232200 |
| G6PC3 | 100.0% | 100.0% | 100.0% | 99.8% | Dursun syndrome, 612541 Neutropenia, severe congenital 4, autosomal recessive, 612541 |
| GAA | 100.0% | 100.0% | 100.0% | 100.0% | Glycogen storage disease II, 232300 |
| GAD1 | 100.0% | 100.0% | 100.0% | 99.3% | Developmental and epileptic encephalopathy 89, 619124 |
| GALC | 100.0% | 100.0% | 100.0% | 99.7% | Krabbe disease, 245200 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| GALE | 100.0% | 100.0% | 100.0% | 99.8% | Galactose epimerase deficiency, 230350 |
| GALK1 | 100.0% | 100.0% | 100.0% | 99.6% | Galactokinase deficiency with cataracts, 230200 |
| GALNS | 100.0% | 100.0% | 100.0% | 99.7% | Mucopolysaccharidosis IVA, 253000 |
| GALNT2 | 100.0% | 100.0% | 100.0% | 99.3% | Congenital disorder of glycosylation, type II, 618885 |
| GALNT3 | 100.0% | 100.0% | 100.0% | 98.8% | Tumoral calcinosis, hyperphosphatemic, familial, 1, 211900 |
| GALT | 100.0% | 100.0% | 100.0% | 99.6% | Galactosemia, 230400 |
| GAMT | 100.0% | 100.0% | 100.0% | 99.6% | Cerebral creatine deficiency syndrome 2, 612736 |
| GAN | 100.0% | 100.0% | 100.0% | 99.5% | Giant axonal neuropathy-1, 256850 |
| GAS8 | 100.0% | 100.0% | 100.0% | 99.8% | Ciliary dyskinesia, primary, 33, 616726 |
| GATM | 100.0% | 100.0% | 100.0% | 99.6% | Cerebral creatine deficiency syndrome 3, 612718 Fanconi renotubular syndrome 1, 134600 |
| GBA | 100.0% | 100.0% | 100.0% | 99.6% | Gaucher disease, type II, 230900 Gaucher disease, type IIIC, 231005 Gaucher disease, type III, 231000 Gaucher disease, type I, 230800 Gaucher disease, perinatal lethal, 608013 |
| GBA2 | 100.0% | 100.0% | 100.0% | 99.5% | Spastic paraplegia 46, autosomal recessive, 614409 |
| GBE1 | 100.0% | 99.9% | 100.0% | 99.4% | Glycogen storage disease IV, 232500 Polyglucosan body disease, adult form, 263570 |
| GCDH | 100.0% | 100.0% | 100.0% | 99.9% | Glutaricaciduria, type I, 231670 |
| GCH1 | 100.0% | 100.0% | 100.0% | 99.5% | Dystonia, DOPA-responsive, 128230 Hyperphenylalaninemia, BH4-deficient, B, 233910 |
| GCK | 100.0% | 100.0% | 100.0% | 99.7% | MODY, type II, 125851 Diabetes mellitus, permanent neonatal 1, 606176 Hyperinsulinemic hypoglycemia, familial, 3, 602485 Diabetes mellitus, noninsulin-dependent, late onset, 125853 |
| GCLC | 100.0% | 100.0% | 100.0% | 99.1% | Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 |
| GCNT2 | 100.0% | 100.0% | 100.0% | 98.7% | Adult i phenotype without cataract, 110800 Cataract 13 with adult i phenotype, 116700 |
| GCSH | 100.0% | 100.0% | 100.0% | 99.3% | Multiple mitochondrial dysfunctions syndrome 7, 620423 |
| GDAP1 | 100.0% | 100.0% | 100.0% | 99.3% | Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 Charcot-Marie-Tooth disease, axonal, type 2K, 607831 Charcot-Marie-Tooth disease, type 4A, 214400 |
| GDAP2 | 100.0% | 99.8% | 100.0% | 99.2% | Spinocerebellar ataxia, autosomal recessive 27, 618369 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| GDF1 | 100.0% | 100.0% | 100.0% | 99.9% | Congenital heart defects, multiple types, 6, 613854 Right atrial isomerism (Ivemark), 208530 |
| GDF5 | 100.0% | 100.0% | 100.0% | 99.8% | Acromesomelic dysplasia 2A, 200700 Acromesomelic dysplasia 2B, 228900 Multiple synostoses syndrome 2, 610017 Symphalangism, proximal, 1B, 615298 Brachydactyly, type A2, 112600 ?Acromesomelic dysplasia 2C, Hunter-Thompson type, 201250 Brachydactyly, type C, 113100 Brachydactyly, type A1, C, 615072 |
| GEMIN4 | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, 617913 |
| GFER | 100.0% | 100.0% | 100.0% | 99.8% | Myopathy, mitochondrial progressive, with congenital cataract and developmental delay, 613076 |
| GFM1 | 100.0% | 100.0% | 100.0% | 99.3% | Combined oxidative phosphorylation deficiency 1, 609060 |
| GFM2 | 100.0% | 100.0% | 100.0% | 99.3% | Combined oxidative phosphorylation deficiency 39, 618397 |
| GFPT1 | 100.0% | 100.0% | 100.0% | 99.6% | Myasthenia, congenital, 12, with tubular aggregates, 610542 |
| GGCX | 100.0% | 100.0% | 100.0% | 99.5% | Vitamin K-dependent clotting factors, combined deficiency of, 1, 277450 Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 |
| GGT1 | 100.0% | 100.0% | 100.0% | 99.2% | ?Glutathioninuria, 231950 |
| GH1 | 100.0% | 100.0% | 100.0% | 100.0% | Kowarski syndrome, 262650 Growth hormone deficiency, isolated, type II, 173100 Growth hormone deficiency, isolated, type IB, 612781 Growth hormone deficiency, isolated, type IA, 262400 |
| GHR | 99.8% | 99.8% | 99.8% | 98.8% | Laron dwarfism, 262500 Increased responsiveness to growth hormone, 604271 Growth hormone insensitivity, partial, 604271 |
| GHRHR | 100.0% | 100.0% | 100.0% | 99.4% | Growth hormone deficiency, isolated, type IV, 618157 |
| GHSR | 100.0% | 100.0% | 100.0% | 99.7% | Growth hormone deficiency, isolated partial, 615925 |
| GINS1 | 100.0% | 100.0% | 100.0% | 99.8% | Immunodeficiency 55, 617827 |
| GIPC3 | 100.0% | 100.0% | 100.0% | 98.9% | Deafness, autosomal recessive 15, 601869 |
| GJA1 | 100.0% | 100.0% | 100.0% | 99.3% | Erythrokeratoderma variabilis et progressiva 3, 617525 Craniometaphyseal dysplasia, autosomal recessive, 218400 Oculodentodigital dysplasia, 164200 Palmoplantar keratoderma with congenital alopecia, 104100 Syndactyly, type III, 186100 Oculodentodigital dysplasia, autosomal recessive, 257850 |

| | | | | | |
|-------|--------|--------|--------|-------|--|
| GJB2 | 100.0% | 100.0% | 100.0% | 99.7% | Keratoderma, palmoplantar, with deafness, 148350 Deafness, autosomal recessive 1A, 220290 Deafness, autosomal dominant 3A, 601544 Hystrix-like ichthyosis with deafness, 602540 Bart-Pumphrey syndrome, 149200 Keratitis-ichthyosis-deafness syndrome, 148210 Vohwinkel syndrome, 124500 |
| GJB6 | 100.0% | 100.0% | 100.0% | 99.8% | Ectodermal dysplasia 2, Clouston type, 129500 Deafness, autosomal dominant 3B, 612643 Deafness, autosomal recessive 1B, 612645 Deafness, digenic GJB2/GJB6, 220290 |
| GJC2 | 99.8% | 98.7% | 100.0% | 98.6% | Lymphatic malformation 3, 613480 ?Spastic paraplegia 44, autosomal recessive, 613206 Leukodystrophy, hypomyelinating, 2, 608804 |
| GLB1 | 100.0% | 100.0% | 100.0% | 99.6% | GM1-gangliosidosis, type I, 230500 GM1-gangliosidosis, type III, 230650 Mucopolysaccharidosis type IVB (Morquio), 253010 GM1-gangliosidosis, type II, 230600 |
| GLDC | 100.0% | 100.0% | 100.0% | 99.6% | Glycine encephalopathy1, 605899 |
| GLDN | 100.0% | 100.0% | 100.0% | 99.5% | Lethal congenital contracture syndrome 11, 617194 |
| GLE1 | 100.0% | 100.0% | 100.0% | 99.4% | Lethal congenital contracture syndrome 1, 253310 Congenital arthrogyriposis with anterior horn cell disease, 611890 |
| GLIS2 | 100.0% | 100.0% | 100.0% | 99.9% | Nephronophthisis 7, 611498 |
| GLIS3 | 100.0% | 100.0% | 100.0% | 99.4% | Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 |
| GLRA1 | 100.0% | 100.0% | 100.0% | 99.7% | Hyperekplexia 1, 149400 |
| GLRB | 100.0% | 100.0% | 100.0% | 99.2% | Hyperekplexia 2, 614619 |
| GLRX5 | 100.0% | 100.0% | 100.0% | 99.6% | Anemia, sideroblastic, 3, pyridoxine-refractory, 616860 Spasticity, childhood-onset, with hyperglycinemia, 616859 |
| GLS | 100.0% | 100.0% | 100.0% | 99.7% | Global developmental delay, progressive ataxia, and elevated glutamine, 618412 ?Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development, 618339 Developmental and epileptic encephalopathy 71, 618328 |
| GLUL | 100.0% | 100.0% | 100.0% | 99.8% | Glutamine deficiency, congenital, 610015 |
| GLYCK | 100.0% | 100.0% | 100.0% | 99.7% | D-glyceric aciduria, 220120 |
| GM2A | 100.0% | 100.0% | 100.0% | 99.8% | GM2-gangliosidosis, AB variant, 272750 |

| | | | | | |
|--------|--------|--------|--------|--------|---|
| GMPPA | 100.0% | 100.0% | 100.0% | 99.6% | Alacrima, achalasia, and impaired intellectual development syndrome, 615510 |
| | | | | | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 14, 615351 |
| GMPPB | 100.0% | 100.0% | 100.0% | 99.8% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 |
| GNAT2 | 100.0% | 100.0% | 100.0% | 99.4% | Achromatopsia 4, 613856 |
| GNB3 | 100.0% | 100.0% | 100.0% | 99.5% | Night blindness, congenital stationary, type 1H, 617024 |
| | | | | | Lodder-Merla syndrome, type 2, with developmental delay and w/wo cardiac arrhythmia, 617182 Lodder-Merla syndrome, type 1, with impaired intellectual development and cardiac arrhythmia, 617173 |
| GNB5 | 100.0% | 100.0% | 100.0% | 99.2% | Sialuria, 269921 |
| GNE | 100.0% | 100.0% | 100.0% | 99.6% | Nonaka myopathy, 605820 |
| GNMT | 100.0% | 100.0% | 100.0% | 98.5% | Glycine N-methyltransferase deficiency, 606664 |
| GNPAT | 100.0% | 100.0% | 100.0% | 99.2% | Rhizomelic chondrodysplasia punctata, type 2, 222765 |
| | | | | | Mucopolysaccharidosis III alpha/beta, 252600 Mucopolysaccharidosis II alpha/beta, 252500 |
| GNPTAB | 100.0% | 100.0% | 100.0% | 99.1% | Mucopolysaccharidosis III gamma, 252605 |
| GNPTG | 100.0% | 100.0% | 100.0% | 99.6% | Hypogonadotropic hypogonadism 7 without anosmia, 146110 |
| GNRHR | 100.0% | 100.0% | 100.0% | 99.8% | Mucopolysaccharidosis type IIID, 252940 |
| GNS | 100.0% | 100.0% | 100.0% | 99.9% | Geroderma osteodysplasticum, 231070 |
| GORAB | 100.0% | 100.0% | 100.0% | 99.2% | Epilepsy, progressive myoclonic 6, 614018 |
| GOSR2 | 100.0% | 100.0% | 100.0% | 99.4% | Muscular dystrophy, congenital, w/wo seizures, 620166 |
| | | | | | Bernard-Soulier syndrome, type A1 (recessive), 231200 Bernard-Soulier syndrome, type A2 (dominant), 153670 von Willebrand disease, platelet-type, 177820 |
| GP1BA | 100.0% | 100.0% | 99.6% | 95.9% | Giant platelet disorder, isolated, 231200 |
| GP1BB | 100.0% | 100.0% | 100.0% | 100.0% | Bernard-Soulier syndrome, type B, 231200 |
| GP6 | 99.1% | 96.2% | 100.0% | 99.9% | Bleeding disorder, platelet-type, 11, 614201 |
| GP9 | 100.0% | 100.0% | 100.0% | 99.8% | Bernard-Soulier syndrome, type C, 231200 |
| GPAA1 | 100.0% | 100.0% | 100.0% | 99.9% | Glycosylphosphatidylinositol biosynthesis defect 15, 617810 |
| GPC6 | 99.9% | 99.5% | 100.0% | 99.6% | Omodysplasia 1, 258315 |
| GPD1 | 100.0% | 100.0% | 100.0% | 99.6% | Hypertriglyceridemia, transient infantile, 614480 |
| GPHN | 100.0% | 99.9% | 100.0% | 99.3% | Molybdenum cofactor deficiency C, 615501 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| GPI | 100.0% | 100.0% | 100.0% | 99.6% | Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 |
| GPIHBP1 | 100.0% | 100.0% | 100.0% | 99.4% | Hyperlipoproteinemia, type 1D, 615947 |
| GPNMB | 95.1% | 95.1% | 100.0% | 99.5% | Amyloidosis, primary localized cutaneous, 3, 617920 |
| GPR179 | 100.0% | 100.0% | 100.0% | 99.5% | Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 |
| GPSM2 | 100.0% | 100.0% | 100.0% | 99.5% | Chudley-McCullough syndrome, 604213 |
| GPT2 | 100.0% | 100.0% | 100.0% | 99.8% | Neurodevelopmental disorder with microcephaly and spastic paraplegia, 616281 |
| GPX4 | 100.0% | 100.0% | 100.0% | 99.1% | Spondylometaphyseal dysplasia, Sedaghatian type, 250220 |
| GRAP | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal recessive 114, 618456 |
| GRHPR | 100.0% | 100.0% | 100.0% | 99.7% | Hyperoxaluria, primary, type II, 260000 |
| GRID2 | 99.9% | 99.9% | 100.0% | 99.6% | Spinocerebellar ataxia, autosomal recessive 18, 616204 |
| | | | | | Neurodevelopmental disorder with impaired language and ataxia and w/wo seizures, 619580 |
| GRIK2 | 95.7% | 95.5% | 100.0% | 99.4% | Intellectual developmental disorder, autosomal recessive 6, 611092 |
| | | | | | Neurodevelopmental disorder w/wo hyperkinetic movements and seizures, autosomal recessive, 617820 |
| | | | | | Developmental and epileptic encephalopathy 101, 619814 |
| GRIN1 | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder w/wo hyperkinetic movements and seizures, autosomal dominant, 614254 |
| GRIP1 | 100.0% | 100.0% | 100.0% | 99.4% | Fraser syndrome 3, 617667 |
| GRK1 | 100.0% | 100.0% | 100.0% | 99.9% | Oguchi disease-2, 613411 |
| | | | | | Spinocerebellar ataxia, autosomal recessive 13, 614831 |
| GRM1 | 100.0% | 100.0% | 100.0% | 99.6% | Spinocerebellar ataxia 44, 617691 |
| GRM6 | 100.0% | 100.0% | 99.9% | 99.5% | Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 |
| | | | | | Aphasia, primary progressive, 607485 |
| | | | | | Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 |
| GRN | 100.0% | 100.0% | 100.0% | 99.8% | Ceroid lipofuscinosis, neuronal, 11, 614706 |
| GRXCR1 | 99.9% | 99.3% | 100.0% | 99.6% | Deafness, autosomal recessive 25, 613285 |
| GSC | 100.0% | 100.0% | 100.0% | 99.3% | Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 |
| | | | | | Hemolytic anemia due to glutathione synthetase deficiency, 231900 |
| GSS | 100.0% | 100.0% | 100.0% | 99.7% | Glutathione synthetase deficiency, 266130 |
| GSX2 | 100.0% | 100.0% | 100.0% | 99.6% | Diencephalic-mesencephalic junction dysplasia syndrome 2, 618646 |
| GTF2E2 | 100.0% | 100.0% | 100.0% | 97.4% | Trichothiodystrophy 6, nonphotosensitive, 616943 |
| GTF2H5 | 70.4% | 70.3% | 100.0% | 99.5% | Trichothiodystrophy 3, photosensitive, 616395 |
| GTPBP2 | 100.0% | 100.0% | 100.0% | 99.3% | Jaberi-Elahi syndrome, 617988 |
| GTPBP3 | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 23, 616198 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| GUCY1A1 | 100.0% | 100.0% | 100.0% | 99.6% | Moyamoya 6 with achalasia, 615750 |
| GUCY2C | 100.0% | 100.0% | 100.0% | 99.1% | Diarrhea 6, 614616 Meconium ileus, 614665 |
| GUCY2D | 100.0% | 100.0% | 100.0% | 99.4% | Cone-rod dystrophy 6, 601777 ?Choroidal dystrophy, central areolar 1, 215500 Leber congenital amaurosis 1, 204000 Night blindness, congenital stationary, type 1I, 618555 |
| GUSB | 100.0% | 100.0% | 100.0% | 99.4% | Mucopolysaccharidosis VII, 253220 |
| GYG1 | 100.0% | 100.0% | 100.0% | 99.6% | ?Glycogen storage disease XV, 613507 Polyglucosan body myopathy 2, 616199 |
| GYS1 | 100.0% | 100.0% | 100.0% | 99.6% | Glycogen storage disease 0, muscle, 611556 |
| GYS2 | 100.0% | 100.0% | 100.0% | 99.5% | Glycogen storage disease 0, liver, 240600 |
| GZF1 | 100.0% | 100.0% | 100.0% | 99.9% | Joint laxity, short stature, and myopia, 617662 |
| H6PD | 100.0% | 100.0% | 100.0% | 99.9% | Cortisone reductase deficiency 1, 604931 |
| HAEO | 100.0% | 100.0% | 100.0% | 99.8% | Vertebral, cardiac, renal, and limb defects syndrome 1, 617660 |
| HACE1 | 100.0% | 100.0% | 100.0% | 99.2% | Spastic paraplegia and psychomotor retardation w/wo seizures, 616756 |
| HADH | 100.0% | 100.0% | 100.0% | 99.6% | Hyperinsulinemic hypoglycemia, familial, 4, 609975 3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 |
| HADHA | 100.0% | 100.0% | 100.0% | 99.3% | HELLP syndrome, maternal, of pregnancy, 609016 LCHAD deficiency, 609016 Mitochondrial trifunctional protein deficiency 1, 609015 Fatty liver, acute, of pregnancy, 609016 |
| HADHB | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial trifunctional protein deficiency 2, 620300 |
| HAMP | 100.0% | 100.0% | 100.0% | 97.7% | Hemochromatosis, type 2B, 613313 |
| HARS1 | 100.0% | 100.0% | 100.0% | 99.2% | Charcot-Marie-Tooth disease, axonal, type 2W, 616625 Usher syndrome type 3B, 614504 |
| HARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Perrault syndrome 2, 614926 |
| HAVCR2 | 100.0% | 100.0% | 100.0% | 99.7% | T-cell lymphoma, subcutaneous panniculitis-like, 618398 |
| HAX1 | 100.0% | 100.0% | 100.0% | 98.6% | Neutropenia, severe congenital 3, autosomal recessive, 610738 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| | | | | | Methemoglobinemia, beta type, 617971 Thalassemia-beta, dominant inclusion-body, 603902 Sickle cell disease, 603903 Thalassemia, beta, 613985 Delta-beta thalassemia, 141749 Hereditary persistence of fetal hemoglobin, 141749 Erythrocytosis, familial, 6, 617980 |
| HBB | 100.0% | 100.0% | 100.0% | 99.9% | Heinz body anemia, 140700 |
| HELLS | 100.0% | 100.0% | 100.0% | 98.8% | Immunodeficiency-centromeric instability-facial anomalies syndrome 4, 616911 |
| | | | | | Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, w/wo impaired intellectual development, 613926 |
| HEPACAM | 100.0% | 100.0% | 100.0% | 99.5% | |
| HERC1 | 100.0% | 100.0% | 100.0% | 99.7% | Macrocephaly, dysmorphic facies, and psychomotor retardation, 617011 |
| HERC2 | 100.0% | 99.9% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 38, 615516 |
| HES7 | 100.0% | 100.0% | 100.0% | 99.3% | Spondylocostal dysostosis 4, autosomal recessive, 613686 |
| | | | | | Pituitary hormone deficiency, combined, 5, 182230 Septooptic dysplasia, 182230 Growth hormone deficiency with pituitary anomalies, 182230 |
| HESX1 | 100.0% | 100.0% | 100.0% | 97.4% | |
| | | | | | GM2-gangliosidosis, several forms, 272800 Tay-Sachs disease, 272800 |
| HEXA | 100.0% | 100.0% | 100.0% | 99.8% | |
| HEXB | 100.0% | 100.0% | 100.0% | 99.0% | Sandhoff disease, infantile, juvenile, and adult forms, 268800 |
| HFM1 | 100.0% | 100.0% | 100.0% | 98.1% | Premature ovarian failure 9, 615724 |
| HGD | 100.0% | 99.7% | 100.0% | 99.5% | Alkaptonuria, 203500 |
| HGF | 100.0% | 100.0% | 100.0% | 99.2% | Deafness, autosomal recessive 39, 608265 |
| | | | | | Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 Retinitis pigmentosa 73, 616544 |
| HGSNAT | 92.4% | 92.4% | 100.0% | 99.6% | |
| HIBCH | 100.0% | 100.0% | 100.0% | 98.8% | 3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 |
| HIKESHI | 100.0% | 100.0% | 100.0% | 99.3% | Leukodystrophy, hypomyelinating, 13, 616881 |
| HINT1 | 100.0% | 100.0% | 100.0% | 99.4% | Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 |
| HJV | 100.0% | 100.0% | 100.0% | 99.6% | Hemochromatosis, type 2A, 602390 |
| | | | | | Retinitis pigmentosa 79, 617460 Neuropathy, hereditary motor and sensory, Russe type, 605285 Neurodevelopmental disorder with visual defects and brain anomalies, 618547 |
| HK1 | 100.0% | 100.0% | 100.0% | 99.6% | Hemolytic anemia due to hexokinase deficiency, 235700 |
| HLCS | 100.0% | 100.0% | 100.0% | 99.6% | Holocarboxylase synthetase deficiency, 253270 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| HMGCL | 100.0% | 100.0% | 100.0% | 99.3% | HMG-CoA lyase deficiency, 246450 |
| HMGCS2 | 100.0% | 100.0% | 100.0% | 99.2% | HMG-CoA synthase-2 deficiency, 605911 |
| HMOX1 | 100.0% | 100.0% | 100.0% | 99.8% | Heme oxygenase-1 deficiency, 614034 |
| HMX1 | 100.0% | 100.0% | 100.0% | 98.6% | Oculoauricular syndrome, 612109 |
| HNMT | 100.0% | 100.0% | 100.0% | 99.1% | Intellectual developmental disorder, autosomal recessive 51, 616739 |
| HOGA1 | 100.0% | 100.0% | 100.0% | 99.7% | Hyperoxaluria, primary, type III, 613616 |
| HOXA1 | 100.0% | 100.0% | 100.0% | 99.4% | Bosley-Salih-Alorainy syndrome, 601536 Athabaskan brainstem dysgenesis syndrome, 601536 |
| HOXA2 | 100.0% | 100.0% | 100.0% | 99.6% | Microtia w/wo hearing impairment (AD), 612290 ?Microtia, hearing impairment, and cleft palate (AR), 612290 |
| HOXB1 | 100.0% | 100.0% | 100.0% | 99.7% | Facial paresis, hereditary congenital, 3, 614744 |
| HOXC13 | 100.0% | 100.0% | 100.0% | 99.8% | Ectodermal dysplasia 9, hair/nail type, 614931 |
| HPCA | 100.0% | 100.0% | 99.9% | 98.1% | Dystonia 2, torsion, autosomal recessive, 224500 |
| HPD | 100.0% | 100.0% | 100.0% | 99.0% | Hawkinsinuria, 140350 Tyrosinemia, type III, 276710 |
| HPDL | 100.0% | 100.0% | 100.0% | 99.4% | Neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, 619026 Spastic paraplegia 83, autosomal recessive, 619027 |
| HPGD | 100.0% | 100.0% | 100.0% | 99.0% | ?Digital clubbing, isolated congenital, 119900 Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 Cranioosteoarthropathy, 259100 |
| HPS1 | 100.0% | 100.0% | 100.0% | 99.9% | Hermansky-Pudlak syndrome 1, 203300 |
| HPS3 | 100.0% | 100.0% | 100.0% | 99.2% | Hermansky-Pudlak syndrome 3, 614072 |
| HPS4 | 100.0% | 100.0% | 100.0% | 99.7% | Hermansky-Pudlak syndrome 4, 614073 |
| HPS5 | 100.0% | 100.0% | 100.0% | 99.6% | Hermansky-Pudlak syndrome 5, 614074 |
| HPS6 | 100.0% | 100.0% | 100.0% | 99.9% | Hermansky-Pudlak syndrome 6, 614075 |
| HPSE2 | 100.0% | 100.0% | 100.0% | 99.5% | Urofacial syndrome 1, 236730 |
| HR | 100.0% | 100.0% | 100.0% | 99.7% | Atrichia with papular lesions, 209500 Alopecia universalis, 203655 |
| HSD11B2 | 100.0% | 100.0% | 100.0% | 99.3% | Apparent mineralocorticoid excess, 218030 |
| HSD17B3 | 100.0% | 100.0% | 100.0% | 99.6% | Pseudohermaphroditism, male, with gynecomastia, 264300 |
| HSD17B4 | 96.6% | 96.6% | 100.0% | 99.3% | D-bifunctional protein deficiency, 261515 Perrault syndrome 1, 233400 |
| HSD3B2 | 99.6% | 99.4% | 100.0% | 99.7% | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency, 201810 |
| HSD3B7 | 100.0% | 100.0% | 100.0% | 100.0% | Bile acid synthesis defect, congenital, 1, 607765 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| HSPA9 | 100.0% | 100.0% | 100.0% | 99.4% | Even-plus syndrome, 616854 Anemia, sideroblastic, 4, 182170 |
| HSPD1 | 100.0% | 100.0% | 100.0% | 99.1% | Spastic paraplegia 13, autosomal dominant, 605280 Leukodystrophy, hypomyelinating, 4, 612233 |
| HSPG2 | 100.0% | 100.0% | 100.0% | 99.8% | Dyssegmental dysplasia, Silverman-Handmaker type, 224410 Schwartz-Jampel syndrome, type 1, 255800 |
| HTRA1 | 100.0% | 100.0% | 100.0% | 99.2% | CARASIL syndrome, 600142 Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2, 616779 |
| HTRA2 | 100.0% | 100.0% | 100.0% | 99.3% | 3-methylglutaconic aciduria, type VIII, 617248 |
| HYAL1 | 100.0% | 100.0% | 100.0% | 99.5% | Mucopolysaccharidosis type IX, 601492 |
| HYDIN | 100.0% | 100.0% | 100.0% | 99.3% | Ciliary dyskinesia, primary, 5, 608647 |
| HYLS1 | 100.0% | 100.0% | 100.0% | 99.9% | Hydrolethalus syndrome, 236680 |
| IARS1 | 100.0% | 100.0% | 100.0% | 99.4% | Growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093 |
| IARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 |
| IBA57 | 100.0% | 100.0% | 100.0% | 100.0% | Multiple mitochondrial dysfunctions syndrome 3, 615330 ?Spastic paraplegia 74, autosomal recessive, 616451 |
| ICOS | 100.0% | 100.0% | 100.0% | 98.0% | Immunodeficiency, common variable, 1, 607594 |
| IDH3B | 100.0% | 100.0% | 100.0% | 99.8% | Retinitis pigmentosa 46, 612572 |
| IDUA | 100.0% | 100.0% | 100.0% | 99.9% | Mucopolysaccharidosis Is, 607016 Mucopolysaccharidosis Ih/s, 607015 Mucopolysaccharidosis Ih, 607014 |
| IER3IP1 | 100.0% | 100.0% | 100.0% | 99.6% | Microcephaly, epilepsy, and diabetes syndrome, 614231 |
| IFNAR2 | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency 45, 616669 |
| IFNGR1 | 100.0% | 100.0% | 100.0% | 99.4% | Immunodeficiency 27A, mycobacteriosis, AR, 209950 Immunodeficiency 27B, mycobacteriosis, AD, 615978 |
| IFNGR2 | 100.0% | 100.0% | 100.0% | 98.8% | Immunodeficiency 28, mycobacteriosis, 614889 |
| IFT122 | 100.0% | 100.0% | 100.0% | 99.6% | Cranioectodermal dysplasia 1, 218330 |
| IFT140 | 100.0% | 100.0% | 100.0% | 99.6% | Short-rib thoracic dysplasia 9 w/wo polydactyly, 266920 Retinitis pigmentosa 80, 617781 |
| IFT172 | 100.0% | 100.0% | 100.0% | 99.4% | Retinitis pigmentosa 71, 616394 Bardet-Biedl syndrome 20, 619471 Short-rib thoracic dysplasia 10 w/wo polydactyly, 615630 |
| IFT27 | 100.0% | 100.0% | 100.0% | 99.4% | Bardet-Biedl syndrome 19, 615996 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| | | | | | ?Cranioectodermal dysplasia 3, 614099 ?Retinitis pigmentosa 81, 617871 |
| IFT43 | 100.0% | 100.0% | 100.0% | 99.6% | Short-rib thoracic dysplasia 18 with polydactyly, 617866 |
| IFT52 | 100.0% | 100.0% | 100.0% | 99.3% | Short-rib thoracic dysplasia 16 w/wo polydactyly, 617102 |
| IFT57 | 100.0% | 100.0% | 100.0% | 99.7% | ?Orofaciodigital syndrome XVIII, 617927 |
| | | | | | Bardet-Biedl syndrome 22, 617119 Spermatogenic failure 58, 619585 |
| IFT74 | 100.0% | 100.0% | 100.0% | 99.1% | Joubert syndrome 40, 619582 |
| IFT80 | 100.0% | 100.0% | 100.0% | 99.1% | Short-rib thoracic dysplasia 2 w/wo polydactyly, 611263 |
| IFT81 | 94.9% | 94.9% | 100.0% | 98.7% | Short-rib thoracic dysplasia 19 w/wo polydactyly, 617895 |
| IGF1 | 100.0% | 100.0% | 100.0% | 99.0% | Insulin-like growth factor I deficiency, 608747 |
| IGF1R | 100.0% | 100.0% | 100.0% | 99.7% | Insulin-like growth factor I, resistance to, 270450 |
| IGFALS | 100.0% | 100.0% | 100.0% | 100.0% | Acid-labile subunit, deficiency of, 615961 |
| IGFBP7 | 100.0% | 100.0% | 100.0% | 99.4% | Retinal arterial macroaneurysm with supra-valvular pulmonic stenosis, 614224 |
| IGHM | 100.0% | 100.0% | 100.0% | 99.9% | Agammaglobulinemia 1, 601495 |
| | | | | | Neuronopathy, distal hereditary motor, type VI, 604320 Charcot-Marie-Tooth disease, axonal, type 2S, 616155 |
| IGHMBP2 | 100.0% | 100.0% | 100.0% | 99.8% | |
| IGKC | 100.0% | 100.0% | 100.0% | 99.9% | Kappa light chain deficiency, 614102 |
| IGLL1 | 100.0% | 100.0% | 100.0% | 99.8% | Agammaglobulinemia 2, 613500 |
| | | | | | Acrocapitofemoral dysplasia, 607778 Brachydactyly, type A1, 112500 |
| IHH | 100.0% | 100.0% | 100.0% | 99.2% | |
| | | | | | Immunodeficiency 15B, 615592 Immunodeficiency 15A, 618204 |
| IKBKB | 100.0% | 100.0% | 100.0% | 98.8% | |
| IL10RA | 100.0% | 100.0% | 100.0% | 99.9% | Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 |
| IL10RB | 100.0% | 100.0% | 100.0% | 99.2% | Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 |
| IL11RA | 100.0% | 100.0% | 100.0% | 99.7% | Craniosynostosis and dental anomalies, 614188 |
| IL12B | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 29, mycobacteriosis, 614890 |
| IL12RB1 | 94.1% | 94.1% | 100.0% | 99.5% | Immunodeficiency 30, 614891 |
| IL17RA | 100.0% | 100.0% | 100.0% | 99.9% | Immunodeficiency 51, 613953 |
| IL17RC | 100.0% | 100.0% | 100.0% | 99.8% | Candidiasis, familial, 9, 616445 |
| | | | | | Chronic recurrent multifocal osteomyelitis 2, with periostitis and pustulosis, 612852 |
| IL1RN | 100.0% | 100.0% | 100.0% | 99.5% | Interleukin 1 receptor antagonist deficiency, 612852 |
| IL21R | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 56, 615207 |
| IL2RA | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 |
| IL2RB | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency 63 with lymphoproliferation and autoimmunity, 618495 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| IL36RN | 100.0% | 100.0% | 100.0% | 99.0% | Psoriasis 14, pustular, 614204 |
| | | | | | Stuve-Wiedemann syndrome 2, 619751 |
| | | | | | Hyper-IgE recurrent infection syndrome 4A, autosomal dominant, 619752 |
| | | | | | ?Immunodeficiency 94 with autoinflammation and dysmorphic facies, 619750 |
| IL6ST | 100.0% | 100.0% | 100.0% | 99.3% | Hyper-IgE recurrent infection syndrome 4B, autosomal recessive, 618523 |
| IL7R | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency 104, severe combined, 608971 |
| ILDR1 | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal recessive 42, 609646 |
| IMPA1 | 100.0% | 100.0% | 100.0% | 98.7% | Intellectual developmental disorder, autosomal recessive 59, 617323 |
| IMPAD1 | 100.0% | 100.0% | 100.0% | 99.9% | Chondrodysplasia with joint dislocations, GPAPP type, 614078 |
| | | | | | Retinitis pigmentosa 56, 613581 |
| IMPG2 | 100.0% | 100.0% | 100.0% | 99.1% | Macular dystrophy, vitelliform, 5, 616152 |
| | | | | | Joubert syndrome 1, 213300 |
| INPP5E | 100.0% | 100.0% | 100.0% | 99.7% | Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 |
| INPP5K | 100.0% | 100.0% | 100.0% | 99.6% | Muscular dystrophy, congenital, with cataracts and intellectual disability, 617404 |
| INPPL1 | 100.0% | 100.0% | 100.0% | 99.8% | Opsismodysplasia, 258480 |
| | | | | | Rabson-Mendenhall syndrome, 262190 |
| | | | | | Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 |
| | | | | | Donohue syndrome, 246200 |
| INSR | 100.0% | 100.0% | 100.0% | 99.5% | Hyperinsulinemic hypoglycemia, familial, 5, 609968 |
| INTS1 | 100.0% | 100.0% | 100.0% | 99.8% | Neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, 618571 |
| INTS8 | 100.0% | 100.0% | 100.0% | 98.2% | ?Neurodevelopmental disorder with cerebellar hypoplasia and spasticity, 618572 |
| | | | | | ?Orofaciodigital syndrome XVII, 617926 |
| INTU | 100.0% | 100.0% | 100.0% | 98.7% | ?Short-rib thoracic dysplasia 20 with polydactyly, 617925 |
| INVS | 100.0% | 100.0% | 100.0% | 99.5% | Nephronophthisis 2, infantile, 602088 |
| IPO8 | 100.0% | 100.0% | 100.0% | 99.3% | VISS syndrome, 619472 |
| IQCB1 | 100.0% | 100.0% | 100.0% | 99.5% | Senior-Loken syndrome 5, 609254 |
| IQSEC1 | 100.0% | 99.9% | 100.0% | 98.6% | Intellectual developmental disorder with short stature and behavioral abnormalities, 618687 |
| IRAK4 | 100.0% | 100.0% | 100.0% | 98.9% | Immunodeficiency 67, 607676 |
| IREB2 | 100.0% | 100.0% | 100.0% | 99.5% | Neurodegeneration, early-onset, with choreoathetoid movements and microcytic anemia, 618451 |
| IRF7 | 100.0% | 100.0% | 100.0% | 99.7% | ?Immunodeficiency 39, 616345 |
| | | | | | Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 |
| IRF8 | 100.0% | 100.0% | 100.0% | 99.4% | Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 226990 |
| IRF9 | 100.0% | 100.0% | 100.0% | 99.8% | Immunodeficiency 65, susceptibility to viral infections, 618648 |
| IRX5 | 100.0% | 100.0% | 100.0% | 98.8% | Hamamy syndrome, 611174 |
| ISCA1 | 92.4% | 92.4% | 100.0% | 99.6% | Multiple mitochondrial dysfunctions syndrome 5, 617613 |

| | | | | | |
|--------|--------|--------|--------|--------|---|
| ISCA2 | 100.0% | 100.0% | 100.0% | 99.6% | Multiple mitochondrial dysfunctions syndrome 4, 616370 |
| ISCU | 100.0% | 100.0% | 100.0% | 99.7% | Myopathy with lactic acidosis, hereditary, 255125 |
| ISG15 | 100.0% | 100.0% | 100.0% | 100.0% | Immunodeficiency 38, 616126 |
| ITCH | 96.0% | 96.0% | 100.0% | 99.2% | Autoimmune disease, multisystem, with facial dysmorphism, 613385 |
| ITGA2B | 100.0% | 100.0% | 100.0% | 99.8% | Glanzmann thrombasthenia 1, 273800 Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 Thrombocytopenia, neonatal alloimmune, BAK antigen related, |
| ITGA3 | 100.0% | 100.0% | 100.0% | 99.8% | Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome, 614748 |
| ITGA6 | 100.0% | 100.0% | 100.0% | 99.5% | Epidermolysis bullosa, junctional 6, with pyloric atresia, 619817 |
| ITGA7 | 100.0% | 100.0% | 100.0% | 99.7% | Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 |
| ITGA8 | 100.0% | 100.0% | 100.0% | 99.3% | Renal hypodysplasia/aplasia 1, 191830 |
| ITGB2 | 100.0% | 100.0% | 100.0% | 99.9% | Leukocyte adhesion deficiency, 116920 |
| ITGB3 | 100.0% | 100.0% | 100.0% | 99.7% | Bleeding disorder, platelet-type, 24, autosomal dominant, 619271 Glanzmann thrombasthenia 2, 619267 Thrombocytopenia, neonatal alloimmune, Purpura, posttransfusion, |
| ITGB4 | 100.0% | 100.0% | 100.0% | 99.8% | Epidermolysis bullosa, junctional 5B, with pyloric atresia, 226730 Epidermolysis bullosa, junctional 5A, intermediate, 619816 |
| ITGB6 | 100.0% | 100.0% | 100.0% | 99.6% | Amelogenesis imperfecta, type IH, 616221 |
| ITK | 100.0% | 100.0% | 100.0% | 99.4% | Lymphoproliferative syndrome 1, 613011 |
| ITPA | 100.0% | 100.0% | 100.0% | 99.0% | Developmental and epileptic encephalopathy 35, 616647 |
| ITPR1 | 100.0% | 100.0% | 100.0% | 99.2% | Gillespie syndrome, 206700 Spinocerebellar ataxia 29, congenital nonprogressive, 117360 Spinocerebellar ataxia 15, 606658 |
| IVD | 100.0% | 100.0% | 100.0% | 99.8% | Isovaleric acidemia, 243500 |
| IYD | 100.0% | 100.0% | 100.0% | 98.7% | Thyroid dyshormonogenesis 4, 274800 |
| JAGN1 | 100.0% | 100.0% | 100.0% | 99.9% | Neutropenia, severe congenital, 6, autosomal recessive, 616022 |
| JAK3 | 100.0% | 100.0% | 100.0% | 99.6% | SCID, autosomal recessive, T-negative/B-positive type, 600802 |
| JAM2 | 92.2% | 92.0% | 100.0% | 99.2% | Basal ganglia calcification, idiopathic, 8, autosomal recessive, 618824 |
| JAM3 | 100.0% | 100.0% | 100.0% | 99.8% | Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 |
| JUP | 100.0% | 100.0% | 100.0% | 99.8% | Naxos disease, 601214 ?Arrhythmogenic right ventricular dysplasia 12, 611528 |
| KALRN | 100.0% | 100.0% | 100.0% | 99.5% | No OMIM disease ID |
| KANK2 | 100.0% | 100.0% | 100.0% | 99.8% | Nephrotic syndrome, type 16, 617783 Palmoplantar keratoderma and woolly hair, 616099 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| | | | | | Deafness, autosomal recessive 89, 613916 Leukoencephalopathy, progressive, infantile-onset, w/wo deafness, 619147 ?Charcot-Marie-Tooth disease, recessive intermediate, B, 613641 |
| KARS1 | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, congenital, and adult-onset progressive leukoencephalopathy, 619196 |
| KATNB1 | 100.0% | 100.0% | 100.0% | 99.9% | Lissencephaly 6, with microcephaly, 616212 |
| KCNE1 | 100.0% | 100.0% | 100.0% | 100.0% | Jervell and Lange-Nielsen syndrome 2, 612347 Long QT syndrome 5, 613695 |
| KCNJ1 | 100.0% | 100.0% | 100.0% | 99.4% | Bartter syndrome, type 2, 241200 |
| KCNJ10 | 100.0% | 100.0% | 100.0% | 99.6% | Enlarged vestibular aqueduct, digenic, 600791 SESAME syndrome, 612780 |
| KCNJ11 | 100.0% | 100.0% | 100.0% | 99.9% | Diabetes, permanent neonatal 2, w/wo neurologic features, 618856 Maturity-onset diabetes of the young, type 13, 616329 Diabetes mellitus, transient neonatal 3, 610582 Hyperinsulinemic hypoglycemia, familial, 2, 601820 |
| KCNJ13 | 100.0% | 100.0% | 100.0% | 99.6% | Snowflake vitreoretinal degeneration, 193230 Leber congenital amaurosis 16, 614186 |
| KCNMA1 | 100.0% | 99.9% | 100.0% | 99.2% | Paroxysmal nonkinesigenic dyskinesia, 3, w/wo generalized epilepsy, 609446 Cerebellar atrophy, developmental delay, and seizures, 617643 Liang-Wang syndrome, 618729 |
| KCNQ1 | 100.0% | 100.0% | 100.0% | 99.6% | Short QT syndrome 2, 609621 Atrial fibrillation, familial, 3, 607554 Long QT syndrome 1, 192500 Jervell and Lange-Nielsen syndrome, 220400 |
| KCNV2 | 100.0% | 100.0% | 100.0% | 100.0% | Retinal cone dystrophy 3B, 610356 |
| KCTD7 | 100.0% | 100.0% | 100.0% | 99.9% | Epilepsy, progressive myoclonic 3, w/wo intracellular inclusions, 611726 |
| KDM5B | 97.5% | 96.3% | 100.0% | 99.4% | Intellectual developmental disorder, autosomal recessive 65, 618109 |
| KERA | 100.0% | 100.0% | 100.0% | 98.2% | Cornea plana 2, autosomal recessive, 217300 |
| KHDC3L | 100.0% | 100.0% | 100.0% | 99.5% | Hydatidiform mole, recurrent, 2, 614293 |
| KIAA0556 | 100.0% | 100.0% | 100.0% | 99.6% | Joubert syndrome 26, 616784 |
| KIAA0586 | 95.6% | 95.5% | 100.0% | 99.0% | Short-rib thoracic dysplasia 14 with polydactyly, 616546 Joubert syndrome 23, 616490 |
| KIAA0753 | 100.0% | 100.0% | 100.0% | 99.4% | ?Orofaciodigital syndrome XV, 617127 ?Joubert syndrome 38, 619476 Short-rib thoracic dysplasia 21 without polydactyly, 619479 |
| KIAA1109 | 100.0% | 99.9% | 100.0% | 99.4% | Alkuraya-Kucinkas syndrome, 617822 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| KIAA1549 | 99.9% | 99.7% | 100.0% | 99.4% | Retinitis pigmentosa 86, 618613 |
| KIF14 | 100.0% | 100.0% | 100.0% | 98.9% | Microcephaly 20, primary, autosomal recessive, 617914 ?Meckel syndrome 12, 616258 |
| KIF1A | 100.0% | 100.0% | 100.0% | 99.8% | NESCAV syndrome, 614255 Neuropathy, hereditary sensory, type IIC, 614213 Spastic paraplegia 30, autosomal dominant, 610357 Spastic paraplegia 30, autosomal recessive, 610357 |
| KIF1C | 100.0% | 100.0% | 100.0% | 99.8% | Spastic ataxia 2, autosomal recessive, 611302 |
| KIF7 | 100.0% | 99.9% | 100.0% | 99.4% | Joubert syndrome 12, 200990 Acrocallosal syndrome, 200990 ?Hydroletharus syndrome 2, 614120 ?Al-Gazali-Bakalinova syndrome, 607131 |
| KIFBP | 95.6% | 95.6% | 100.0% | 99.4% | Goldberg-Shprintzen megacolon syndrome, 609460 |
| KISS1R | 100.0% | 100.0% | 100.0% | 99.9% | Hypogonadotropic hypogonadism 8 w/wo anosmia, 614837 ?Precocious puberty, central, 1, 176400 |
| KIZ | 100.0% | 100.0% | 100.0% | 99.2% | Retinitis pigmentosa 69, 615780 |
| KL | 99.8% | 99.2% | 99.9% | 98.7% | ?Tumoral calcinosis, hyperphosphatemic, familial, 3, 617994 |
| KLC2 | 100.0% | 100.0% | 100.0% | 100.0% | Spastic paraplegia, optic atrophy, and neuropathy, 609541 |
| KLHL3 | 100.0% | 100.0% | 100.0% | 99.8% | Pseudohypaldosteronism, type IID, 614495 |
| KLHL40 | 100.0% | 100.0% | 100.0% | 99.7% | Nemaline myopathy 8, autosomal recessive, 615348 |
| KLHL41 | 100.0% | 100.0% | 100.0% | 99.2% | Nemaline myopathy 9, 615731 |
| KLHL7 | 100.0% | 100.0% | 100.0% | 99.5% | Retinitis pigmentosa 42, 612943 PERCHING syndrome, 617055 |
| KLK4 | 100.0% | 100.0% | 100.0% | 99.6% | Amelogenesis imperfecta, type IIA1, 204700 |
| KLKB1 | 100.0% | 100.0% | 100.0% | 99.4% | Fletcher factor (prekallikrein) deficiency, 612423 |
| KMT2B | 99.8% | 99.5% | 99.9% | 98.2% | Intellectual developmental disorder, autosomal dominant 68, 619934 Dystonia 28, childhood-onset, 617284 |
| KNL1 | 98.7% | 98.7% | 100.0% | 99.4% | Microcephaly 4, primary, autosomal recessive, 604321 |
| KPTN | 100.0% | 100.0% | 99.9% | 99.2% | Intellectual developmental disorder, autosomal recessive 41, 615637 |
| KRT10 | 100.0% | 100.0% | 100.0% | 96.7% | Ichthyosis, annular epidermolytic 1, 607602 Epidermolytic hyperkeratosis 2, 620150 ?Ichthyosis histrix, Lambert type, 146600 Ichthyosis with confetti, 609165 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| | | | | | Epidermolysis bullosa simplex 1D, generalized, intermediate or severe, autosomal recessive, 601001 Epidermolysis bullosa simplex 1C, localized, 131800 Dermatopathia pigmentosa reticularis, 125595 Epidermolysis bullosa simplex 1A, generalized severe, 131760 Naegeli-Franceschetti-Jadassohn syndrome, 161000 |
| KRT14 | 100.0% | 100.0% | 100.0% | 99.7% | Epidermolysis bullosa simplex 1B, generalized intermediate, 131900 |
| KRT18 | 100.0% | 100.0% | 100.0% | 99.7% | Cirrhosis, cryptogenic, 215600 |
| | | | | | Epidermolysis bullosa simplex 2A, generalized severe, 619555 Dowling-Degos disease 1, 179850 Epidermolysis bullosa simplex 2F, with mottled pigmentation, 131960 Epidermolysis bullosa simplex 2D, generalized, intermediate or severe, autosomal recessive, 619599 Epidermolysis bullosa simplex 2B, generalized intermediate, 619588 Epidermolysis bullosa simplex 2C, localized, 619594 |
| KRT5 | 100.0% | 100.0% | 100.0% | 99.7% | Epidermolysis bullosa simplex 2E, with migratory circinate erythema, 609352 |
| KRT8 | 100.0% | 100.0% | 100.0% | 99.7% | No OMIM disease ID |
| KRT85 | 100.0% | 100.0% | 100.0% | 99.7% | Ectodermal dysplasia 4, hair/nail type, 602032 |
| KY | 100.0% | 100.0% | 100.0% | 99.7% | Myopathy, myofibrillar, 7, 617114 |
| | | | | | ?Hydroxykynureninuria, 236800 |
| KYNU | 100.0% | 100.0% | 100.0% | 98.6% | Vertebral, cardiac, renal, and limb defects syndrome 2, 617661 |
| L2HGDH | 100.0% | 100.0% | 100.0% | 99.4% | L-2-hydroxyglutaric aciduria, 236792 |
| LAMA1 | 100.0% | 100.0% | 100.0% | 99.6% | Poretti-Boltshauser syndrome, 615960 |
| | | | | | Muscular dystrophy, limb-girdle, autosomal recessive 23, 618138 |
| LAMA2 | 99.8% | 99.5% | 100.0% | 99.5% | Muscular dystrophy, congenital, merosin deficient or partially deficient, 607855 |
| | | | | | Epidermolysis bullosa, junctional 2A, intermediate, 619783 Epidermolysis bullosa, junctional 2C, laryngoonychocutaneous, 245660 |
| LAMA3 | 100.0% | 100.0% | 100.0% | 99.4% | Epidermolysis bullosa, junctional 2B, severe, 619784 |
| LAMB1 | 100.0% | 100.0% | 100.0% | 99.4% | Lissencephaly 5, 615191 |
| | | | | | Nephrotic syndrome, type 5, w/wo ocular abnormalities, 614199 |
| LAMB2 | 100.0% | 100.0% | 100.0% | 99.9% | Pierson syndrome, 609049 |
| | | | | | Epidermolysis bullosa, junctional 1B, severe, 226700 Epidermolysis bullosa, junctional 1A, intermediate, 226650 |
| LAMB3 | 100.0% | 100.0% | 100.0% | 99.7% | Amelogenesis imperfecta, type IA, 104530 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| LAMC2 | 100.0% | 100.0% | 100.0% | 99.7% | Epidermolysis bullosa, junctional 3B, severe, 619786 Epidermolysis bullosa, junctional 3A, intermediate, 619785 |
| LAMC3 | 100.0% | 100.0% | 100.0% | 99.6% | Cortical malformations, occipital, 614115 |
| LAMTOR2 | 100.0% | 100.0% | 100.0% | 99.9% | Immunodeficiency due to defect in MAPBP-interacting protein, 610798 |
| LARGE1 | 100.0% | 100.0% | 100.0% | 99.7% | Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 6, 608840 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 |
| LARP7 | 100.0% | 100.0% | 100.0% | 98.5% | Alazami syndrome, 615071 |
| LARS1 | 100.0% | 100.0% | 100.0% | 99.3% | ?Infantile liver failure syndrome 1, 615438 |
| LARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Perrault syndrome 4, 615300 Hydrops, lactic acidosis, and sideroblastic anemia, 617021 |
| LAT | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 52, 617514 |
| LBR | 100.0% | 100.0% | 100.0% | 99.3% | Pelger-Huet anomaly, 169400 ?Reynolds syndrome, 613471 Rhizomelic skeletal dysplasia w/wo Pelger-Huet anomaly, 618019 Greenberg skeletal dysplasia, 215140 |
| LCA5 | 100.0% | 100.0% | 100.0% | 98.6% | Leber congenital amaurosis 5, 604537 |
| LCAT | 100.0% | 100.0% | 100.0% | 99.8% | Fish-eye disease, 136120 Norum disease, 245900 |
| LCK | 100.0% | 100.0% | 100.0% | 99.8% | ?Immunodeficiency 22, 615758 |
| LCT | 100.0% | 100.0% | 100.0% | 99.6% | Lactase deficiency, congenital, 223000 |
| LDHA | 100.0% | 100.0% | 100.0% | 99.1% | Glycogen storage disease XI, 612933 |
| LDHD | 100.0% | 100.0% | 100.0% | 99.9% | D-lactic aciduria with susceptibility to gout, 245450 |
| LEMD2 | 100.0% | 100.0% | 100.0% | 99.0% | Marbach-Rustad progeroid syndrome, 619322 Cataract 46, juvenile-onset, 212500 |
| LEP | 100.0% | 100.0% | 100.0% | 99.4% | Obesity, morbid, due to leptin deficiency, 614962 |
| LEPR | 94.6% | 94.6% | 100.0% | 99.3% | Obesity, morbid, due to leptin receptor deficiency, 614963 |
| LFNG | 99.1% | 96.5% | 100.0% | 99.0% | Spondylocostal dysostosis 3, autosomal recessive, 609813 |
| LGI4 | 100.0% | 100.0% | 100.0% | 99.8% | Arthrogryposis multiplex congenita 1, neurogenic, with myelin defect, 617468 |
| LHB | 100.0% | 100.0% | 100.0% | 100.0% | Hypogonadotropic hypogonadism 23 w/wo anosmia, 228300 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| | | | | | Leydig cell adenoma, somatic, with precocious puberty, 176410 Leydig cell hypoplasia with pseudohermaphroditism, 238320 Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 Luteinizing hormone resistance, female, 238320 Precocious puberty, male, 176410 |
| LHCGR | 100.0% | 100.0% | 100.0% | 99.6% | |
| LHFPL5 | 100.0% | 100.0% | 100.0% | 99.6% | Deafness, autosomal recessive 67, 610265 |
| LHX3 | 100.0% | 100.0% | 100.0% | 99.8% | Pituitary hormone deficiency, combined, 3, 221750 |
| LIAS | 100.0% | 100.0% | 100.0% | 99.7% | Hyperglycinemia, lactic acidosis, and seizures, 614462 |
| LIFR | 100.0% | 100.0% | 100.0% | 98.9% | Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 |
| LIG4 | 100.0% | 100.0% | 100.0% | 99.4% | LIG4 syndrome, 606593 |
| LIM2 | 100.0% | 100.0% | 100.0% | 99.6% | Cataract 19, multiple types, 615277 |
| LIMS2 | 100.0% | 100.0% | 100.0% | 99.8% | ?Muscular dystrophy, autosomal recessive, with cardiomyopathy and triangular tongue, 616827 |
| LINGO1 | 100.0% | 100.0% | 100.0% | 100.0% | Intellectual developmental disorder, autosomal recessive 64, 618103 |
| LINS1 | 100.0% | 100.0% | 100.0% | 98.7% | Intellectual developmental disorder, autosomal recessive 27, 614340 |
| | | | | | Wolman disease, 620151 |
| LIPA | 96.6% | 95.2% | 100.0% | 99.1% | Cholesteryl ester storage disease, 278000 |
| LIPE | 100.0% | 100.0% | 100.0% | 99.7% | Lipodystrophy, familial partial, type 6, 615980 |
| | | | | | Hypotrichosis 7, 604379 |
| LIPH | 100.0% | 100.0% | 100.0% | 99.3% | Woolly hair, autosomal recessive 2 w/wo hypotrichosis, 604379 |
| LIPN | 100.0% | 100.0% | 100.0% | 99.5% | Ichthyosis, congenital, autosomal recessive 8, 613943 |
| LIPT1 | 100.0% | 100.0% | 100.0% | 98.6% | Lipoyltransferase 1 deficiency, 616299 |
| LIPT2 | 100.0% | 100.0% | 100.0% | 99.6% | Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, 617668 |
| LMAN1 | 100.0% | 100.0% | 100.0% | 99.2% | Combined factor V and VIII deficiency, 227300 |
| | | | | | ?Intellectual developmental disorder, autosomal dominant 69, 617863 |
| LMAN2L | 100.0% | 100.0% | 100.0% | 99.2% | ?Intellectual developmental disorder, autosomal recessive 52, 616887 |
| | | | | | Triphalangeal thumb, type I, 174500 Syndactyly, type IV, 186200 Laurin-Sandrow syndrome, 135750 Hypoplastic or aplastic tibia with polydactyly, 188740 Polydactyly, preaxial type II, 174500 Acheiropody, 200500 |
| LMBR1 | 99.9% | 99.4% | 100.0% | 99.4% | Triphalangeal thumb-polysyndactyly syndrome, 190605 |
| LMBRD1 | 100.0% | 99.8% | 100.0% | 98.6% | Methylmalonic aciduria and homocystinuria, cblF type, 277380 |
| LMF1 | 100.0% | 100.0% | 100.0% | 99.8% | Lipase deficiency, combined, 246650 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| | | | | | Mandibuloacral dysplasia, 248370 Heart-hand syndrome, Slovenian type, 610140 Cardiomyopathy, dilated, 1A, 115200 Emery-Dreifuss muscular dystrophy 3, autosomal recessive, 616516 Restrictive dermopathy 2, 619793 Charcot-Marie-Tooth disease, type 2B1, 605588 Emery-Dreifuss muscular dystrophy 2, autosomal dominant, 181350 Hutchinson-Gilford progeria, 176670 Lipodystrophy, familial partial, type 2, 151660 Muscular dystrophy, congenital, 613205 Malouf syndrome, 212112 |
| LMNA | 100.0% | 100.0% | 100.0% | 99.7% | |
| LMNB2 | 100.0% | 99.8% | 100.0% | 99.4% | Microcephaly 27, primary, autosomal dominant, 619180 ?Epilepsy, progressive myoclonic, 9, 616540 |
| LMOD3 | 100.0% | 100.0% | 100.0% | 98.7% | Nemaline myopathy 10, 616165 |
| LNPK | 93.1% | 93.1% | 100.0% | 99.0% | Neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, 618090 |
| LONP1 | 100.0% | 100.0% | 100.0% | 99.8% | CODAS syndrome, 600373 |
| LOXHD1 | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal recessive 77, 613079 |
| LPAR6 | 100.0% | 99.8% | 100.0% | 97.7% | Hypotrichosis 8, 278150 Woolly hair, autosomal recessive 1, w/wo hypotrichosis, 278150 |
| LPIN1 | 100.0% | 100.0% | 100.0% | 99.5% | Myoglobinuria, acute recurrent, autosomal recessive, 268200 |
| LPIN2 | 100.0% | 100.0% | 100.0% | 99.1% | Majeed syndrome, 609628 |
| LPL | 100.0% | 100.0% | 100.0% | 99.5% | Lipoprotein lipase deficiency, 238600 Combined hyperlipidemia, familial, 144250 |
| LRAT | 100.0% | 100.0% | 100.0% | 99.8% | Leber congenital amaurosis 14, 613341 Retinal dystrophy, early-onset severe, 613341 Retinitis pigmentosa, juvenile, 613341 |
| LRBA | 100.0% | 99.9% | 100.0% | 99.3% | Immunodeficiency, common variable, 8, with autoimmunity, 614700 |
| LRIG2 | 100.0% | 100.0% | 100.0% | 99.1% | Urofacial syndrome 2, 615112 |
| LRIT3 | 100.0% | 100.0% | 100.0% | 99.6% | Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 |
| LRMDA | 97.8% | 97.8% | 100.0% | 99.7% | Albinism, oculocutaneous, type VII, 615179 |
| LRP1 | 100.0% | 100.0% | 100.0% | 99.9% | ?Keratosi pilari atrophicans, 604093 |
| LRP2 | 100.0% | 100.0% | 100.0% | 99.6% | Donnai-Barrow syndrome, 222448 |
| LRP4 | 100.0% | 100.0% | 100.0% | 99.7% | ?Myasthenic syndrome, congenital, 17, 616304 Sclerosteosis 2, 614305 Cenani-Lenz syndactyly syndrome, 212780 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| LRP5 | 100.0% | 100.0% | 100.0% | 99.6% | Osteopetrosis, autosomal dominant 1, 607634 Polycystic liver disease 4 w/wo kidney cysts, 617875 Endosteal hyperostosis, 144750 Osteoporosis-pseudoglioma syndrome, 259770 Exudative vitreoretinopathy 4, 601813 |
| LRPAP1 | 100.0% | 100.0% | 100.0% | 99.8% | Myopia 23, autosomal recessive, 615431 |
| LRPPRC | 100.0% | 100.0% | 100.0% | 99.2% | Mitochondrial complex IV deficiency, nuclear type 5, (French-Canadian), 220111 |
| LRRC56 | 100.0% | 100.0% | 100.0% | 99.8% | Ciliary dyskinesia, primary, 39, 618254 |
| LRRC6 | 100.0% | 100.0% | 100.0% | 99.5% | Ciliary dyskinesia, primary, 19, 614935 |
| LRSAM1 | 100.0% | 100.0% | 100.0% | 99.8% | Charcot-Marie-Tooth disease, axonal, type 2P, 614436 |
| LRTOMT | 100.0% | 100.0% | 100.0% | 98.5% | Deafness, autosomal recessive 63, 611451 |
| LSS | 100.0% | 100.0% | 100.0% | 99.9% | Hypotrichosis 14, 618275 Cataract 44, 616509 Alopecia-intellectual disability syndrome 4, 618840 |
| LTBP1 | 100.0% | 100.0% | 100.0% | 99.5% | Cutis laxa, autosomal recessive, type IIE, 619451 |
| LTBP2 | 100.0% | 100.0% | 100.0% | 99.8% | Glaucoma 3, primary congenital, D, 613086 Microspherophakia and/or megalocornea, with ectopia lentis and w/wo secondary glaucoma, 251750 ?Weill-Marchesani syndrome 3, recessive, 614819 |
| LTBP3 | 100.0% | 100.0% | 100.0% | 99.5% | Dental anomalies and short stature, 601216 Geleophysic dysplasia 3, 617809 |
| LTBP4 | 100.0% | 100.0% | 100.0% | 99.7% | Cutis laxa, autosomal recessive, type IC, 613177 |
| LTC4S | 100.0% | 100.0% | 100.0% | 99.9% | No OMIM disease ID |
| LYRM7 | 100.0% | 100.0% | 100.0% | 98.7% | Mitochondrial complex III deficiency, nuclear type 8, 615838 |
| LYST | 100.0% | 99.8% | 100.0% | 99.4% | Chediak-Higashi syndrome, 214500 |
| LZTFL1 | 100.0% | 100.0% | 100.0% | 98.9% | Bardet-Biedl syndrome 17, 615994 |
| LZTR1 | 100.0% | 100.0% | 100.0% | 99.8% | Noonan syndrome 2, 605275 Noonan syndrome 10, 616564 |
| MAB21L1 | 100.0% | 100.0% | 100.0% | 97.7% | Cerebellar, ocular, craniofacial, and genital syndrome, 618479 |
| MAB21L2 | 100.0% | 100.0% | 100.0% | 100.0% | Microphthalmia/coloboma and skeletal dysplasia syndrome, 615877 |
| MADD | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with dysmorphic facies, impaired speech and hypotonia, 619005 DEEAH syndrome, 619004 |
| MAG | 100.0% | 100.0% | 100.0% | 99.3% | Spastic paraplegia 75, autosomal recessive, 616680 |
| MAGI2 | 98.9% | 97.3% | 99.9% | 96.8% | Nephrotic syndrome, type 15, 617609 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| MAK | 100.0% | 100.0% | 100.0% | 99.0% | Retinitis pigmentosa 62, 614181 |
| MALT1 | 100.0% | 100.0% | 100.0% | 99.4% | Immunodeficiency 12, 615468 |
| MAN1B1 | 100.0% | 100.0% | 100.0% | 99.9% | Rafiq syndrome, 614202 |
| MAN2B1 | 100.0% | 100.0% | 100.0% | 99.7% | Mannosidosis, alpha-, types I and II, 248500 |
| MANBA | 100.0% | 100.0% | 100.0% | 99.5% | Mannosidosis, beta, 248510 |
| MAP11 | 100.0% | 100.0% | 100.0% | 99.8% | ?Microcephaly 25, primary, autosomal recessive, 618351 |
| MAP3K20 | 100.0% | 100.0% | 100.0% | 99.1% | Centronuclear myopathy 6 with fiber-type disproportion, 617760 Split-foot malformation with mesoaxial polydactyly, 616890 |
| MAPKBP1 | 100.0% | 100.0% | 100.0% | 99.7% | Nephronophthisis 20, 617271 |
| MAPT | 100.0% | 100.0% | 100.0% | 99.6% | Supranuclear palsy, progressive, 601104 Supranuclear palsy, progressive atypical, 260540 Dementia, frontotemporal, w/wo parkinsonism, 600274 Pick disease, 172700 |
| MARS1 | 100.0% | 100.0% | 100.0% | 99.6% | Spastic paraplegia 70, autosomal recessive, 620323 Interstitial lung and liver disease, 615486 ?Trichothiodystrophy 9, nonphotosensitive, 619692 Charcot-Marie-Tooth disease, axonal, type 2U, 616280 |
| MARS2 | 100.0% | 100.0% | 100.0% | 99.9% | ?Combined oxidative phosphorylation deficiency 25, 616430 Spastic ataxia 3, autosomal recessive, 611390 |
| MARVELD2 | 100.0% | 100.0% | 100.0% | 99.6% | Deafness, autosomal recessive 49, 610153 |
| MASP1 | 100.0% | 100.0% | 100.0% | 99.8% | 3MC syndrome 1, 257920 |
| MAT1A | 100.0% | 100.0% | 100.0% | 99.9% | Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 Methionine adenosyltransferase deficiency, autosomal recessive, 250850 |
| MATN3 | 100.0% | 100.0% | 100.0% | 99.8% | Spondyloepimetaphyseal dysplasia, Borochowitz-Cormier-Daire type, 608728 Epiphyseal dysplasia, multiple, 5, 607078 |
| MBOAT7 | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 57, 617188 |
| MBTPS1 | 100.0% | 100.0% | 100.0% | 99.5% | ?Spondyloepiphyseal dysplasia, Kondo-Fu type, 618392 |
| MC2R | 100.0% | 100.0% | 100.0% | 99.5% | Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 |
| MCCC1 | 100.0% | 100.0% | 100.0% | 99.6% | 3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 |
| MCCC2 | 100.0% | 100.0% | 100.0% | 98.6% | 3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 |
| MCEE | 100.0% | 100.0% | 100.0% | 99.7% | Methylmalonyl-CoA epimerase deficiency, 251120 |
| MCFD2 | 100.0% | 100.0% | 100.0% | 99.6% | Factor V and factor VIII, combined deficiency of, 613625 |
| MCM3AP | 100.0% | 100.0% | 100.0% | 99.6% | Peripheral neuropathy, autosomal recessive, w/wo impaired intellectual development, 618124 |
| MCM4 | 95.3% | 95.3% | 100.0% | 99.3% | Immunodeficiency 54, 609981 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| MCM5 | 100.0% | 100.0% | 100.0% | 99.7% | ?Meier-Gorlin syndrome 8, 617564 |
| MCM9 | 100.0% | 100.0% | 100.0% | 99.1% | Ovarian dysgenesis 4, 616185 |
| MCOLN1 | 100.0% | 100.0% | 100.0% | 99.9% | Mucopolipidosis IV, 252650 |
| MCPH1 | 100.0% | 100.0% | 100.0% | 99.2% | Microcephaly 1, primary, autosomal recessive, 251200 |
| MDH2 | 100.0% | 100.0% | 100.0% | 99.3% | Developmental and epileptic encephalopathy 51, 617339 |
| MECR | 100.0% | 100.0% | 100.0% | 99.6% | Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282 |
| MED17 | 100.0% | 100.0% | 100.0% | 99.1% | Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 |
| MED23 | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 18, w/wo epilepsy, 614249 |
| MED25 | 100.0% | 100.0% | 100.0% | 99.7% | Basel-Vanagait-Smirin-Yosef syndrome, 616449 |
| MEFV | 96.1% | 96.1% | 100.0% | 99.7% | Neutrophilic dermatosis, acute febrile, 608068 Familial Mediterranean fever, AR, 249100 Familial Mediterranean fever, AD, 134610 |
| MEGF10 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital myopathy 10A, severe variant, 614399 Congenital myopathy 10B, mild variant, 620249 |
| MEGF8 | 100.0% | 100.0% | 99.9% | 99.0% | Carpenter syndrome 2, 614976 |
| MEOX1 | 100.0% | 100.0% | 100.0% | 99.5% | Klippel-Feil syndrome 2, 214300 |
| MERTK | 98.5% | 98.5% | 100.0% | 99.6% | Retinitis pigmentosa 38, 613862 |
| MESD | 100.0% | 100.0% | 100.0% | 98.9% | Osteogenesis imperfecta, type XX, 618644 |
| MESP2 | 100.0% | 99.7% | 100.0% | 99.8% | Spondylocostal dysostosis 2, autosomal recessive, 608681 |
| MET | 100.0% | 100.0% | 100.0% | 99.5% | Renal cell carcinoma, papillary, 1, familial and somatic, 605074 ?Arthrogyposis, distal, type 11, 620019 Hepatocellular carcinoma, childhood type, somatic, 114550 ?Deafness, autosomal recessive 97, 616705 |
| METTL23 | 100.0% | 100.0% | 100.0% | 99.6% | Intellectual developmental disorder, autosomal recessive 44, 615942 |
| MFF | 100.0% | 100.0% | 100.0% | 99.6% | Encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086 |
| MFN2 | 100.0% | 100.0% | 100.0% | 99.5% | Lipomatosis, multiple symmetric, w/wo peripheral neuropathy, 151800 Charcot-Marie-Tooth disease, axonal, type 2A2A, 609260 Charcot-Marie-Tooth disease, axonal, type 2A2B, 617087 Hereditary motor and sensory neuropathy VIA, 601152 |
| MFRP | 100.0% | 100.0% | 100.0% | 99.7% | Microphthalmia, isolated 5, 611040 Nanophthalmos 2, 609549 |
| MFSD2A | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain abnormalities, 616486 |
| MFSD8 | 100.0% | 100.0% | 100.0% | 99.6% | Macular dystrophy with central cone involvement, 616170 Ceroid lipofuscinosis, neuronal, 7, 610951 |
| MGAT2 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type IIa, 212066 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| MGME1 | 100.0% | 100.0% | 100.0% | 97.9% | Mitochondrial DNA depletion syndrome 11, 615084 |
| MGP | 100.0% | 100.0% | 100.0% | 99.1% | Keutel syndrome, 245150 |
| MICOS13 | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 37, 618329 |
| MICU1 | 100.0% | 99.9% | 100.0% | 99.7% | Myopathy with extrapyramidal signs, 615673 |
| MIPEP | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 31, 617228 |
| MITF | 99.9% | 99.7% | 100.0% | 99.5% | Waardenburg syndrome, type 2A, 193510 Tietz albinism-deafness syndrome, 103500 COMMAD syndrome, 617306 |
| MKKS | 100.0% | 100.0% | 100.0% | 99.6% | McKusick-Kaufman syndrome, 236700 Bardet-Biedl syndrome 6, 605231 |
| MKS1 | 100.0% | 100.0% | 100.0% | 99.7% | Bardet-Biedl syndrome 13, 615990 Meckel syndrome 1, 249000 Joubert syndrome 28, 617121 |
| MLC1 | 100.0% | 100.0% | 100.0% | 99.8% | Megalencephalic leukoencephalopathy with subcortical cysts 1, 604004 |
| MLH1 | 100.0% | 100.0% | 100.0% | 99.1% | Lynch syndrome 2, 609310 Muir-Torre syndrome, 158320 Mismatch repair cancer syndrome 1, 276300 |
| MLPH | 100.0% | 100.0% | 100.0% | 99.8% | GrisCELLI syndrome, type 3, 609227 |
| MLYCD | 100.0% | 100.0% | 100.0% | 99.9% | Malonyl-CoA decarboxylase deficiency, 248360 |
| MMAA | 100.0% | 100.0% | 100.0% | 99.1% | Methylmalonic aciduria, vitamin B12-responsive, cblA type, 251100 |
| MMAB | 100.0% | 100.0% | 100.0% | 99.0% | Methylmalonic aciduria, vitamin B12-responsive, cblB type, 251110 |
| MMACHC | 100.0% | 100.0% | 100.0% | 99.2% | Methylmalonic aciduria and homocystinuria, cblC type, 277400 |
| MMADHC | 89.3% | 89.3% | 100.0% | 98.9% | Methylmalonic aciduria, cblD type, variant 2, 277410 Methylmalonic aciduria and homocystinuria, cblD type, 277410 Homocystinuria, cblD type, variant 1, 277410 |
| MME | 97.6% | 97.4% | 100.0% | 98.9% | ?Spinocerebellar ataxia 43, 617018 Charcot-Marie-Tooth disease, axonal, type 2T, 617017 |
| MMP13 | 92.2% | 92.2% | 100.0% | 98.8% | ?Spondyloepimetaphyseal dysplasia, Missouri type, 602111 Metaphyseal anadysplasia 1, 602111 Metaphyseal dysplasia, Spahr type, 250400 |
| MMP14 | 100.0% | 100.0% | 100.0% | 99.7% | ?Winchester syndrome, 277950 |
| MMP2 | 100.0% | 100.0% | 100.0% | 99.7% | Multicentric osteolysis, nodulosis, and arthropathy, 259600 |
| MMP20 | 100.0% | 100.0% | 100.0% | 99.2% | Amelogenesis imperfecta, type IIA2, 612529 |
| MMP21 | 100.0% | 100.0% | 100.0% | 99.8% | Heterotaxy, visceral, 7, autosomal, 616749 |
| MMP9 | 100.0% | 100.0% | 100.0% | 99.8% | Metaphyseal anadysplasia 2, 613073 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| MMUT | 100.0% | 100.0% | 100.0% | 99.0% | Methylmalonic aciduria, mut(0) type, 251000 |
| MOCOS | 100.0% | 100.0% | 100.0% | 99.4% | Xanthinuria, type II, 603592 |
| MOCS1 | 100.0% | 100.0% | 100.0% | 99.4% | Molybdenum cofactor deficiency A, 252150 |
| MOCS2 | 100.0% | 100.0% | 100.0% | 99.7% | Molybdenum cofactor deficiency B, 252160 |
| MOGS | 100.0% | 100.0% | 100.0% | 99.9% | Congenital disorder of glycosylation, type IIb, 606056 |
| MPC1 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial pyruvate carrier deficiency, 614741 |
| MPDU1 | 100.0% | 100.0% | 100.0% | 97.7% | Congenital disorder of glycosylation, type If, 609180 |
| MPDZ | 99.5% | 99.1% | 100.0% | 99.3% | Hydrocephalus, congenital, 2, w/wo brain or eye anomalies, 615219 |
| MPI | 100.0% | 100.0% | 100.0% | 99.7% | Congenital disorder of glycosylation, type Ib, 602579 |
| | | | | | Myelofibrosis with myeloid metaplasia, somatic, 254450 |
| | | | | | Thrombocythemia 2, 601977 |
| MPL | 100.0% | 100.0% | 100.0% | 99.5% | Thrombocytopenia, congenital amegakaryocytic, 604498 |
| MPLKIP | 100.0% | 100.0% | 100.0% | 99.1% | Trichothiodystrophy 4, nonphotosensitive, 234050 |
| MPO | 100.0% | 100.0% | 100.0% | 99.7% | Myeloperoxidase deficiency, 254600 |
| | | | | | Charcot-Marie-Tooth disease, axonal, type 2EE, 618400 |
| MPV17 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 |
| | | | | | Charcot-Marie-Tooth disease, type 2I, 607677 |
| | | | | | Dejerine-Sottas disease, 145900 |
| | | | | | Charcot-Marie-Tooth disease, type 1B, 118200 |
| | | | | | Roussy-Levy syndrome, 180800 |
| | | | | | Charcot-Marie-Tooth disease, dominant intermediate D, 607791 |
| | | | | | Hypomyelinating neuropathy, congenital, 2, 618184 |
| MPZ | 100.0% | 100.0% | 100.0% | 99.6% | Charcot-Marie-Tooth disease, type 2J, 607736 |
| MPZL2 | 100.0% | 100.0% | 100.0% | 99.7% | Deafness, autosomal recessive 111, 618145 |
| MRAP | 100.0% | 100.0% | 100.0% | 99.9% | Glucocorticoid deficiency 2, 607398 |
| MRE11 | 100.0% | 100.0% | 100.0% | 98.9% | Ataxia-telangiectasia-like disorder 1, 604391 |
| MRM2 | 97.0% | 97.0% | 100.0% | 99.0% | ?Mitochondrial DNA depletion syndrome 17, 618567 |
| MRPL3 | 100.0% | 100.0% | 100.0% | 99.7% | Combined oxidative phosphorylation deficiency 9, 614582 |
| MRPL44 | 100.0% | 100.0% | 100.0% | 99.4% | Combined oxidative phosphorylation deficiency 16, 615395 |
| MRPS16 | 100.0% | 100.0% | 100.0% | 99.9% | Combined oxidative phosphorylation deficiency 2, 610498 |
| MRPS2 | 100.0% | 100.0% | 100.0% | 99.9% | Combined oxidative phosphorylation deficiency 36, 617950 |
| | | | | | Ovarian dysgenesis 7, 618117 |
| MRPS22 | 100.0% | 100.0% | 100.0% | 98.9% | Combined oxidative phosphorylation deficiency 5, 611719 |
| MRPS34 | 100.0% | 100.0% | 100.0% | 99.9% | Combined oxidative phosphorylation deficiency 32, 617664 |
| MS4A1 | 100.0% | 100.0% | 100.0% | 98.3% | ?Immunodeficiency, common variable, 5, 613495 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| MSH2 | 100.0% | 100.0% | 100.0% | 98.9% | Lynch syndrome 1, 120435 Muir-Torre syndrome, 158320 Mismatch repair cancer syndrome 2, 619096 |
| MSH3 | 100.0% | 100.0% | 100.0% | 98.1% | Familial adenomatous polyposis 4, 617100 Endometrial carcinoma, somatic, 608089 |
| MSH6 | 100.0% | 100.0% | 100.0% | 99.4% | Lynch syndrome 5, 614350 Mismatch repair cancer syndrome 3, 619097 |
| MSMO1 | 100.0% | 100.0% | 100.0% | 99.4% | Microcephaly, congenital cataract, and psoriasiform dermatitis, 616834 |
| MSRB3 | 100.0% | 100.0% | 100.0% | 98.2% | Deafness, autosomal recessive 74, 613718 |
| MSTO1 | 100.0% | 100.0% | 100.0% | 99.1% | Myopathy, mitochondrial, and ataxia, 617675 |
| MTFMT | 100.0% | 100.0% | 100.0% | 99.4% | Combined oxidative phosphorylation deficiency 15, 614947 Mitochondrial complex I deficiency, nuclear type 27, 618248 |
| MTHFD1 | 100.0% | 100.0% | 100.0% | 99.2% | Combined immunodeficiency and megaloblastic anemia w/wo hyperhomocysteinemia, 617780 |
| MTHFR | 100.0% | 100.0% | 100.0% | 99.7% | Homocystinuria due to MTHFR deficiency, 236250 |
| MTHFS | 100.0% | 100.0% | 100.0% | 99.1% | Neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination, 618367 |
| MTMR2 | 100.0% | 100.0% | 100.0% | 99.5% | Charcot-Marie-Tooth disease, type 4B1, 601382 |
| MTO1 | 93.7% | 91.1% | 100.0% | 99.5% | Combined oxidative phosphorylation deficiency 10, 614702 |
| MTPAP | 100.0% | 100.0% | 100.0% | 99.3% | ?Spastic ataxia 4, autosomal recessive, 613672 |
| MTR | 100.0% | 100.0% | 100.0% | 99.3% | Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 |
| MTRR | 100.0% | 100.0% | 100.0% | 98.9% | Homocystinuria-megaloblastic anemia, cbl E type, 236270 |
| MTTP | 100.0% | 100.0% | 100.0% | 99.3% | Abetalipoproteinemia, 200100 |
| MUSK | 100.0% | 100.0% | 100.0% | 99.6% | Fetal akinesia deformation sequence 1, 208150 Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 |
| MUTYH | 100.0% | 100.0% | 100.0% | 99.7% | Adenomas, multiple colorectal, 608456 Gastric cancer, somatic, 613659 |
| MVK | 90.4% | 90.4% | 100.0% | 100.0% | Hyper-IgD syndrome, 260920 Porokeratosis 3, multiple types, 175900 Mevalonic aciduria, 610377 |
| MYBPC1 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital myopathy 16, 618524 Lethal congenital contracture syndrome 4, 614915 Arthrogryposis, distal, type 1B, 614335 |
| MYD88 | 100.0% | 100.0% | 100.0% | 99.9% | Macroglobulinemia, Waldenstrom, somatic, 153600 Immunodeficiency 68, 612260 |
| MYF5 | 100.0% | 100.0% | 100.0% | 99.6% | Ophthalmoplegia, external, with rib and vertebral anomalies, 618155 |
| MYH2 | 100.0% | 100.0% | 100.0% | 98.9% | Congenital myopathy 6 with ophthalmoplegia, 605637 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| | | | | | Contractures, pterygia, and spondylocarpostarsal fusion syndrome 1A, 178110 Contractures, pterygia, and spondylocarpotarsal fusion syndrome 1B, 618469 Arthrogryposis, distal, type 2B3 (Sheldon-Hall), 618436 |
| MYH3 | 100.0% | 100.0% | 100.0% | 98.9% | Arthrogryposis, distal, type 2A (Freeman-Sheldon), 193700 |
| MYL1 | 100.0% | 100.0% | 100.0% | 99.1% | Congenital myopathy 14, 618414 |
| | | | | | Cardiomyopathy, hypertrophic, 10, 608758 |
| MYL2 | 100.0% | 100.0% | 100.0% | 98.7% | Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy, 619424 |
| MYL3 | 100.0% | 100.0% | 100.0% | 99.4% | Cardiomyopathy, hypertrophic, 8, 608751 |
| | | | | | Megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210 |
| MYLK | 100.0% | 100.0% | 100.0% | 99.5% | Aortic aneurysm, familial thoracic 7, 613780 |
| MYMK | 100.0% | 100.0% | 100.0% | 99.6% | Carey-Fineman-Ziter syndrome, 254940 |
| MYO15A | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal recessive 3, 600316 |
| MYO18B | 100.0% | 100.0% | 100.0% | 99.0% | Klippel-Feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism, 616549 |
| MYO1E | 100.0% | 100.0% | 100.0% | 99.5% | Glomerulosclerosis, focal segmental, 6, 614131 |
| MYO3A | 100.0% | 100.0% | 100.0% | 99.1% | Deafness, autosomal recessive 30, 607101 |
| MYO5A | 100.0% | 100.0% | 100.0% | 99.3% | Griscelli syndrome, type 1, 214450 |
| | | | | | Diarrhea 2, with microvillus atrophy, w/wo cholestasis, 251850 |
| MYO5B | 100.0% | 99.9% | 100.0% | 99.4% | Cholestasis, progressive familial intrahepatic, 10, 619868 |
| | | | | | Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 |
| | | | | | Deafness, autosomal dominant 22, 606346 |
| MYO6 | 100.0% | 100.0% | 100.0% | 99.1% | Deafness, autosomal recessive 37, 607821 |
| | | | | | Deafness, autosomal recessive 2, 600060 |
| | | | | | Usher syndrome, type 1B, 276900 |
| MYO7A | 100.0% | 100.0% | 100.0% | 99.5% | Deafness, autosomal dominant 11, 601317 |
| MYO9A | 100.0% | 100.0% | 100.0% | 99.4% | Myasthenic syndrome, congenital, 24, presynaptic, 618198 |
| MYORG | 100.0% | 100.0% | 100.0% | 100.0% | Basal ganglia calcification, idiopathic, 7, autosomal recessive, 618317 |
| | | | | | Cardiomyopathy, hypertrophic, 22, 615248 |
| | | | | | Congenital myopathy 24, 617336 |
| | | | | | Cardiomyopathy, familial restrictive, 4, 615248 |
| MYPN | 100.0% | 100.0% | 100.0% | 99.5% | Cardiomyopathy, dilated, 1KK, 615248 |
| MYSM1 | 100.0% | 100.0% | 100.0% | 99.1% | Bone marrow failure syndrome 4, 618116 |
| NADK2 | 100.0% | 100.0% | 100.0% | 99.1% | 2,4-dienoyl-CoA reductase deficiency, 616034 |
| NADSYN1 | 100.0% | 100.0% | 100.0% | 99.9% | Vertebral, cardiac, renal, and limb defects syndrome 3, 618845 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| NAGA | 100.0% | 100.0% | 100.0% | 99.7% | Schindler disease, type I, 609241 Kanzaki disease, 609242 Schindler disease, type III, 609241 |
| NAGLU | 100.0% | 100.0% | 100.0% | 99.9% | ?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 |
| NAGS | 100.0% | 100.0% | 100.0% | 99.6% | N-acetylglutamate synthase deficiency, 237310 |
| NALCN | 100.0% | 100.0% | 100.0% | 99.4% | Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 Hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419 |
| NANS | 100.0% | 100.0% | 99.9% | 99.1% | Spondyloepimetaphyseal dysplasia, Camera-Genevieve type, 610442 |
| NARS2 | 100.0% | 100.0% | 100.0% | 99.6% | Combined oxidative phosphorylation deficiency 24, 616239 ?Deafness, autosomal recessive 94, 618434 |
| NAT8L | 98.8% | 93.4% | 99.9% | 94.5% | ?N-acetylaspartate deficiency, 614063 |
| NAXD | 100.0% | 100.0% | 100.0% | 99.8% | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2, 618321 |
| NAXE | 100.0% | 100.0% | 100.0% | 99.7% | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186 |
| NBAS | 100.0% | 99.9% | 100.0% | 99.4% | Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 Infantile liver failure syndrome 2, 616483 |
| NBEAL2 | 100.0% | 100.0% | 100.0% | 99.9% | Gray platelet syndrome, 139090 |
| NBN | 100.0% | 100.0% | 100.0% | 98.8% | Leukemia, acute lymphoblastic, 613065 Aplastic anemia, 609135 Nijmegen breakage syndrome, 251260 |
| NCAPD2 | 100.0% | 100.0% | 100.0% | 99.2% | ?Microcephaly 21, primary, autosomal recessive, 617983 |
| NCAPD3 | 100.0% | 100.0% | 100.0% | 99.7% | Microcephaly 22, primary, autosomal recessive, 617984 |
| NCAPG2 | 100.0% | 100.0% | 100.0% | 99.3% | Khan-Khan-Katsanis syndrome, 618460 |
| NCAPH | 100.0% | 100.0% | 100.0% | 99.6% | ?Microcephaly 23, primary, autosomal recessive, 617985 |
| NCF1 | 100.0% | 99.6% | 100.0% | 98.9% | Chronic granulomatous disease 1, autosomal recessive, 233700 |
| NCF2 | 100.0% | 100.0% | 100.0% | 99.5% | Chronic granulomatous disease 2, autosomal recessive, 233710 |
| NCF4 | 100.0% | 100.0% | 100.0% | 99.8% | Chronic granulomatous disease 3, autosomal recessive, 613960 |
| NDE1 | 100.0% | 100.0% | 100.0% | 99.2% | Microhydranencephaly, 605013 Lissencephaly 4 (with microcephaly), 614019 |
| NDRG1 | 100.0% | 100.0% | 100.0% | 99.5% | Charcot-Marie-Tooth disease, type 4D, 601455 |
| NDST1 | 100.0% | 100.0% | 100.0% | 99.8% | Intellectual developmental disorder, autosomal recessive 46, 616116 |
| NDUFA10 | 100.0% | 100.0% | 100.0% | 99.1% | Mitochondrial complex I deficiency, nuclear type 22, 618243 |
| NDUFA11 | 100.0% | 98.8% | 100.0% | 98.4% | Mitochondrial complex I deficiency, nuclear type 14, 618236 |
| NDUFA12 | 100.0% | 100.0% | 100.0% | 98.5% | Mitochondrial complex I deficiency, nuclear type 23, 618244 |
| NDUFA13 | 100.0% | 100.0% | 100.0% | 99.7% | ?Mitochondrial complex I deficiency, nuclear type 28, 618249 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| NDUFA2 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex I deficiency, nuclear type 13, 618235 |
| NDUFA6 | 100.0% | 100.0% | 100.0% | 99.9% | Mitochondrial complex I deficiency, nuclear type 33, 618253 |
| NDUFA9 | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial complex I deficiency, nuclear type 26, 618247 |
| NDUF AF1 | 100.0% | 100.0% | 100.0% | 98.7% | Mitochondrial complex I deficiency, nuclear type 11, 618234 |
| NDUF AF2 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex I deficiency, nuclear type 10, 618233 |
| NDUF AF3 | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial complex I deficiency, nuclear type 18, 618240 |
| NDUF AF4 | 100.0% | 100.0% | 100.0% | 98.6% | Mitochondrial complex I deficiency, nuclear type 15, 618237 |
| NDUF AF5 | 100.0% | 100.0% | 100.0% | 98.1% | Mitochondrial complex I deficiency, nuclear type 16, 618238 |
| NDUF AF6 | 100.0% | 100.0% | 100.0% | 98.5% | Mitochondrial complex I deficiency, nuclear type 17, 618239 Fanconi renotubular syndrome 5, 618913 |
| NDUFB11 | 99.7% | 97.9% | 93.6% | 63.1% | Linear skin defects with multiple congenital anomalies 3, 300952 ?Mitochondrial complex I deficiency, nuclear type 30, 301021 |
| NDUFB3 | 100.0% | 100.0% | 100.0% | 99.8% | Mitochondrial complex I deficiency, nuclear type 25, 618246 |
| NDUFB8 | 100.0% | 100.0% | 100.0% | 99.2% | Mitochondrial complex I deficiency, nuclear type 32, 618252 |
| NDUFB9 | 100.0% | 100.0% | 100.0% | 99.4% | ?Mitochondrial complex I deficiency, nuclear type 24, 618245 |
| NDUFS1 | 100.0% | 100.0% | 100.0% | 99.1% | Mitochondrial complex I deficiency, nuclear type 5, 618226 |
| NDUFS2 | 100.0% | 100.0% | 100.0% | 99.2% | Mitochondrial complex I deficiency, nuclear type 6, 618228 |
| NDUFS3 | 96.6% | 91.3% | 100.0% | 99.5% | Mitochondrial complex I deficiency, nuclear type 8, 618230 |
| NDUFS4 | 100.0% | 99.9% | 100.0% | 99.1% | Mitochondrial complex I deficiency, nuclear type 1, 252010 |
| NDUFS6 | 100.0% | 100.0% | 99.9% | 99.0% | Mitochondrial complex I deficiency, nuclear type 9, 618232 |
| NDUFS7 | 100.0% | 100.0% | 100.0% | 100.0% | Mitochondrial complex I deficiency, nuclear type 3, 618224 |
| NDUFS8 | 100.0% | 100.0% | 100.0% | 99.9% | Mitochondrial complex I deficiency, nuclear type 2, 618222 |
| NDUFV1 | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial complex I deficiency, nuclear type 4, 618225 |
| NDUFV2 | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial complex I deficiency, nuclear type 7, 618229 |
| NEB | 99.7% | 99.2% | 99.7% | 98.1% | Nemaline myopathy 2, autosomal recessive, 256030 Arthrogyrosis multiplex congenita 6, 619334 |
| NECAP1 | 100.0% | 100.0% | 100.0% | 99.6% | Developmental and epileptic encephalopathy 21, 615833 |
| NECTIN1 | 100.0% | 100.0% | 100.0% | 99.7% | Cleft lip/palate-ectodermal dysplasia syndrome, 225060 Orofacial cleft 7, 225060 |
| NECTIN4 | 100.0% | 100.0% | 100.0% | 99.8% | Ectodermal dysplasia-syndactyly syndrome 1, 613573 |
| NEK1 | 100.0% | 100.0% | 100.0% | 99.0% | Short-rib thoracic dysplasia 6 w/wo polydactyly, 263520 |
| NEK2 | 95.9% | 95.9% | 100.0% | 99.6% | ?Retinitis pigmentosa 67, 615565 |
| NEK8 | 100.0% | 100.0% | 100.0% | 99.8% | Renal-hepatic-pancreatic dysplasia 2, 615415 ?Nephronophthisis 9, 613824 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| | | | | | ?Arthrogryposis, Perthes disease, and upward gaze palsy, 614262 Nevus comedonicus, somatic, 617025 Lethal congenital contracture syndrome 10, 617022 |
| NEK9 | 100.0% | 100.0% | 100.0% | 99.5% | |
| NEPRO | 100.0% | 100.0% | 100.0% | 98.7% | Anauxetic dysplasia 3, 618853 |
| | | | | | Sialidosis, type II, 256550 |
| NEU1 | 100.0% | 100.0% | 100.0% | 99.3% | Sialidosis, type I, 256550 |
| NEUROG3 | 100.0% | 100.0% | 100.0% | 99.7% | Diarrhea 4, malabsorptive, congenital, 610370 |
| NFASC | 100.0% | 100.0% | 100.0% | 99.8% | Neurodevelopmental disorder with central and peripheral motor dysfunction, 618356 |
| NFU1 | 100.0% | 100.0% | 100.0% | 99.4% | Multiple mitochondrial dysfunctions syndrome 1, 605711 |
| NGF | 100.0% | 100.0% | 100.0% | 99.8% | Neuropathy, hereditary sensory and autonomic, type V, 608654 |
| NGLY1 | 100.0% | 100.0% | 100.0% | 99.3% | Congenital disorder of deglycosylation 1, 615273 |
| | | | | | Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 |
| NHEJ1 | 100.0% | 100.0% | 100.0% | 99.7% | |
| NHLRC1 | 100.0% | 100.0% | 100.0% | 99.9% | Epilepsy, progressive myoclonic 2B (Lafora), 254780 |
| NHLRC2 | 100.0% | 99.9% | 100.0% | 99.6% | FINCA syndrome, 618278 |
| NHP2 | 100.0% | 100.0% | 100.0% | 99.3% | Dyskeratosis congenita, autosomal recessive 2, 613987 |
| NIN | 100.0% | 100.0% | 100.0% | 99.0% | ?Seckel syndrome 7, 614851 |
| NIPAL4 | 100.0% | 100.0% | 100.0% | 99.2% | Ichthyosis, congenital, autosomal recessive 6, 612281 |
| | | | | | Persistent truncus arteriosus, 217095 |
| NKX2-6 | 100.0% | 100.0% | 100.0% | 100.0% | Conotruncal heart malformations, 217095 |
| NKX3-2 | 100.0% | 100.0% | 100.0% | 99.7% | Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 |
| NKX6-2 | 100.0% | 100.0% | 100.0% | 95.3% | Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy, 617560 |
| | | | | | ?Respiratory papillomatosis, juvenile recurrent, congenital, 618803 |
| NLRP1 | 100.0% | 100.0% | 100.0% | 99.6% | Autoinflammation with arthritis and dyskeratosis, 617388 Palmoplantar carcinoma, multiple self-healing, 615225 |
| NLRP7 | 100.0% | 100.0% | 100.0% | 99.4% | Hydatidiform mole, recurrent, 1, 231090 |
| NME8 | 99.9% | 99.5% | 100.0% | 99.1% | ?Ciliary dyskinesia, primary, 6, 610852 |
| | | | | | Spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and Leber congenital amaurosis, 619260 |
| NMNAT1 | 99.9% | 97.7% | 100.0% | 97.6% | Leber congenital amaurosis 9, 608553 |
| NNT | 96.4% | 96.3% | 100.0% | 99.6% | Glucocorticoid deficiency 4, w/wo mineralocorticoid deficiency, 614736 |
| | | | | | ?Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400 |
| | | | | | ?Cataracts, hearing impairment, nephrotic syndrome, and enterocolitis 2, 620425 |
| NOP10 | 100.0% | 100.0% | 100.0% | 99.8% | ?Dyskeratosis congenita, autosomal recessive 1, 224230 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| NPC1 | 100.0% | 100.0% | 100.0% | 99.5% | Niemann-Pick disease, type C1, 257220 Niemann-Pick disease, type D, 257220 |
| NPC2 | 100.0% | 100.0% | 100.0% | 98.9% | Niemann-pick disease, type C2, 607625 |
| NPHP1 | 100.0% | 100.0% | 100.0% | 99.4% | Joubert syndrome 4, 609583 Nephronophthisis 1, juvenile, 256100 Senior-Loken syndrome-1, 266900 |
| NPHP3 | 100.0% | 100.0% | 100.0% | 99.3% | Nephronophthisis 3, 604387 Renal-hepatic-pancreatic dysplasia 1, 208540 Meckel syndrome 7, 267010 |
| NPHP4 | 100.0% | 100.0% | 100.0% | 99.7% | Senior-Loken syndrome 4, 606996 Nephronophthisis 4, 606966 |
| NPHS1 | 100.0% | 100.0% | 100.0% | 99.4% | Nephrotic syndrome, type 1, 256300 |
| NPHS2 | 100.0% | 100.0% | 100.0% | 99.6% | Nephrotic syndrome, type 2, 600995 |
| NPPA | 100.0% | 100.0% | 100.0% | 99.6% | Atrial standstill 2, 615745 Atrial fibrillation, familial, 6, 612201 |
| NPR2 | 100.0% | 100.0% | 100.0% | 99.8% | Epiphyseal chondrodysplasia, Miura type, 615923 Short stature with nonspecific skeletal abnormalities, 616255 Acromesomelic dysplasia 1, Maroteaux type, 602875 |
| NROB2 | 100.0% | 100.0% | 100.0% | 99.7% | Obesity, mild, early-onset, 601665 |
| NR1H4 | 100.0% | 100.0% | 100.0% | 99.1% | Cholestasis, progressive familial intrahepatic, 5, 617049 |
| NR2E3 | 100.0% | 100.0% | 100.0% | 99.6% | Retinitis pigmentosa 37, 611131 Enhanced S-cone syndrome, 268100 |
| NRCAM | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with neuromuscular and skeletal abnormalities, 619833 |
| NRROS | 100.0% | 100.0% | 100.0% | 99.8% | Seizures, early-onset, with neurodegeneration and brain calcification, 618875 |
| NRXN1 | 99.8% | 99.7% | 100.0% | 99.8% | Pitt-Hopkins-like syndrome 2, 614325 |
| NSMCE2 | 100.0% | 100.0% | 100.0% | 98.2% | Seckel syndrome 10, 617253 |
| NSMCE3 | 100.0% | 100.0% | 100.0% | 99.5% | Lung disease, immunodeficiency, and chromosome breakage syndrome, 617241 |
| NSUN2 | 100.0% | 100.0% | 100.0% | 99.4% | Intellectual developmental disorder, autosomal recessive 5, 611091 |
| NT5C2 | 100.0% | 100.0% | 100.0% | 99.4% | Spastic paraplegia 45, autosomal recessive, 613162 |
| NT5C3A | 100.0% | 100.0% | 100.0% | 99.2% | Anemia, hemolytic, due to UMPH1 deficiency, 266120 |
| NT5E | 100.0% | 100.0% | 100.0% | 99.4% | Calcification of joints and arteries, 211800 |
| NTHL1 | 100.0% | 100.0% | 100.0% | 99.8% | Familial adenomatous polyposis 3, 616415 |
| NTNG2 | 100.0% | 100.0% | 100.0% | 99.8% | Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, 618718 |
| NTRK1 | 100.0% | 100.0% | 100.0% | 99.6% | Insensitivity to pain, congenital, with anhidrosis, 256800 |
| NUBPL | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial complex I deficiency, nuclear type 21, 618242 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| NUP107 | 100.0% | 100.0% | 100.0% | 99.0% | ?Ovarian dysgenesis 6, 618078 Galloway-Mowat syndrome 7, 618348 Nephrotic syndrome, type 11, 616730 |
| NUP133 | 100.0% | 100.0% | 100.0% | 99.3% | ?Galloway-Mowat syndrome 8, 618349 Nephrotic syndrome, type 18, 618177 |
| NUP160 | 100.0% | 100.0% | 100.0% | 99.4% | ?Nephrotic syndrome, type 19, 618178 |
| NUP188 | 100.0% | 100.0% | 100.0% | 99.6% | Sandestig-Stefanova syndrome, 618804 |
| NUP205 | 100.0% | 100.0% | 100.0% | 99.5% | ?Nephrotic syndrome, type 13, 616893 |
| NUP214 | 100.0% | 100.0% | 100.0% | 99.4% | Leukemia, T-cell acute lymphoblastic, somatic, 613065 Leukemia, acute myeloid, somatic, 601626 |
| NUP37 | 100.0% | 100.0% | 100.0% | 98.9% | ?Microcephaly 24, primary, autosomal recessive, 618179 |
| NUP62 | 100.0% | 100.0% | 100.0% | 99.9% | Striatonigral degeneration, infantile, 271930 |
| NUP85 | 100.0% | 100.0% | 100.0% | 98.9% | Nephrotic syndrome, type 17, 618176 |
| NUP88 | 100.0% | 100.0% | 100.0% | 99.5% | Fetal akinesia deformation sequence 4, 618393 |
| NUP93 | 95.5% | 95.5% | 100.0% | 99.7% | Nephrotic syndrome, type 12, 616892 |
| NUS1 | 100.0% | 100.0% | 100.0% | 99.7% | Intellectual developmental disorder, autosomal dominant 55, with seizures, 617831 ?Congenital disorder of glycosylation, type 1aa, 617082 |
| NXN | 100.0% | 100.0% | 100.0% | 99.5% | Robinow syndrome, autosomal recessive 2, 618529 |
| OAT | 100.0% | 100.0% | 100.0% | 99.6% | Gyrate atrophy of choroid and retina w/wo ornithinemia, 258870 |
| OBSL1 | 100.0% | 100.0% | 100.0% | 99.9% | 3-M syndrome 2, 612921 |
| OCA2 | 100.0% | 100.0% | 100.0% | 99.7% | Albinism, brown oculocutaneous, 203200 Albinism, oculocutaneous, type II, 203200 |
| OCLN | 100.0% | 100.0% | 99.9% | 97.1% | Pseudo-TORCH syndrome 1, 251290 |
| ODAPH | 100.0% | 100.0% | 100.0% | 99.2% | Amelogenesis imperfecta, type IIA4, 614832 |
| OGDH | 100.0% | 100.0% | 100.0% | 99.7% | Oxoglutarate dehydrogenase deficiency, 203740 |
| OGDHL | 100.0% | 100.0% | 100.0% | 99.7% | Yoon-Bellen neurodevelopmental syndrome, 619701 |
| OPA1 | 100.0% | 100.0% | 100.0% | 99.4% | Optic atrophy plus syndrome, 125250 Optic atrophy 1, 165500 Behr syndrome, 210000 ?Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type), 616896 |
| OPA3 | 100.0% | 100.0% | 100.0% | 99.8% | 3-methylglutaconic aciduria, type III, 258501 Optic atrophy 3 with cataract, 165300 |
| OPLAH | 100.0% | 100.0% | 100.0% | 99.7% | 5-oxoprolinase deficiency, 260005 |
| ORAI1 | 100.0% | 100.0% | 100.0% | 98.8% | Immunodeficiency 9, 612782 Myopathy, tubular aggregate, 2, 615883 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| ORC1 | 100.0% | 100.0% | 100.0% | 99.6% | Meier-Gorlin syndrome 1, 224690 |
| ORC4 | 99.1% | 98.3% | 100.0% | 98.7% | Meier-Gorlin syndrome 2, 613800 |
| ORC6 | 100.0% | 100.0% | 100.0% | 99.3% | Meier-Gorlin syndrome 3, 613803 |
| OSGEP | 100.0% | 100.0% | 100.0% | 99.6% | Galloway-Mowat syndrome 3, 617729 |
| OSTM1 | 100.0% | 100.0% | 100.0% | 99.7% | Osteopetrosis, autosomal recessive 5, 259720 |
| OTOA | 100.0% | 100.0% | 100.0% | 99.6% | Deafness, autosomal recessive 22, 607039 |
| OTOF | 100.0% | 100.0% | 100.0% | 99.5% | Auditory neuropathy, autosomal recessive, 1, 601071 Deafness, autosomal recessive 9, 601071 |
| OTOG | 100.0% | 100.0% | 100.0% | 99.7% | Deafness, autosomal recessive 18B, 614945 |
| OTOGL | 100.0% | 100.0% | 100.0% | 99.6% | Deafness, autosomal recessive 84B, 614944 |
| OTUD6B | 100.0% | 100.0% | 100.0% | 99.0% | Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452 |
| OTULIN | 100.0% | 100.0% | 100.0% | 99.9% | Autoinflammation, panniculitis, and dermatosis syndrome, 617099 |
| OXCT1 | 100.0% | 100.0% | 100.0% | 99.1% | Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 |
| P2RY12 | 100.0% | 100.0% | 100.0% | 98.7% | Bleeding disorder, platelet-type, 8, 609821 |
| P3H1 | 100.0% | 100.0% | 100.0% | 99.6% | Osteogenesis imperfecta, type VIII, 610915 |
| P3H2 | 100.0% | 100.0% | 100.0% | 99.7% | Myopia, high, with cataract and vitreoretinal degeneration, 614292 |
| P4HTM | 100.0% | 100.0% | 100.0% | 99.4% | Hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493 |
| PAH | 100.0% | 100.0% | 100.0% | 99.7% | Phenylketonuria, 261600 |
| PAM16 | 85.2% | 84.5% | 100.0% | 99.8% | Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type, 613320 |
| PANK2 | 100.0% | 100.0% | 100.0% | 99.6% | HARP syndrome, 607236 Neurodegeneration with brain iron accumulation 1, 234200 |
| PAPSS2 | 100.0% | 99.6% | 100.0% | 99.3% | Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 |
| PARK7 | 100.0% | 100.0% | 100.0% | 99.5% | Parkinson disease 7, autosomal recessive early-onset, 606324 |
| PARN | 97.0% | 95.9% | 100.0% | 99.5% | Dyskeratosis congenita, autosomal recessive 6, 616353 Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 4, 616371 |
| PARS2 | 100.0% | 100.0% | 100.0% | 99.7% | Developmental and epileptic encephalopathy 75, 618437 |
| PATL2 | 100.0% | 100.0% | 100.0% | 98.9% | Oocyte/zygote/embryo maturation arrest 4, 617743 |
| PAX1 | 100.0% | 100.0% | 100.0% | 99.2% | Otofaciocervical syndrome 2, 615560 |
| PAX3 | 100.0% | 99.8% | 100.0% | 99.4% | Craniofacial-deafness-hand syndrome, 122880 Waardenburg syndrome, type 3, 148820 Waardenburg syndrome, type 1, 193500 Rhabdomyosarcoma 2, alveolar, 268220 |
| PAX7 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital myopathy 19, 618578 Rhabdomyosarcoma 2, alveolar, 268220 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| PC | 100.0% | 100.0% | 100.0% | 99.8% | Pyruvate carboxylase deficiency, 266150 |
| PCARE | 100.0% | 100.0% | 100.0% | 98.8% | Retinitis pigmentosa 54, 613428 |
| PCBD1 | 100.0% | 100.0% | 100.0% | 99.9% | Hyperphenylalaninemia, BH4-deficient, D, 264070 |
| PCCA | 100.0% | 100.0% | 100.0% | 99.1% | Propionicacidemia, 606054 |
| PCCB | 99.9% | 98.0% | 100.0% | 99.4% | Propionicacidemia, 606054 |
| PCDH12 | 100.0% | 100.0% | 100.0% | 99.8% | Diencephalic-mesencephalic junction dysplasia syndrome 1, 251280 |
| | | | | | Usher syndrome, type 1D/F digenic, 601067 |
| | | | | | Deafness, autosomal recessive 23, 609533 |
| PCDH15 | 100.0% | 100.0% | 100.0% | 99.5% | Usher syndrome, type 1F, 602083 |
| PCK1 | 100.0% | 100.0% | 100.0% | 99.8% | Phosphoenolpyruvate carboxykinase deficiency, cytosolic, 261680 |
| PCK2 | 100.0% | 100.0% | 100.0% | 99.9% | No OMIM disease ID |
| PCLO | 99.9% | 99.7% | 100.0% | 98.3% | ?Pontocerebellar hypoplasia, type 3, 608027 |
| PCNT | 100.0% | 100.0% | 100.0% | 99.6% | Microcephalic osteodysplastic primordial dwarfism, type II, 210720 |
| PCSK1 | 100.0% | 100.0% | 100.0% | 99.5% | Endocrinopathy due to proprotein convertase 1/3 deficiency, 600955 |
| PCYT1A | 100.0% | 100.0% | 100.0% | 99.0% | Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 |
| | | | | | Striatal degeneration, autosomal dominant, 616922 |
| PDE10A | 99.7% | 98.7% | 99.8% | 94.6% | Dyskinesia, limb and orofacial, infantile-onset, 616921 |
| PDE6A | 100.0% | 100.0% | 100.0% | 99.2% | Retinitis pigmentosa 43, 613810 |
| | | | | | Retinitis pigmentosa-40, 613801 |
| PDE6B | 100.0% | 100.0% | 100.0% | 99.8% | Night blindness, congenital stationary, autosomal dominant 2, 163500 |
| PDE6C | 100.0% | 100.0% | 100.0% | 98.5% | Cone dystrophy 4, 613093 |
| PDE6D | 100.0% | 100.0% | 100.0% | 99.1% | Joubert syndrome 22, 615665 |
| PDE6G | 100.0% | 100.0% | 100.0% | 98.5% | Retinitis pigmentosa 57, 613582 |
| | | | | | Retinal cone dystrophy 3, 610024 |
| PDE6H | 100.0% | 99.9% | 100.0% | 98.9% | Achromatopsia 6, 610024 |
| PDHB | 100.0% | 100.0% | 100.0% | 99.2% | Pyruvate dehydrogenase E1-beta deficiency, 614111 |
| PDHX | 100.0% | 99.8% | 100.0% | 99.3% | Lacticacidemia due to PDX1 deficiency, 245349 |
| PDP1 | 100.0% | 100.0% | 100.0% | 99.9% | Pyruvate dehydrogenase phosphatase deficiency, 608782 |
| PDSS1 | 100.0% | 100.0% | 100.0% | 99.5% | Coenzyme Q10 deficiency, primary, 2, 614651 |
| PDSS2 | 100.0% | 100.0% | 100.0% | 99.3% | Coenzyme Q10 deficiency, primary, 3, 614652 |
| | | | | | Pancreatic agenesis 1, 260370 |
| PDX1 | 100.0% | 100.0% | 100.0% | 100.0% | MODY, type IV, 606392 |
| PDXK | 99.6% | 97.0% | 100.0% | 99.7% | Neuropathy, hereditary motor and sensory, type VIC, with optic atrophy, 618511 |
| | | | | | Deafness, autosomal recessive 57, 618003 |
| PDZD7 | 100.0% | 99.2% | 100.0% | 99.6% | Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| PEPD | 100.0% | 100.0% | 100.0% | 99.9% | Prolidase deficiency, 170100 |
| PET100 | 100.0% | 100.0% | 100.0% | 99.8% | Mitochondrial complex IV deficiency, nuclear type 12, 619055 |
| PEX1 | 100.0% | 100.0% | 100.0% | 99.3% | Heimler syndrome 1, 234580 Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 Peroxisome biogenesis disorder 1A (Zellweger), 214100 |
| PEX10 | 100.0% | 100.0% | 100.0% | 100.0% | Peroxisome biogenesis disorder 6A (Zellweger), 614870 Peroxisome biogenesis disorder 6B, 614871 |
| PEX11B | 100.0% | 100.0% | 100.0% | 97.4% | Peroxisome biogenesis disorder 14B, 614920 |
| PEX12 | 100.0% | 100.0% | 100.0% | 99.4% | Peroxisome biogenesis disorder 3B, 266510 Peroxisome biogenesis disorder 3A (Zellweger), 614859 |
| PEX13 | 100.0% | 100.0% | 100.0% | 99.0% | Peroxisome biogenesis disorder 11A (Zellweger), 614883 Peroxisome biogenesis disorder 11B, 614885 |
| PEX14 | 100.0% | 100.0% | 100.0% | 99.8% | Peroxisome biogenesis disorder 13A (Zellweger), 614887 |
| PEX16 | 100.0% | 100.0% | 100.0% | 99.3% | Peroxisome biogenesis disorder 8B, 614877 Peroxisome biogenesis disorder 8A (Zellweger), 614876 |
| PEX19 | 100.0% | 100.0% | 100.0% | 99.6% | Peroxisome biogenesis disorder 12A (Zellweger), 614886 |
| PEX2 | 100.0% | 100.0% | 100.0% | 99.6% | Peroxisome biogenesis disorder 5A (Zellweger), 614866 Peroxisome biogenesis disorder 5B, 614867 |
| PEX26 | 100.0% | 100.0% | 100.0% | 99.2% | Peroxisome biogenesis disorder 7B, 614873 Peroxisome biogenesis disorder 7A (Zellweger), 614872 |
| PEX3 | 100.0% | 100.0% | 100.0% | 98.9% | Peroxisome biogenesis disorder 10A (Zellweger), 614882 ?Peroxisome biogenesis disorder 10B, 617370 |
| PEX5 | 100.0% | 100.0% | 100.0% | 99.4% | Peroxisome biogenesis disorder 2B, 202370 Peroxisome biogenesis disorder 2A (Zellweger), 214110 Rhizomelic chondrodysplasia punctata, type 5, 616716 |
| PEX6 | 100.0% | 100.0% | 100.0% | 99.5% | Peroxisome biogenesis disorder 4B, 614863 Peroxisome biogenesis disorder 4A (Zellweger), 614862 Heimler syndrome 2, 616617 |
| PEX7 | 91.2% | 91.2% | 100.0% | 99.6% | Rhizomelic chondrodysplasia punctata, type 1, 215100 Peroxisome biogenesis disorder 9B, 614879 |
| PFKM | 100.0% | 100.0% | 100.0% | 99.7% | Glycogen storage disease VII, 232800 |
| PGAM2 | 100.0% | 100.0% | 100.0% | 99.9% | Glycogen storage disease X, 261670 |
| PGAP1 | 100.0% | 100.0% | 100.0% | 99.2% | Neurodevelopmental disorder with dysmorphic features, spasticity, and brain abnormalities, 615802 |
| PGAP2 | 100.0% | 100.0% | 100.0% | 99.7% | Hyperphosphatasia with impaired intellectual development syndrome 3, 614207 |
| PGAP3 | 100.0% | 100.0% | 100.0% | 99.8% | Hyperphosphatasia with impaired intellectual development syndrome 4, 615716 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| PGM1 | 94.0% | 94.0% | 100.0% | 99.1% | Congenital disorder of glycosylation, type It, 614921 |
| PGM3 | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 23, 615816 |
| PHGDH | 100.0% | 100.0% | 100.0% | 99.8% | Neu-Laxova syndrome 1, 256520 Phosphoglycerate dehydrogenase deficiency, 601815 |
| PHKB | 100.0% | 100.0% | 100.0% | 99.5% | Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 |
| PHKG2 | 100.0% | 100.0% | 100.0% | 99.5% | Glycogen storage disease IXc, 613027 |
| PHOX2A | 100.0% | 100.0% | 100.0% | 99.7% | Fibrosis of extraocular muscles, congenital, 2, 602078 |
| PHYH | 100.0% | 100.0% | 100.0% | 99.1% | Refsum disease, 266500 |
| PI4KA | 100.0% | 99.8% | 100.0% | 99.5% | Spastic paraplegia 84, autosomal recessive, 619621 Gastrointestinal defects and immunodeficiency syndrome 2, 619708 Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531 |
| PIBF1 | 100.0% | 100.0% | 100.0% | 97.0% | Joubert syndrome 33, 617767 |
| PIEZO1 | 100.0% | 100.0% | 100.0% | 99.8% | Lymphatic malformation 6, 616843 Dehydrated hereditary stomatocytosis w/wo pseudohyperkalemia and/or perinatal edema, 194380 |
| PIEZO2 | 100.0% | 100.0% | 100.0% | 99.5% | Arthrogryposis, distal, type 5, 108145 Arthrogryposis, distal, with impaired proprioception and touch, 617146 Arthrogryposis, distal, type 3, 114300 ?Marden-Walker syndrome, 248700 |
| PIGB | 100.0% | 100.0% | 100.0% | 98.9% | Developmental and epileptic encephalopathy 80, 618580 |
| PIGC | 100.0% | 100.0% | 100.0% | 100.0% | Glycosylphosphatidylinositol biosynthesis defect 16, 617816 |
| PIGG | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder w/wo hypotonia, seizures, and cerebellar atrophy, 616917 |
| PIGH | 80.9% | 75.0% | 100.0% | 99.5% | Glycosylphosphatidylinositol biosynthesis defect 17, 618010 |
| PIGK | 100.0% | 100.0% | 100.0% | 98.9% | Neurodevelopmental disorder with hypotonia and cerebellar atrophy, w/wo seizures, 618879 |
| PIGL | 100.0% | 100.0% | 100.0% | 98.8% | CHIME syndrome, 280000 |
| PIGM | 100.0% | 100.0% | 100.0% | 99.2% | Glycosylphosphatidylinositol deficiency, 610293 |
| PIGN | 100.0% | 99.9% | 100.0% | 99.2% | Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 |
| PIGO | 100.0% | 100.0% | 100.0% | 99.9% | Hyperphosphatasia with impaired intellectual development syndrome 2, 614749 |
| PIGP | 100.0% | 100.0% | 100.0% | 99.2% | Developmental and epileptic encephalopathy 55, 617599 |
| PIGQ | 100.0% | 100.0% | 100.0% | 99.9% | Multiple congenital anomalies-hypotonia-seizures syndrome 4, 618548 |
| PIGS | 100.0% | 100.0% | 100.0% | 99.7% | Developmental and epileptic encephalopathy 95, 618143 |
| PIGT | 100.0% | 100.0% | 100.0% | 99.3% | ?Paroxysmal nocturnal hemoglobinuria 2, 615399 Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 |
| PIGU | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with brain anomalies, seizures, and scoliosis, 618590 |
| PIGV | 100.0% | 100.0% | 100.0% | 99.8% | Hyperphosphatasia with impaired intellectual development syndrome 1, 239300 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| PIGW | 100.0% | 100.0% | 100.0% | 99.6% | Glycosylphosphatidylinositol biosynthesis defect 11, 616025 |
| PIGY | 100.0% | 100.0% | 100.0% | 99.3% | Hyperphosphatasia with impaired intellectual development syndrome 6, 616809 |
| PIK3C2A | 100.0% | 100.0% | 100.0% | 99.3% | Oculoskeletodental syndrome, 618440 |
| PIK3R1 | 100.0% | 100.0% | 100.0% | 99.2% | Immunodeficiency 36, 616005 ?Agammaglobulinemia 7, autosomal recessive, 615214 SHORT syndrome, 269880 |
| PIK3R5 | 100.0% | 100.0% | 100.0% | 99.7% | Ataxia-oculomotor apraxia 3, 615217 |
| PINK1 | 100.0% | 100.0% | 100.0% | 99.7% | Parkinson disease 6, early onset, 605909 |
| PIP5K1C | 100.0% | 100.0% | 100.0% | 99.4% | Lethal congenital contractural syndrome 3, 611369 |
| PJVK | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal recessive 59, 610220 |
| PKD1L1 | 100.0% | 100.0% | 100.0% | 99.4% | Heterotaxy, visceral, 8, autosomal, 617205 |
| PKHD1 | 100.0% | 100.0% | 100.0% | 99.6% | Polycystic kidney disease 4, w/wo hepatic disease, 263200 |
| PKLR | 100.0% | 100.0% | 100.0% | 99.8% | Adenosine triphosphate, elevated, of erythrocytes, 102900 Pyruvate kinase deficiency, 266200 |
| PKP1 | 100.0% | 100.0% | 100.0% | 99.7% | Ectodermal dysplasia/skin fragility syndrome, 604536 |
| PLA2G6 | 100.0% | 99.9% | 100.0% | 99.4% | Parkinson disease 14, autosomal recessive, 612953 Neurodegeneration with brain iron accumulation 2B, 610217 Infantile neuroaxonal dystrophy 1, 256600 |
| PLA2G7 | 100.0% | 100.0% | 100.0% | 99.0% | Platelet-activating factor acetylhydrolase deficiency, 614278 |
| PLAA | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527 |
| PLCB1 | 100.0% | 100.0% | 100.0% | 99.2% | Developmental and epileptic encephalopathy 12, 613722 |
| PLCB4 | 100.0% | 99.9% | 100.0% | 99.3% | Auriculocondylar syndrome 2B, 620458 Auriculocondylar syndrome 2A, 614669 |
| PLCD1 | 100.0% | 100.0% | 100.0% | 100.0% | Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 |
| PLCE1 | 100.0% | 99.8% | 100.0% | 99.2% | Nephrotic syndrome, type 3, 610725 |
| PLD1 | 100.0% | 100.0% | 100.0% | 99.3% | Cardiac valvular dysplasia 1, 212093 |
| PLEC | 100.0% | 100.0% | 100.0% | 100.0% | ?Epidermolysis bullosa simplex 5D, generalized intermediate, autosomal recessive, 616487 Epidermolysis bullosa simplex 5B, with muscular dystrophy, 226670 Epidermolysis bullosa simplex 5C, with pyloric atresia, 612138 Epidermolysis bullosa simplex 5A, Ogna type, 131950 Muscular dystrophy, limb-girdle, autosomal recessive 17, 613723 |
| PLEKHG2 | 100.0% | 100.0% | 100.0% | 99.6% | Leukodystrophy and acquired microcephaly w/wo dystonia, 616763 |
| PLEKHG5 | 100.0% | 100.0% | 100.0% | 99.9% | Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 Charcot-Marie-Tooth disease, recessive intermediate C, 615376 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| PLEKHM1 | 100.0% | 100.0% | 100.0% | 99.5% | ?Osteopetrosis, autosomal recessive 6, 611497 Osteopetrosis, autosomal dominant 3, 618107 |
| PLG | 100.0% | 100.0% | 100.0% | 99.4% | Dysplasminogenemia, 217090 Angioedema, hereditary, 4, 619360 Plasminogen deficiency, type I, 217090 |
| PLK4 | 100.0% | 100.0% | 100.0% | 99.1% | Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 |
| PLOD1 | 100.0% | 100.0% | 100.0% | 99.0% | Ehlers-Danlos syndrome, kyphoscoliotic type, 1, 225400 |
| PLOD2 | 100.0% | 100.0% | 99.9% | 98.4% | Bruck syndrome 2, 609220 |
| PLOD3 | 100.0% | 100.0% | 100.0% | 99.4% | Lysyl hydroxylase 3 deficiency, 612394 |
| PLPBP | 100.0% | 100.0% | 100.0% | 99.5% | Epilepsy, early-onset, 1, vitamin B6-dependent, 617290 |
| PLVAP | 100.0% | 100.0% | 100.0% | 99.8% | Diarrhea 10, protein-losing enteropathy type, 618183 |
| PMM2 | 100.0% | 100.0% | 100.0% | 98.7% | Congenital disorder of glycosylation, type Ia, 212065 |
| PMPCA | 100.0% | 100.0% | 100.0% | 99.8% | Spinocerebellar ataxia, autosomal recessive 2, 213200 |
| PMPCB | 100.0% | 100.0% | 100.0% | 99.4% | Multiple mitochondrial dysfunctions syndrome 6, 617954 |
| PMS2 | 100.0% | 100.0% | 99.7% | 96.6% | Lynch syndrome 4, 614337 Mismatch repair cancer syndrome 4, 619101 |
| PNKP | 100.0% | 100.0% | 100.0% | 99.9% | ?Charcot-Marie-Tooth disease, type 2B2, 605589 Ataxia-oculomotor apraxia 4, 616267 Microcephaly, seizures, and developmental delay, 613402 |
| PNLIP | 100.0% | 100.0% | 100.0% | 99.3% | ?Pancreatic lipase deficiency, 614338 |
| PNP | 100.0% | 100.0% | 100.0% | 99.8% | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 |
| PNPLA1 | 100.0% | 99.9% | 100.0% | 98.3% | Ichthyosis, congenital, autosomal recessive 10, 615024 |
| PNPLA2 | 100.0% | 100.0% | 100.0% | 99.8% | Neutral lipid storage disease with myopathy, 610717 |
| PNPLA6 | 100.0% | 100.0% | 100.0% | 99.9% | Spastic paraplegia 39, autosomal recessive, 612020 Oliver-McFarlane syndrome, 275400 ?Laurence-Moon syndrome, 245800 Boucher-Neuhauser syndrome, 215470 |
| PNPLA8 | 100.0% | 100.0% | 100.0% | 98.7% | ?Mitochondrial myopathy with lactic acidosis, 251950 |
| PNPO | 100.0% | 100.0% | 100.0% | 99.8% | Pyridoxamine 5'-phosphate oxidase deficiency, 610090 |
| PNPT1 | 100.0% | 100.0% | 100.0% | 99.3% | Spinocerebellar ataxia 25, 608703 Deafness, autosomal recessive 70, w/wo adult-onset neurodegeneration, 614934 Combined oxidative phosphorylation deficiency 13, 614932 |
| POC1A | 100.0% | 100.0% | 100.0% | 99.8% | Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 |
| POC1B | 100.0% | 100.0% | 100.0% | 99.6% | Cone-rod dystrophy 20, 615973 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| POGLUT1 | 100.0% | 100.0% | 100.0% | 99.3% | Dowling-Degos disease 4, 615696 Muscular dystrophy, limb-girdle, autosomal recessive 21, 617232 |
| POLE | 100.0% | 100.0% | 100.0% | 99.7% | FILS syndrome, 615139 IMAGE-I syndrome, 618336 |
| POLG | 100.0% | 100.0% | 100.0% | 99.8% | Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 Progressive external ophthalmoplegia, autosomal dominant 1, 157640 Progressive external ophthalmoplegia, autosomal recessive 1, 258450 |
| POLH | 100.0% | 100.0% | 100.0% | 99.7% | Xeroderma pigmentosum, variant type, 278750 |
| POLR1C | 83.3% | 83.2% | 100.0% | 99.8% | Leukodystrophy, hypomyelinating, 11, 616494 Treacher Collins syndrome 3, 248390 |
| POLR1D | 100.0% | 100.0% | 100.0% | 99.7% | Treacher Collins syndrome 2, 613717 |
| POLR3A | 100.0% | 100.0% | 100.0% | 99.5% | Wiedemann-Rautenstrauch syndrome, 264090 Leukodystrophy, hypomyelinating, 7, w/wo oligodontia and/or hypogonadotropic hypogonadism, 607694 |
| POLR3B | 100.0% | 99.9% | 100.0% | 99.0% | Leukodystrophy, hypomyelinating, 8, w/wo oligodontia and/or hypogonadotropic hypogonadism, 614381 Charcot-Marie-Tooth disease, demyelinating, type 1I, 619742 |
| POMC | 100.0% | 100.0% | 100.0% | 99.8% | Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 |
| POMGNT1 | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 3, 613151 Retinitis pigmentosa 76, 617123 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 |
| POMGNT2 | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 8, 614830 Muscular dystrophy-dystroglycanopathy (limb-girdle) type C, 8, 618135 |
| POMK | 100.0% | 100.0% | 100.0% | 99.7% | ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 |
| POMP | 100.0% | 100.0% | 100.0% | 98.6% | Proteasome-associated autoinflammatory syndrome 2, 618048 Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| POMT1 | 100.0% | 100.0% | 100.0% | 99.7% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 1, 613155 |
| POMT2 | 100.0% | 100.0% | 100.0% | 98.8% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 Muscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 2, 613156 |
| POP1 | 100.0% | 100.0% | 100.0% | 99.5% | Anauxetic dysplasia 2, 617396 |
| POR | 100.0% | 100.0% | 100.0% | 100.0% | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 |
| POU1F1 | 100.0% | 100.0% | 100.0% | 99.6% | Pituitary hormone deficiency, combined or isolated, 1, 613038 |
| PPA2 | 100.0% | 99.9% | 100.0% | 98.7% | ?Sudden cardiac failure, alcohol-induced, 617223 Sudden cardiac failure, infantile, 617222 |
| PPCS | 100.0% | 100.0% | 100.0% | 99.8% | Cardiomyopathy, dilated, 2C, 618189 |
| PPIB | 100.0% | 100.0% | 100.0% | 99.6% | Osteogenesis imperfecta, type IX, 259440 |
| PPIL1 | 100.0% | 100.0% | 100.0% | 99.6% | Pontocerebellar hypoplasia, type 14, 619301 |
| PPIP5K2 | 100.0% | 100.0% | 100.0% | 99.7% | Deafness, autosomal recessive 100, 618422 |
| PPM1K | 100.0% | 100.0% | 100.0% | 99.6% | ?Maple syrup urine disease, mild variant, 615135 |
| PPP1R15B | 100.0% | 100.0% | 100.0% | 99.1% | Microcephaly, short stature, and impaired glucose metabolism 2, 616817 |
| PPP1R21 | 100.0% | 100.0% | 100.0% | 99.1% | Neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, 619383 |
| PPP2R3C | 100.0% | 100.0% | 100.0% | 99.3% | Spermatogenic failure 36, 618420 Myoectodermal gonadal dysgenesis syndrome, 618419 |
| PPT1 | 90.3% | 90.3% | 100.0% | 99.4% | Ceroid lipofuscinosis, neuronal, 1, 256730 |
| PRCD | 100.0% | 100.0% | 100.0% | 96.3% | Retinitis pigmentosa 36, 610599 |
| PRDM12 | 95.7% | 92.4% | 100.0% | 99.0% | Neuropathy, hereditary sensory and autonomic, type VIII, 616488 |
| PRDM13 | 100.0% | 100.0% | 100.0% | 99.6% | Pontocerebellar hypoplasia, type 17, 619909 Cerebellar dysfunction, impaired intellectual development, and hypogonadotropic hypogonadism, 619761 |
| PRDM5 | 100.0% | 100.0% | 100.0% | 99.4% | Brittle cornea syndrome 2, 614170 |
| PRDX1 | 100.0% | 100.0% | 100.0% | 97.9% | Methylmalonic aciduria and homocystinuria, cblC type, digenic, 277400 |
| PREPL | 100.0% | 100.0% | 100.0% | 99.0% | Myasthenic syndrome, congenital, 22, 616224 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| | | | | | Hemophagocytic lymphohistiocytosis, familial, 2, 603553 |
| PRF1 | 100.0% | 100.0% | 100.0% | 100.0% | Aplastic anemia, 609135 Lymphoma, non-Hodgkin, 605027 |
| PRG4 | 100.0% | 100.0% | 99.9% | 95.2% | Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 |
| PRICKLE1 | 100.0% | 100.0% | 100.0% | 99.1% | Epilepsy, progressive myoclonic 1B, 612437 |
| PRKCD | 100.0% | 100.0% | 100.0% | 99.8% | Autoimmune lymphoproliferative syndrome, type III, 615559 |
| PRKDC | 100.0% | 100.0% | 100.0% | 99.4% | Immunodeficiency 26, w/wo neurologic abnormalities, 615966 |
| PRKN | 91.9% | 91.1% | 100.0% | 99.2% | Adenocarcinoma of lung, somatic, 211980 Parkinson disease, juvenile, type 2, 600116 Ovarian cancer, somatic, 167000 |
| PRKRA | 100.0% | 100.0% | 100.0% | 99.4% | Dystonia 16, 612067 |
| PRMT7 | 100.0% | 100.0% | 100.0% | 99.9% | Short stature, brachydactyly, intellectual developmental disability, and seizures, 617157 |
| PROC | 100.0% | 100.0% | 100.0% | 100.0% | Thrombophilia 3 due to protein C deficiency, autosomal dominant, 176860 Thrombophilia 3 due to protein C deficiency, autosomal recessive, 612304 |
| PRODH | 100.0% | 100.0% | 100.0% | 99.9% | Hyperprolinemia, type I, 239500 |
| PROM1 | 100.0% | 100.0% | 100.0% | 99.1% | Macular dystrophy, retinal, 2, 608051 Retinitis pigmentosa 41, 612095 Stargardt disease 4, 603786 Cone-rod dystrophy 12, 612657 |
| PROP1 | 100.0% | 100.0% | 99.9% | 96.3% | Pituitary hormone deficiency, combined, 2, 262600 |
| PRORP | 100.0% | 100.0% | 100.0% | 99.1% | Combined oxidative phosphorylation deficiency 54, 619737 |
| PROS1 | 100.0% | 100.0% | 100.0% | 99.4% | Thrombophilia 5 due to protein S deficiency, autosomal recessive, 614514 Thrombophilia 5 due to protein S deficiency, autosomal dominant, 612336 |
| PRSS12 | 100.0% | 100.0% | 100.0% | 99.8% | Intellectual developmental disorder, autosomal recessive 1, 249500 |
| PRSS56 | 100.0% | 100.0% | 100.0% | 99.8% | Microphthalmia, isolated 6, 613517 |
| PRUNE1 | 93.4% | 93.1% | 100.0% | 99.2% | Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481 |
| PRX | 100.0% | 100.0% | 100.0% | 99.8% | Charcot-Marie-Tooth disease, type 4F, 614895 Dejerine-Sottas disease, 145900 |
| PSAP | 100.0% | 100.0% | 100.0% | 99.8% | Combined SAP deficiency, 611721 Krabbe disease, atypical, 611722 Metachromatic leukodystrophy due to SAP-b deficiency, 249900 Gaucher disease, atypical, 610539 |
| PSAT1 | 100.0% | 100.0% | 100.0% | 99.3% | Neu-Laxova syndrome 2, 616038 ?Phosphoserine aminotransferase deficiency, 610992 |
| PSMB4 | 100.0% | 100.0% | 100.0% | 98.8% | ?Proteasome-associated autoinflammatory syndrome 3 and digenic forms, 617591 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| PSMB8 | 100.0% | 100.0% | 100.0% | 99.2% | Proteasome-associated autoinflammatory syndrome 1 and digenic forms, 256040 |
| PSMB9 | 100.0% | 100.0% | 100.0% | 99.5% | ?Proteasome-associated autoinflammatory syndrome 3, digenic, 617591 |
| PSMC3IP | 100.0% | 100.0% | 100.0% | 99.6% | Ovarian dysgenesis 3, 614324 |
| PSPH | 100.0% | 100.0% | 100.0% | 98.8% | Phosphoserine phosphatase deficiency, 614023 |
| PTF1A | 100.0% | 100.0% | 100.0% | 98.6% | Pancreatic and cerebellar agenesis, 609069 |
| | | | | | Pancreatic agenesis 2, 615935 |
| PTH1R | 100.0% | 100.0% | 100.0% | 99.7% | Metaphyseal chondrodysplasia, Murk Jansen type, 156400 |
| | | | | | Eiken syndrome, 600002 |
| | | | | | Failure of tooth eruption, primary, 125350 |
| PTPN14 | 100.0% | 100.0% | 100.0% | 99.7% | Chondrodysplasia, Blomstrand type, 215045 |
| PTPN23 | 100.0% | 100.0% | 100.0% | 99.7% | Choanal atresia and lymphedema, 613611 |
| PTPN23 | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder and structural brain anomalies w/wo seizures and spasticity, 618890 |
| PTPRC | 100.0% | 99.8% | 100.0% | 99.3% | Immunodeficiency 105, severe combined, 619924 |
| PTPRO | 99.8% | 99.1% | 100.0% | 99.5% | Nephrotic syndrome, type 6, 614196 |
| PTPRQ | 91.9% | 91.9% | 100.0% | 99.4% | Deafness, autosomal dominant 73, 617663 |
| | | | | | Deafness, autosomal recessive 84A, 613391 |
| PTRH2 | 100.0% | 100.0% | 100.0% | 99.9% | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 |
| PTS | 100.0% | 100.0% | 100.0% | 99.0% | Hyperphenylalaninemia, BH4-deficient, A, 261640 |
| PUS1 | 100.0% | 100.0% | 100.0% | 99.8% | Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462 |
| PUS3 | 100.0% | 100.0% | 100.0% | 99.7% | Neurodevelopmental disorder with microcephaly and gray sclerae, 617051 |
| PUS7 | 100.0% | 100.0% | 100.0% | 99.1% | Intellectual developmental disorder with abnormal behavior, microcephaly, and short stature, 618342 |
| PXDN | 100.0% | 100.0% | 100.0% | 99.8% | Anterior segment dysgenesis 7, with sclerocornea, 269400 |
| PYCR1 | 100.0% | 100.0% | 100.0% | 100.0% | Cutis laxa, autosomal recessive, type IIIB, 614438 |
| | | | | | Cutis laxa, autosomal recessive, type IIB, 612940 |
| PYCR2 | 100.0% | 100.0% | 100.0% | 99.9% | Leukodystrophy, hypomyelinating, 10, 616420 |
| PYGL | 100.0% | 100.0% | 100.0% | 99.5% | Glycogen storage disease VI, 232700 |
| PYGM | 100.0% | 100.0% | 100.0% | 99.9% | McArdle disease, 232600 |
| PYROXD1 | 100.0% | 100.0% | 100.0% | 99.0% | Myopathy, myofibrillar, 8, 617258 |
| QARS1 | 100.0% | 100.0% | 100.0% | 99.7% | Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 |
| QDPR | 100.0% | 100.0% | 100.0% | 98.9% | Hyperphenylalaninemia, BH4-deficient, C, 261630 |
| RAB18 | 100.0% | 100.0% | 100.0% | 99.6% | Warburg micro syndrome 3, 614222 |
| RAB23 | 100.0% | 100.0% | 100.0% | 98.9% | Carpenter syndrome, 201000 |
| RAB27A | 100.0% | 100.0% | 100.0% | 100.0% | GrisCELLI syndrome, type 2, 607624 |
| RAB28 | 100.0% | 100.0% | 100.0% | 99.5% | Cone-rod dystrophy 18, 615374 |
| RAB33B | 100.0% | 100.0% | 100.0% | 99.5% | Smith-McCort dysplasia 2, 615222 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| RAB3GAP1 | 99.0% | 99.0% | 100.0% | 99.0% | Martsof syndrome 2, 619420 Warburg micro syndrome 1, 600118 |
| RAB3GAP2 | 100.0% | 100.0% | 100.0% | 99.0% | Martsof syndrome 1, 212720 Warburg micro syndrome 2, 614225 |
| RAD50 | 100.0% | 100.0% | 100.0% | 98.7% | Nijmegen breakage syndrome-like disorder, 613078 |
| RAD51C | 100.0% | 100.0% | 100.0% | 98.9% | Fanconi anemia, complementation group O, 613390 |
| RAG1 | 100.0% | 100.0% | 100.0% | 99.7% | Omenn syndrome, 603554 Severe combined immunodeficiency, B cell-negative, 601457 Combined cellular and humoral immune defects with granulomas, 233650 Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 |
| RAG2 | 100.0% | 100.0% | 100.0% | 99.3% | Severe combined immunodeficiency, B cell-negative, 601457 Combined cellular and humoral immune defects with granulomas, 233650 Omenn syndrome, 603554 |
| RALGAPA1 | 100.0% | 99.9% | 100.0% | 99.3% | Neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, 618797 |
| RAPSN | 100.0% | 100.0% | 100.0% | 99.9% | Fetal akinesia deformation sequence 2, 618388 Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 |
| RARB | 100.0% | 100.0% | 100.0% | 99.8% | Microphthalmia, syndromic 12, 615524 |
| RARS1 | 94.4% | 94.3% | 100.0% | 98.8% | Leukodystrophy, hypomyelinating, 9, 616140 |
| RARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Pontocerebellar hypoplasia, type 6, 611523 |
| RASGRP1 | 100.0% | 100.0% | 100.0% | 99.8% | Immunodeficiency 64, 618534 |
| RAX | 100.0% | 100.0% | 100.0% | 99.5% | Microphthalmia, syndromic 16, 611038 |
| RBBP8 | 100.0% | 100.0% | 100.0% | 98.7% | Seckel syndrome 2, 606744 Jawad syndrome, 251255 Pancreatic carcinoma, somatic, |
| RBCK1 | 100.0% | 100.0% | 100.0% | 99.6% | Polyglucosan body myopathy 1 w/wo immunodeficiency, 615895 |
| RBM8A | 100.0% | 100.0% | 100.0% | 99.2% | Thrombocytopenia-absent radius syndrome, 274000 |
| RBP3 | 100.0% | 100.0% | 100.0% | 99.9% | ?Retinitis pigmentosa 66, 615233 |
| RBP4 | 100.0% | 100.0% | 100.0% | 99.6% | Microphthalmia, isolated, with coloboma 10, 616428 Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 |
| RCBTB1 | 100.0% | 100.0% | 100.0% | 99.6% | Retinal dystrophy w/wo extraocular anomalies, 617175 |
| RD3 | 100.0% | 100.0% | 100.0% | 100.0% | Leber congenital amaurosis 12, 610612 |
| RDH11 | 100.0% | 100.0% | 100.0% | 99.7% | ?Retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| RDH12 | 100.0% | 100.0% | 100.0% | 99.5% | Leber congenital amaurosis 13, 612712 |
| RDH5 | 100.0% | 100.0% | 100.0% | 99.8% | Fundus albipunctatus, 136880 |
| RDX | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal recessive 24, 611022 |
| RECQL4 | 100.0% | 100.0% | 100.0% | 100.0% | Baller-Gerold syndrome, 218600 Rothmund-Thomson syndrome, type 2, 268400 RAPADILINO syndrome, 266280 |
| REEP2 | 100.0% | 100.0% | 100.0% | 99.7% | ?Spastic paraplegia 72, autosomal dominant, 615625 ?Spastic paraplegia 72, autosomal recessive, 615625 |
| REEP6 | 100.0% | 100.0% | 100.0% | 99.6% | Retinitis pigmentosa 77, 617304 |
| RELB | 100.0% | 99.9% | 100.0% | 99.7% | ?Immunodeficiency 53, 617585 |
| RELN | 99.9% | 99.7% | 100.0% | 99.5% | Lissencephaly 2 (Norman-Roberts type), 257320 |
| REN | 100.0% | 100.0% | 100.0% | 99.1% | Renal tubular dysgenesis, 267430 Tubulointerstitial kidney disease, autosomal dominant, 4, 613092 |
| REPS1 | 100.0% | 100.0% | 100.0% | 99.4% | ?Neurodegeneration with brain iron accumulation 7, 617916 |
| RETREG1 | 100.0% | 100.0% | 100.0% | 99.2% | Neuropathy, hereditary sensory and autonomic, type IIB, 613115 |
| RFC1 | 100.0% | 100.0% | 100.0% | 98.5% | Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, 614575 |
| RFT1 | 100.0% | 100.0% | 100.0% | 99.4% | Congenital disorder of glycosylation, type In, 612015 |
| RFWD3 | 100.0% | 100.0% | 100.0% | 99.3% | ?Fanconi anemia, complementation group W, 617784 |
| RFX5 | 100.0% | 100.0% | 100.0% | 99.4% | Bare lymphocyte syndrome, type II, complementation group C, 209920 Bare lymphocyte syndrome, type II, complementation group E, 209920 |
| RFX6 | 100.0% | 100.0% | 100.0% | 99.4% | Mitchell-Riley syndrome, 615710 |
| RFXANK | 100.0% | 100.0% | 100.0% | 100.0% | Bare lymphocyte syndrome, type II, complementation group B, 209920 |
| RFXAP | 100.0% | 100.0% | 100.0% | 99.4% | Bare lymphocyte syndrome, type II, complementation group D, 209920 |
| RGR | 100.0% | 100.0% | 100.0% | 99.9% | Retinitis pigmentosa 44, 613769 |
| RHO | 100.0% | 100.0% | 100.0% | 99.8% | Night blindness, congenital stationary, autosomal dominant 1, 610445 Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 Retinitis punctata albescens, 136880 |
| RIMS2 | 100.0% | 99.9% | 100.0% | 99.2% | Cone-rod synaptic disorder syndrome, congenital nonprogressive, 618970 |
| RIN2 | 100.0% | 100.0% | 100.0% | 99.1% | Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 |
| RINT1 | 100.0% | 100.0% | 100.0% | 99.3% | Infantile liver failure syndrome 3, 618641 |
| RIPK1 | 100.0% | 100.0% | 100.0% | 99.3% | Immunodeficiency 57 with autoinflammation, 618108 Autoinflammation with episodic fever and lymphadenopathy, 618852 |
| RIPK4 | 100.0% | 100.0% | 100.0% | 99.9% | CHAND syndrome, 214350 Popliteal pterygium syndrome, Bartsocas-Papas type 1, 263650 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| RIPOR2 | 100.0% | 100.0% | 100.0% | 99.2% | Deafness, autosomal dominant 21, 607017 ?Deafness, autosomal recessive 104, 616515 |
| RIPPLY2 | 100.0% | 100.0% | 100.0% | 97.5% | ?Spondylocostal dysostosis 6, 616566 |
| RLBP1 | 100.0% | 100.0% | 100.0% | 99.7% | Bothnia retinal dystrophy, 607475 Newfoundland rod-cone dystrophy, 607476 Retinitis punctata albescens, 136880 Fundus albipunctatus, 136880 |
| RMND1 | 100.0% | 100.0% | 100.0% | 99.3% | Combined oxidative phosphorylation deficiency 11, 614922 |
| RMRP | | | | | Anauxetic dysplasia 1, 607095 Metaphyseal dysplasia without hypotrichosis, 250460 Cartilage-hair hypoplasia, 250250 |
| RNASEH1 | 100.0% | 100.0% | 100.0% | 99.3% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, 616479 |
| RNASEH2A | 100.0% | 100.0% | 100.0% | 99.9% | Aicardi-Goutieres syndrome 4, 610333 |
| RNASEH2B | 91.4% | 91.4% | 100.0% | 98.7% | Aicardi-Goutieres syndrome 2, 610181 |
| RNASEH2C | 100.0% | 100.0% | 100.0% | 99.7% | Aicardi-Goutieres syndrome 3, 610329 |
| RNASET2 | 100.0% | 100.0% | 100.0% | 99.3% | Leukoencephalopathy, cystic, without megalencephaly, 612951 |
| RNF168 | 100.0% | 100.0% | 100.0% | 99.4% | RIDDLE syndrome, 611943 |
| RNF216 | 100.0% | 100.0% | 100.0% | 99.4% | Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 |
| RNPC3 | 100.0% | 100.0% | 100.0% | 98.6% | Pituitary hormone deficiency, combined or isolated, 7, 618160 |
| ROBO3 | 100.0% | 100.0% | 100.0% | 99.4% | Gaze palsy, familial horizontal, with progressive scoliosis, 1, 607313 |
| ROGDI | 100.0% | 100.0% | 100.0% | 99.8% | Kohlschutter-Tonz syndrome, 226750 |
| ROR2 | 100.0% | 100.0% | 100.0% | 99.8% | Brachydactyly, type B1, 113000 Robinow syndrome, autosomal recessive, 268310 |
| RORC | 100.0% | 100.0% | 100.0% | 99.9% | Immunodeficiency 42, 616622 |
| RP1 | 100.0% | 100.0% | 100.0% | 97.8% | Retinitis pigmentosa 1, 180100 |
| RP1L1 | 100.0% | 100.0% | 100.0% | 99.4% | Occult macular dystrophy, 613587 Retinitis pigmentosa 88, 618826 |
| RPE65 | 100.0% | 100.0% | 100.0% | 99.0% | Retinitis pigmentosa 20, 613794 Retinitis pigmentosa 87 with choroidal involvement, 618697 Leber congenital amaurosis 2, 204100 |
| RPGRIP1 | 100.0% | 100.0% | 100.0% | 99.2% | Cone-rod dystrophy 13, 608194 Leber congenital amaurosis 6, 613826 |
| RPGRIP1L | 100.0% | 100.0% | 100.0% | 98.8% | Joubert syndrome 7, 611560 Meckel syndrome 5, 611561 ?COACH syndrome 3, 619113 |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| RPIA | 100.0% | 100.0% | 100.0% | 99.5% | Ribose 5-phosphate isomerase deficiency, 608611 |
| | | | | | Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 Rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunction, 268315 |
| RRM2B | 100.0% | 100.0% | 100.0% | 98.9% | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5, 613077 |
| RSPH1 | 100.0% | 100.0% | 100.0% | 99.7% | Ciliary dyskinesia, primary, 24, 615481 |
| RSPH3 | 100.0% | 100.0% | 100.0% | 99.5% | Ciliary dyskinesia, primary, 32, 616481 |
| RSPH4A | 100.0% | 100.0% | 100.0% | 98.4% | Ciliary dyskinesia, primary, 11, 612649 |
| RSPH9 | 100.0% | 100.0% | 100.0% | 99.7% | Ciliary dyskinesia, primary, 12, 612650 |
| | | | | | Palmoplantar hyperkeratosis and true hermaphroditism, 610644 Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 |
| RSPO1 | 100.0% | 100.0% | 100.0% | 99.9% | |
| | | | | | ?Humero-femoral hypoplasia with radiotibial ray deficiency, 618022 |
| RSPO2 | 100.0% | 99.9% | 100.0% | 99.5% | Tetraamelia syndrome 2, 618021 |
| RSPO4 | 100.0% | 100.0% | 100.0% | 99.7% | Anonychia congenita, 206800 |
| RSPRY1 | 100.0% | 100.0% | 100.0% | 99.2% | Spondyloepimetaphyseal dysplasia, Faden-Alkuraya type, 616723 |
| RSRC1 | 100.0% | 99.9% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 70, 618402 |
| | | | | | Dyskeratosis congenita, autosomal dominant 4, 615190 Dyskeratosis congenita, autosomal recessive 5, 615190 |
| RTEL1 | 100.0% | 100.0% | 100.0% | 99.9% | Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 3, 616373 |
| RTN4IP1 | 100.0% | 100.0% | 100.0% | 99.4% | Optic atrophy 10 w/wo ataxia, impaired intellectual development and seizures, 616732 |
| RTTN | 100.0% | 99.9% | 100.0% | 99.4% | Microcephaly, short stature, and polymicrogyria with seizures, 614833 |
| RUBCN | 100.0% | 100.0% | 100.0% | 99.5% | Spinocerebellar ataxia, autosomal recessive 15, 615705 |
| RUSC2 | 100.0% | 100.0% | 100.0% | 99.8% | Intellectual developmental disorder, autosomal recessive 61, 617773 |
| RXYLT1 | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 |
| | | | | | Congenital myopathy 1B, autosomal recessive, 255320 Congenital myopathy 1A, autosomal dominant, with susceptibility to malignant hyperthermia, 117000 |
| RYR1 | 100.0% | 99.9% | 100.0% | 99.7% | King-Denborough syndrome, 619542 |
| S1PR2 | 100.0% | 100.0% | 100.0% | 99.9% | Deafness, autosomal recessive 68, 610419 |
| SACS | 100.0% | 100.0% | 100.0% | 99.2% | Spastic ataxia, Charlevoix-Saguenay type, 270550 |
| | | | | | Retinitis pigmentosa 47, autosomal recessive, 613758 Retinitis pigmentosa 96, autosomal dominant, 620228 |
| SAG | 100.0% | 100.0% | 100.0% | 99.4% | Oguchi disease-1, 258100 |

| | | | | | |
|--------|--------|--------|--------|-------|---|
| SAMD9 | 100.0% | 100.0% | 100.0% | 99.0% | Tumoral calcinosis, familial, normophosphatemic, 610455 Monosomy 7 myelodysplasia and leukemia syndrome 2, 619041 MIRAGE syndrome, 617053 |
| SAMHD1 | 100.0% | 100.0% | 100.0% | 99.3% | ?Chilblain lupus 2, 614415 Aicardi-Goutieres syndrome 5, 612952 |
| SAR1B | 100.0% | 100.0% | 100.0% | 98.3% | Chylomicron retention disease, 246700 |
| SARS1 | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709 |
| SARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 |
| SASH1 | 100.0% | 100.0% | 100.0% | 99.3% | Dyschromatosis universalis hereditaria 1, 127500 ?Cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma, 618373 |
| SASS6 | 100.0% | 100.0% | 100.0% | 98.7% | Microcephaly 14, primary, autosomal recessive, 616402 |
| SBDS | 100.0% | 100.0% | 100.0% | 99.1% | Shwachman-Diamond syndrome 1, 260400 |
| SBF1 | 100.0% | 100.0% | 100.0% | 99.9% | Charcot-Marie-Tooth disease, type 4B3, 615284 |
| SBF2 | 100.0% | 100.0% | 100.0% | 99.2% | Charcot-Marie-Tooth disease, type 4B2, 604563 |
| SC5D | 100.0% | 100.0% | 100.0% | 98.7% | Lathosterolosis, 607330 |
| SCAPER | 100.0% | 100.0% | 100.0% | 99.2% | Intellectual developmental disorder and retinitis pigmentosa, 618195 |
| SCARB2 | 100.0% | 100.0% | 100.0% | 99.5% | Epilepsy, progressive myoclonic 4, w/wo renal failure, 254900 |
| SCARF2 | 100.0% | 100.0% | 100.0% | 98.3% | Van den Ende-Gupta syndrome, 600920 |
| SCN1B | 100.0% | 100.0% | 100.0% | 99.7% | Generalized epilepsy with febrile seizures plus, type 1, 604233 Developmental and epileptic encephalopathy 52, 617350 Cardiac conduction defect, nonspecific, 612838 Atrial fibrillation, familial, 13, 615377 Brugada syndrome 5, 612838 |
| SCN4A | 100.0% | 100.0% | 100.0% | 99.2% | Paramyotonia congenita, 168300 Hyperkalemic periodic paralysis, 170500 Congenital myopathy 22B, severe fetal, 620369 Hypokalemic periodic paralysis, type 2, 613345 Myotonia congenita, atypical, acetazolamide-responsive, 608390 Myasthenic syndrome, congenital, 16, 614198 Congenital myopathy 22A, classic, 620351 |
| SCN9A | 100.0% | 99.9% | 100.0% | 98.9% | Erythralgia, primary, 133020 Insensitivity to pain, congenital, 243000 Small fiber neuropathy, 133020 Paroxysmal extreme pain disorder, 167400 Neuropathy, hereditary sensory and autonomic, type IID, 243000 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| SCNN1A | 100.0% | 100.0% | 100.0% | 99.5% | Pseudohypoaldosteronism, type IB1, autosomal recessive, 264350 ?Liddle syndrome 3, 618126 Bronchiectasis w/wo elevated sweat chloride 2, 613021 |
| SCNN1B | 100.0% | 100.0% | 100.0% | 99.7% | Bronchiectasis w/wo elevated sweat chloride 1, 211400 Pseudohypoaldosteronism, type IB2, autosomal recessive, 620125 Liddle syndrome 1, 177200 |
| SCNN1G | 100.0% | 100.0% | 100.0% | 99.8% | Bronchiectasis w/wo elevated sweat chloride 3, 613071 Pseudohypoaldosteronism, type IB3, autosomal recessive, 620126 Liddle syndrome 2, 618114 |
| SCO1 | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex IV deficiency, nuclear type 4, 619048 |
| SCO2 | 100.0% | 100.0% | 100.0% | 99.7% | Myopia 6, 608908 Mitochondrial complex IV deficiency, nuclear type 2, 604377 |
| SCP2 | 100.0% | 100.0% | 100.0% | 99.3% | ?Leukoencephalopathy with dystonia and motor neuropathy, 613724 |
| SCYL1 | 100.0% | 100.0% | 100.0% | 99.5% | Spinocerebellar ataxia, autosomal recessive 21, 616719 |
| SDCCAG8 | 100.0% | 100.0% | 100.0% | 99.0% | Senior-Loken syndrome 7, 613615 Bardet-Biedl syndrome 16, 615993 |
| SDHA | 100.0% | 100.0% | 100.0% | 99.9% | Cardiomyopathy, dilated, 1GG, 613642 Mitochondrial complex II deficiency, nuclear type 1, 252011 Neurodegeneration with ataxia and late-onset optic atrophy, 619259 Parangliomas 5, 614165 |
| SDHAF1 | 100.0% | 100.0% | 100.0% | 100.0% | Mitochondrial complex II deficiency, nuclear type 2, 619166 |
| SDHB | 100.0% | 100.0% | 100.0% | 99.5% | Parangliomas 4, 115310 Mitochondrial complex II deficiency, nuclear type 4, 619224 Gastrointestinal stromal tumor, 606764 Pheochromocytoma, 171300 Paranglioma and gastric stromal sarcoma, 606864 |
| SDHD | 78.9% | 78.9% | 100.0% | 99.6% | Parangliomas 1, w/wo deafness, 168000 Paranglioma and gastric stromal sarcoma, 606864 Mitochondrial complex II deficiency, nuclear type 3, 619167 Pheochromocytoma, 171300 |
| SDR9C7 | 100.0% | 100.0% | 100.0% | 99.7% | Ichthyosis, congenital, autosomal recessive 13, 617574 |
| SEC23A | 100.0% | 100.0% | 100.0% | 99.1% | Craniolenticulosutural dysplasia, 607812 |
| SEC23B | 100.0% | 100.0% | 100.0% | 99.3% | ?Cowden syndrome 7, 616858 Dyserythropoietic anemia, congenital, type II, 224100 |
| SEC24D | 100.0% | 99.9% | 100.0% | 99.6% | Cole-Carpenter syndrome 2, 616294 |

| | | | | | |
|----------|--------|--------|--------|-------|---|
| SEC31A | 100.0% | 100.0% | 100.0% | 99.1% | ?Halperin-Birk syndrome, 618651 |
| SECISBP2 | 100.0% | 100.0% | 100.0% | 99.6% | Thyroid hormone metabolism, abnormal, 1, 609698 |
| SELENON | 93.1% | 91.1% | 100.0% | 99.2% | Congenital myopathy 3 with rigid spine, 602771 |
| SEMA4A | 100.0% | 100.0% | 100.0% | 98.7% | Retinitis pigmentosa 35, 610282 Cone-rod dystrophy 10, 610283 |
| SEPSECS | 100.0% | 100.0% | 100.0% | 99.5% | Pontocerebellar hypoplasia type 2D, 613811 |
| SERAC1 | 100.0% | 100.0% | 100.0% | 99.1% | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 |
| SERPINA1 | 100.0% | 100.0% | 100.0% | 99.5% | Hemorrhagic diathesis due to antithrombin Pittsburgh, 613490 Emphysema due to AAT deficiency, 613490 Emphysema-cirrhosis, due to AAT deficiency, 613490 |
| SERPINA6 | 100.0% | 100.0% | 100.0% | 99.7% | Corticosteroid-binding globulin deficiency, 611489 |
| SERPINB7 | 100.0% | 100.0% | 100.0% | 99.1% | Palmoplantar keratoderma, Nagashima type, 615598 |
| SERPINB8 | 100.0% | 100.0% | 100.0% | 99.1% | Peeling skin syndrome 5, 617115 |
| SERPINC1 | 100.0% | 100.0% | 100.0% | 99.7% | Thrombophilia 7 due to antithrombin III deficiency, 613118 |
| SERPINE1 | 100.0% | 100.0% | 100.0% | 99.0% | Plasminogen activator inhibitor-1 deficiency, 613329 |
| SERPINF1 | 100.0% | 100.0% | 100.0% | 99.4% | Osteogenesis imperfecta, type VI, 613982 |
| SERPINF2 | 100.0% | 100.0% | 100.0% | 99.2% | Alpha-2-plasmin inhibitor deficiency, 262850 |
| SERPING1 | 100.0% | 100.0% | 100.0% | 98.9% | Angioedema, hereditary, 1 and 2, 106100 Complement component 4, partial deficiency of, 120790 |
| SERPINH1 | 100.0% | 100.0% | 100.0% | 99.7% | Osteogenesis imperfecta, type X, 613848 |
| SETX | 100.0% | 100.0% | 100.0% | 99.2% | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2, 606002 Amyotrophic lateral sclerosis 4, juvenile, 602433 |
| SFRP4 | 100.0% | 100.0% | 100.0% | 99.9% | Pyle disease, 265900 |
| SFTPB | 100.0% | 100.0% | 100.0% | 99.9% | Surfactant metabolism dysfunction, pulmonary, 1, 265120 |
| SFXN4 | 100.0% | 100.0% | 100.0% | 97.9% | Combined oxidative phosphorylation deficiency 18, 615578 |
| SGCA | 100.0% | 100.0% | 100.0% | 99.9% | Muscular dystrophy, limb-girdle, autosomal recessive 3, 608099 |
| SGCB | 100.0% | 100.0% | 100.0% | 99.3% | Muscular dystrophy, limb-girdle, autosomal recessive 4, 604286 |
| SGCD | 100.0% | 99.8% | 100.0% | 99.1% | Cardiomyopathy, dilated, 1L, 606685 Muscular dystrophy, limb-girdle, autosomal recessive 6, 601287 |
| SGCG | 100.0% | 100.0% | 100.0% | 99.7% | Muscular dystrophy, limb-girdle, autosomal recessive 5, 253700 |
| SGO1 | 100.0% | 100.0% | 100.0% | 98.0% | Chronic atrial and intestinal dysrhythmia, 616201 |
| SGPL1 | 100.0% | 100.0% | 100.0% | 99.5% | RENI syndrome, 617575 |
| SGSH | 100.0% | 100.0% | 100.0% | 99.9% | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900 |
| SH3PXD2B | 100.0% | 100.0% | 100.0% | 99.5% | Frank-ter Haar syndrome, 249420 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| SH3TC2 | 100.0% | 100.0% | 100.0% | 99.8% | Charcot-Marie-Tooth disease, type 4C, 601596 Mononeuropathy of the median nerve, mild, 613353 |
| SI | 99.0% | 98.3% | 100.0% | 99.5% | Sucrase-isomaltase deficiency, congenital, 222900 |
| SIGMAR1 | 100.0% | 100.0% | 100.0% | 100.0% | ?Spinal muscular atrophy, distal, autosomal recessive, 2, 605726 ?Amyotrophic lateral sclerosis 16, juvenile, 614373 |
| SIK3 | 100.0% | 100.0% | 100.0% | 99.5% | ?Spondyloepimetaphyseal dysplasia, Krakow type, 618162 |
| SIL1 | 100.0% | 100.0% | 100.0% | 99.7% | Marinesco-Sjogren syndrome, 248800 |
| SIX6 | 100.0% | 100.0% | 100.0% | 100.0% | Optic disc anomalies with retinal and/or macular dystrophy, 212550 |
| SKIV2L | 100.0% | 100.0% | 100.0% | 99.7% | Trichohepatoenteric syndrome 2, 614602 |
| SLC10A7 | 100.0% | 100.0% | 100.0% | 99.6% | Short stature, amelogenesis imperfecta, and skeletal dysplasia with scoliosis, 618363 |
| SLC11A2 | 100.0% | 100.0% | 100.0% | 99.5% | Anemia, hypochromic microcytic, with iron overload 1, 206100 |
| SLC12A1 | 96.3% | 96.2% | 100.0% | 99.4% | Bartter syndrome, type 1, 601678 |
| SLC12A2 | 100.0% | 100.0% | 100.0% | 98.9% | Kilquist syndrome, 619080 Delpire-McNeill syndrome, 619083 Deafness, autosomal dominant 78, 619081 |
| SLC12A3 | 100.0% | 100.0% | 100.0% | 99.5% | Gitelman syndrome, 263800 |
| SLC12A5 | 100.0% | 100.0% | 100.0% | 99.5% | Developmental and epileptic encephalopathy 34, 616645 |
| SLC12A6 | 100.0% | 100.0% | 100.0% | 99.5% | Agenesis of the corpus callosum with peripheral neuropathy, 218000 Charcot-Marie-Tooth disease, axonal, type 2II, 620068 |
| SLC13A3 | 100.0% | 100.0% | 100.0% | 99.4% | Leukoencephalopathy, acute reversible, with increased urinary alpha-ketoglutarate, 618384 |
| SLC13A5 | 100.0% | 100.0% | 100.0% | 99.8% | Developmental and epileptic encephalopathy 25, with amelogenesis imperfecta, 615905 |
| SLC16A1 | 100.0% | 100.0% | 100.0% | 100.0% | Hyperinsulinemic hypoglycemia, familial, 7, 610021 Erythrocyte lactate transporter defect, 245340 Monocarboxylate transporter 1 deficiency, 616095 |
| SLC17A5 | 100.0% | 100.0% | 100.0% | 99.1% | Salla disease, 604369 Sialic acid storage disorder, infantile, 269920 |
| SLC18A2 | 100.0% | 100.0% | 100.0% | 99.6% | ?Parkinsonism-dystonia, infantile, 2, 618049 |
| SLC18A3 | 100.0% | 100.0% | 100.0% | 100.0% | Myasthenic syndrome, congenital, 21, presynaptic, 617239 |
| SLC19A2 | 100.0% | 100.0% | 100.0% | 99.6% | Thiamine-responsive megaloblastic anemia syndrome, 249270 |
| SLC19A3 | 99.6% | 98.4% | 100.0% | 99.6% | Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 |
| SLC1A1 | 100.0% | 100.0% | 100.0% | 99.5% | Dicarboxylic aminoaciduria, 222730 |
| SLC1A4 | 100.0% | 100.0% | 100.0% | 99.9% | Spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657 |
| SLC22A12 | 100.0% | 99.8% | 100.0% | 97.9% | Hypouricemia, renal, 220150 |
| SLC22A5 | 100.0% | 100.0% | 100.0% | 99.6% | Carnitine deficiency, systemic primary, 212140 |
| SLC24A1 | 100.0% | 100.0% | 100.0% | 99.0% | Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| SLC24A4 | 100.0% | 100.0% | 100.0% | 99.6% | Amelogenesis imperfecta, type IIA5, 615887 |
| SLC24A5 | 100.0% | 99.6% | 100.0% | 99.5% | Albinism, oculocutaneous, type VI, 113750 |
| SLC25A1 | 100.0% | 100.0% | 100.0% | 99.0% | Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 Myasthenic syndrome, congenital, 23, presynaptic, 618197 |
| SLC25A12 | 100.0% | 100.0% | 100.0% | 99.2% | Developmental and epileptic encephalopathy 39, 612949 |
| SLC25A13 | 100.0% | 100.0% | 100.0% | 99.5% | Citrullinemia, type II, neonatal-onset, 605814 Citrullinemia, adult-onset type II, 603471 |
| SLC25A15 | 100.0% | 100.0% | 100.0% | 99.9% | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 |
| SLC25A19 | 100.0% | 100.0% | 100.0% | 99.5% | Microcephaly, Amish type, 607196 Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 |
| SLC25A20 | 100.0% | 100.0% | 100.0% | 99.7% | Carnitine-acylcarnitine translocase deficiency, 212138 |
| SLC25A22 | 100.0% | 100.0% | 100.0% | 99.8% | Developmental and epileptic encephalopathy 3, 609304 |
| SLC25A26 | 100.0% | 100.0% | 100.0% | 99.2% | Combined oxidative phosphorylation deficiency 28, 616794 |
| SLC25A3 | 100.0% | 100.0% | 100.0% | 99.8% | Mitochondrial phosphate carrier deficiency, 610773 |
| SLC25A38 | 100.0% | 100.0% | 100.0% | 99.4% | Anemia, sideroblastic, 2, pyridoxine-refractory, 205950 |
| SLC25A4 | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type) AR, 615418 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2, 609283 Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type) AD, 617184 |
| SLC25A42 | 100.0% | 100.0% | 100.0% | 99.9% | Metabolic crises, recurrent, with variable encephalomyopathic features and neurologic regression, 618416 |
| SLC25A46 | 100.0% | 100.0% | 100.0% | 99.1% | Neuropathy, hereditary motor and sensory, type VIB, 616505 Pontocerebellar hypoplasia, type 1E, 619303 |
| SLC26A1 | 100.0% | 100.0% | 100.0% | 100.0% | ?Hypersulfaturia, 620372 ?Nephrolithiasis, calcium oxalate, 1, 167030 |
| SLC26A2 | 100.0% | 100.0% | 100.0% | 99.4% | Epiphyseal dysplasia, multiple, 4, 226900 De la Chapelle dysplasia, 256050 Diastrophic dysplasia, 222600 Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 Achondrogenesis Ib, 600972 Atelosteogenesis, type II, 256050 |
| SLC26A3 | 100.0% | 100.0% | 100.0% | 99.6% | Diarrhea 1, secretory chloride, congenital, 214700 |
| SLC26A4 | 100.0% | 100.0% | 100.0% | 99.1% | Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 Pendred syndrome, 274600 |
| SLC27A4 | 100.0% | 100.0% | 100.0% | 99.8% | Ichthyosis prematurity syndrome, 608649 |
| SLC29A3 | 100.0% | 100.0% | 100.0% | 99.8% | Histiocytosis-lymphadenopathy plus syndrome, 602782 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| | | | | | Dystonia 9, 601042 |
| | | | | | GLUT1 deficiency syndrome 1, infantile onset, severe, 606777 |
| | | | | | Stomatin-deficient cryohydrocytosis with neurologic defects, 608885 |
| SLC2A1 | 100.0% | 100.0% | 100.0% | 99.8% | GLUT1 deficiency syndrome 2, childhood onset, 612126 |
| SLC2A10 | 100.0% | 100.0% | 100.0% | 99.8% | Arterial tortuosity syndrome, 208050 |
| SLC2A2 | 100.0% | 100.0% | 100.0% | 99.7% | Fanconi-Bickel syndrome, 227810 |
| SLC2A9 | 100.0% | 100.0% | 100.0% | 99.5% | Hypouricemia, renal, 2, 612076 |
| SLC30A10 | 100.0% | 100.0% | 100.0% | 99.8% | Hypermanganesemia with dystonia 1, 613280 |
| SLC30A9 | 100.0% | 100.0% | 100.0% | 99.5% | Birk-Landau-Perez syndrome, 617595 |
| | | | | | Spastic paraplegia 42, autosomal dominant, 612539 |
| SLC33A1 | 100.0% | 100.0% | 100.0% | 99.4% | Congenital cataracts, hearing loss, and neurodegeneration, 614482 |
| | | | | | ?Fanconi renotubular syndrome 2, 613388 |
| | | | | | Hypercalcemia, infantile, 2, 616963 |
| SLC34A1 | 100.0% | 100.0% | 100.0% | 99.7% | Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 |
| SLC34A2 | 100.0% | 100.0% | 100.0% | 99.3% | Pulmonary alveolar microlithiasis, 265100 |
| SLC34A3 | 100.0% | 100.0% | 100.0% | 99.1% | Hypophosphatemic rickets with hypercalciuria, 241530 |
| SLC35A1 | 100.0% | 100.0% | 100.0% | 99.8% | Congenital disorder of glycosylation, type II f, 603585 |
| SLC35A3 | 97.7% | 93.3% | 100.0% | 97.5% | Arthrogryposis, impaired intellectual development, and seizures, 615553 |
| SLC35C1 | 100.0% | 100.0% | 100.0% | 100.0% | Congenital disorder of glycosylation, type II c, 266265 |
| SLC35D1 | 100.0% | 100.0% | 100.0% | 99.5% | Schneckenbecken dysplasia, 269250 |
| | | | | | Glycogen storage disease Ib, 232220 |
| | | | | | Congenital disorder of glycosylation, type II w, 619525 |
| SLC37A4 | 100.0% | 100.0% | 100.0% | 99.6% | Glycogen storage disease Ic, 232240 |
| SLC38A8 | 100.0% | 100.0% | 100.0% | 99.6% | Foveal hypoplasia 2, w/wo optic nerve misrouting and/or anterior segment dysgenesis, 609218 |
| SLC39A13 | 100.0% | 100.0% | 100.0% | 100.0% | Ehlers-Danlos syndrome, spondylodysplastic type, 3, 612350 |
| | | | | | ?Hyperostosis cranialis interna, 144755 |
| SLC39A14 | 93.6% | 93.6% | 100.0% | 99.8% | Hypermanganesemia with dystonia 2, 617013 |
| SLC39A4 | 100.0% | 100.0% | 100.0% | 99.9% | Acrodermatitis enteropathica, 201100 |
| SLC39A8 | 100.0% | 100.0% | 100.0% | 99.2% | Congenital disorder of glycosylation, type II n, 616721 |
| SLC3A1 | 96.2% | 96.2% | 100.0% | 99.3% | Cystinuria, 220100 |
| SLC44A1 | 100.0% | 100.0% | 100.0% | 99.0% | Neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline, 618868 |
| SLC45A1 | 100.0% | 100.0% | 100.0% | 98.5% | Intellectual developmental disorder with neuropsychiatric features, 617532 |
| SLC45A2 | 100.0% | 100.0% | 100.0% | 99.9% | Albinism, oculocutaneous, type IV, 606574 |
| SLC46A1 | 100.0% | 100.0% | 100.0% | 99.8% | Folate malabsorption, hereditary, 229050 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| SLC4A1 | 100.0% | 100.0% | 100.0% | 99.6% | Distal renal tubular acidosis 1, 179800 Spherocytosis, type 4, 612653 Distal renal tubular acidosis 4 with hemolytic anemia, 611590 Cryohydrocytosis, 185020 Ovalocytosis, SA type, 166900 |
| SLC4A11 | 100.0% | 100.0% | 100.0% | 99.6% | Corneal endothelial dystrophy, autosomal recessive, 217700 Corneal dystrophy, Fuchs endothelial, 4, 613268 Corneal endothelial dystrophy and perceptive deafness, 217400 |
| SLC4A4 | 100.0% | 99.7% | 100.0% | 99.3% | Renal tubular acidosis, proximal, with ocular abnormalities, 604278 |
| SLC52A2 | 100.0% | 100.0% | 100.0% | 100.0% | Brown-Vialetto-Van Laere syndrome 2, 614707 |
| SLC52A3 | 100.0% | 100.0% | 100.0% | 99.9% | ?Fazio-Londe disease, 211500 Brown-Vialetto-Van Laere syndrome 1, 211530 |
| SLC5A1 | 100.0% | 100.0% | 100.0% | 99.6% | Glucose/galactose malabsorption, 606824 |
| SLC5A2 | 100.0% | 100.0% | 100.0% | 99.9% | Renal glucosuria, 233100 |
| SLC5A5 | 100.0% | 100.0% | 100.0% | 99.2% | Thyroid dysmorphogenesis 1, 274400 |
| SLC5A7 | 100.0% | 100.0% | 100.0% | 99.8% | Neuronopathy, distal hereditary motor, type VIIA, 158580 Myasthenic syndrome, congenital, 20, presynaptic, 617143 |
| SLC6A17 | 100.0% | 100.0% | 100.0% | 98.6% | Intellectual developmental disorder, autosomal recessive 48, 616269 |
| SLC6A19 | 100.0% | 100.0% | 100.0% | 99.8% | Hartnup disorder, 234500 |
| SLC6A3 | 100.0% | 100.0% | 100.0% | 99.9% | Parkinsonism-dystonia, infantile, 1, 613135 |
| SLC6A5 | 100.0% | 100.0% | 100.0% | 99.5% | Hyperekplexia 3, 614618 |
| SLC6A9 | 100.0% | 100.0% | 100.0% | 99.9% | Glycine encephalopathy with normal serum glycine, 617301 |
| SLC7A14 | 100.0% | 100.0% | 100.0% | 99.5% | Retinitis pigmentosa 68, 615725 |
| SLC7A7 | 100.0% | 100.0% | 100.0% | 99.1% | Lysinuric protein intolerance, 222700 |
| SLC7A9 | 100.0% | 100.0% | 100.0% | 99.6% | Cystinuria, 220100 |
| SLC9A1 | 100.0% | 100.0% | 100.0% | 99.8% | Lichtenstein-Knorr syndrome, 616291 |
| SLC9A3 | 100.0% | 99.6% | 100.0% | 98.7% | Diarrhea 8, secretory sodium, congenital, 616868 |
| SLCO2A1 | 100.0% | 100.0% | 100.0% | 99.6% | Hypertrophic osteoarthropathy, primary, autosomal dominant, 167100 Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 |
| SLITRK6 | 100.0% | 100.0% | 100.0% | 99.3% | Deafness and myopia, 221200 |
| SLURP1 | 100.0% | 100.0% | 100.0% | 100.0% | Meleda disease, 248300 |
| SLX4 | 100.0% | 100.0% | 100.0% | 99.6% | Fanconi anemia, complementation group P, 613951 |
| SMARCAL1 | 100.0% | 100.0% | 100.0% | 99.4% | Schimke immunoosseous dysplasia, 242900 |
| SMARCD2 | 100.0% | 100.0% | 100.0% | 99.6% | Specific granule deficiency 2, 617475 |

| | | | | | |
|----------|--------|--------|--------|-------|--|
| SMG9 | 100.0% | 100.0% | 100.0% | 99.8% | Heart and brain malformation syndrome, 616920 Neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, 619995 |
| SMN1 | 93.9% | 93.9% | 99.9% | 96.4% | Spinal muscular atrophy-2, 253550 Spinal muscular atrophy-4, 271150 Spinal muscular atrophy-3, 253400 Spinal muscular atrophy-1, 253300 |
| SMO | 100.0% | 100.0% | 100.0% | 99.8% | Pallister-Hall-like syndrome, 241800 Basal cell carcinoma, somatic, 605462 Curry-Jones syndrome, somatic mosaic, 601707 |
| SMOC1 | 100.0% | 100.0% | 100.0% | 99.5% | Microphthalmia with limb anomalies, 206920 |
| SMOC2 | 100.0% | 100.0% | 100.0% | 99.7% | Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 |
| SMPD1 | 100.0% | 100.0% | 100.0% | 99.4% | Niemann-Pick disease, type B, 607616 Niemann-Pick disease, type A, 257200 |
| SMPD4 | 100.0% | 100.0% | 100.0% | 99.7% | Neurodevelopmental disorder with microcephaly, arthrogyriposis, and structural brain anomalies, 618622 |
| SNAI2 | 100.0% | 100.0% | 100.0% | 99.7% | No OMIM disease ID |
| SNAP29 | 100.0% | 100.0% | 100.0% | 99.5% | Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 |
| SNIP1 | 100.0% | 100.0% | 100.0% | 98.5% | Neurodevelopmental disorder with hypotonia, craniofacial abnormalities, and seizures, 614501 |
| SNORD118 | | | | | Leukoencephalopathy, brain calcifications, and cysts, 614561 |
| SNX10 | 100.0% | 100.0% | 100.0% | 99.6% | Osteopetrosis, autosomal recessive 8, 615085 |
| SNX14 | 100.0% | 100.0% | 100.0% | 99.0% | Spinocerebellar ataxia, autosomal recessive 20, 616354 |
| SOBP | 100.0% | 99.5% | 100.0% | 98.7% | ?Impaired intellectual development, anterior maxillary protrusion, and strabismus, 613671 |
| SOD1 | 100.0% | 100.0% | 100.0% | 99.8% | Spastic tetraplegia and axial hypotonia, progressive, 618598 Amyotrophic lateral sclerosis 1, 105400 |
| SORD | 92.6% | 89.6% | 97.9% | 90.5% | Sorbitol dehydrogenase deficiency with peripheral neuropathy, 618912 |
| SOST | 100.0% | 100.0% | 100.0% | 99.9% | Sclerosteosis 1, 269500 Craniodiaphyseal dysplasia, autosomal dominant, 122860 |
| SOX18 | 99.8% | 98.8% | 100.0% | 99.1% | Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 |
| SP110 | 100.0% | 99.7% | 100.0% | 99.2% | Hepatic venoocclusive disease with immunodeficiency, 235550 |
| SP7 | 100.0% | 100.0% | 100.0% | 99.1% | Osteogenesis imperfecta, type XII, 613849 |
| SPAG1 | 100.0% | 100.0% | 100.0% | 98.8% | Ciliary dyskinesia, primary, 28, 615505 |
| SPARC | 100.0% | 100.0% | 100.0% | 99.5% | Osteogenesis imperfecta, type XVII, 616507 |
| SPART | 100.0% | 100.0% | 100.0% | 99.3% | Troyer syndrome, 275900 |
| SPATA5 | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with hearing loss, seizures, and brain abnormalities, 616577 |

| | | | | | |
|----------|--------|--------|--------|-------|---|
| SPATA5L1 | 100.0% | 100.0% | 100.0% | 99.4% | Deafness, autosomal recessive 119, 619615 Neurodevelopmental disorder with hearing loss and spasticity, 619616 |
| SPATA7 | 100.0% | 100.0% | 100.0% | 98.7% | Leber congenital amaurosis 3, 604232 Retinitis pigmentosa 94, variable age at onset, autosomal recessive, 604232 |
| SPEG | 100.0% | 100.0% | 100.0% | 99.8% | Centronuclear myopathy 5, 615959 |
| SPG11 | 100.0% | 100.0% | 100.0% | 99.3% | Amyotrophic lateral sclerosis 5, juvenile, 602099 Charcot-Marie-Tooth disease, axonal, type 2X, 616668 Spastic paraplegia 11, autosomal recessive, 604360 |
| SPG21 | 100.0% | 100.0% | 100.0% | 99.1% | Mast syndrome, 248900 |
| SPG7 | 100.0% | 100.0% | 100.0% | 99.6% | Spastic paraplegia 7, autosomal recessive, 607259 |
| SPINK5 | 100.0% | 100.0% | 100.0% | 99.4% | Netherton syndrome, 256500 |
| SPINT2 | 100.0% | 100.0% | 100.0% | 99.7% | Diarrhea 3, secretory sodium, congenital, syndromic, 270420 |
| SPR | 100.0% | 100.0% | 100.0% | 99.7% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 |
| SPRED2 | 100.0% | 100.0% | 100.0% | 99.8% | Noonan syndrome 14, 619745 |
| SPRTN | 100.0% | 100.0% | 100.0% | 99.2% | Ruijs-Aalfs syndrome, 616200 |
| SPTA1 | 100.0% | 99.8% | 100.0% | 99.5% | Spherocytosis, type 3, 270970 Elliptocytosis-2, 130600 Pyropoikilocytosis, 266140 |
| SPTB | 100.0% | 100.0% | 100.0% | 99.7% | Anemia, neonatal hemolytic, fatal or near-fatal, 617948 Elliptocytosis-3, 617948 Spherocytosis, type 2, 616649 |
| SPTBN2 | 100.0% | 99.8% | 100.0% | 99.8% | Spinocerebellar ataxia 5, 600224 Spinocerebellar ataxia, autosomal recessive 14, 615386 |
| SPTBN4 | 100.0% | 100.0% | 100.0% | 99.5% | Neurodevelopmental disorder with hypotonia, neuropathy, and deafness, 617519 |
| SQSTM1 | 100.0% | 100.0% | 100.0% | 99.7% | Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 Myopathy, distal, with rimmed vacuoles, 617158 Paget disease of bone 3, 167250 |
| SRD5A2 | 100.0% | 100.0% | 100.0% | 99.6% | Pseudovaginal perineoscrotal hypospadias, 264600 |
| SRD5A3 | 100.0% | 100.0% | 100.0% | 99.7% | Kahrizi syndrome, 612713 Congenital disorder of glycosylation, type Iq, 612379 |
| ST14 | 100.0% | 100.0% | 100.0% | 99.9% | Ichthyosis, congenital, autosomal recessive 11, 602400 |
| ST3GAL3 | 97.4% | 95.3% | 100.0% | 99.6% | Developmental and epileptic encephalopathy 15, 615006 Intellectual developmental disorder, autosomal recessive 12, 611090 |
| ST3GAL5 | 98.3% | 98.3% | 100.0% | 99.3% | Salt and pepper developmental regression syndrome, 609056 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| STAC3 | 100.0% | 100.0% | 100.0% | 99.2% | Congenital myopathy 13, 255995 |
| STAMBP | 100.0% | 100.0% | 100.0% | 99.4% | Microcephaly-capillary malformation syndrome, 614261 |
| STAR | 100.0% | 100.0% | 100.0% | 99.9% | Lipoid adrenal hyperplasia, 201710 |
| STAT1 | 96.1% | 95.9% | 100.0% | 99.6% | Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant, 614162 Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 |
| STAT2 | 100.0% | 100.0% | 100.0% | 99.7% | Pseudo-TORCH syndrome 3, 618886 Immunodeficiency 44, 616636 |
| STAT5B | 100.0% | 100.0% | 100.0% | 99.6% | Growth hormone insensitivity with immune dysregulation 1, autosomal recessive, 245590 Growth hormone insensitivity with immune dysregulation 2, autosomal dominant, 618985 Leukemia, acute promyelocytic, somatic, 102578 |
| STIL | 100.0% | 100.0% | 100.0% | 99.3% | Microcephaly 7, primary, autosomal recessive, 612703 |
| STIM1 | 100.0% | 100.0% | 100.0% | 99.7% | Myopathy, tubular aggregate, 1, 160565 Stormorken syndrome, 185070 Immunodeficiency 10, 612783 |
| STK4 | 100.0% | 100.0% | 100.0% | 99.4% | T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 |
| STN1 | 100.0% | 100.0% | 100.0% | 99.5% | Cerebroretinal microangiopathy with calcifications and cysts 2, 617341 |
| STRA6 | 100.0% | 100.0% | 100.0% | 99.7% | Microphthalmia, syndromic 9, 601186 Microphthalmia, isolated, with coloboma 8, 601186 |
| STRADA | 100.0% | 100.0% | 100.0% | 99.4% | Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 |
| STRC | 100.0% | 100.0% | 100.0% | 99.2% | Deafness, autosomal recessive 16, 603720 |
| STT3A | 100.0% | 100.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type lw, autosomal dominant, 619714 Congenital disorder of glycosylation, type lw, autosomal recessive, 615596 |
| STT3B | 100.0% | 100.0% | 100.0% | 98.6% | Congenital disorder of glycosylation, type lx, 615597 |
| STUB1 | 100.0% | 100.0% | 100.0% | 99.4% | Spinocerebellar ataxia 48, 618093 Spinocerebellar ataxia, autosomal recessive 16, 615768 |
| STX11 | 100.0% | 100.0% | 100.0% | 100.0% | Hemophagocytic lymphohistiocytosis, familial, 4, 603552 |
| STXBP2 | 100.0% | 99.9% | 100.0% | 99.9% | Hemophagocytic lymphohistiocytosis, familial, 5, w/wo microvillus inclusion disease, 613101 |
| SUCLA2 | 100.0% | 99.6% | 100.0% | 99.4% | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic w/wo methylmalonic aciduria), 612073 |
| SUCLG1 | 100.0% | 100.0% | 100.0% | 98.5% | Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 |
| SUFU | 100.0% | 100.0% | 100.0% | 99.8% | Joubert syndrome 32, 617757 Basal cell nevus syndrome 2, 620343 |
| SULT2B1 | 100.0% | 100.0% | 100.0% | 99.7% | Ichthyosis, congenital, autosomal recessive 14, 617571 |
| SUMF1 | 100.0% | 100.0% | 100.0% | 99.8% | Multiple sulfatase deficiency, 272200 |
| SUOX | 100.0% | 100.0% | 100.0% | 99.5% | Sulfite oxidase deficiency, 272300 |

| | | | | | |
|---------|--------|--------|--------|-------|---|
| SURF1 | 100.0% | 100.0% | 100.0% | 99.4% | Charcot-Marie-Tooth disease, type 4K, 616684 Mitochondrial complex IV deficiency, nuclear type 1, 220110 |
| SVBP | 100.0% | 100.0% | 100.0% | 99.1% | Neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, 618569 |
| SYNE1 | 99.8% | 99.5% | 100.0% | 99.4% | Arthrogryposis multiplex congenita 3, myogenic type, 618484 Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 Spinocerebellar ataxia, autosomal recessive 8, 610743 |
| SYNE4 | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal recessive 76, 615540 |
| SYNJ1 | 100.0% | 100.0% | 100.0% | 99.3% | Parkinson disease 20, early-onset, 615530 Developmental and epileptic encephalopathy 53, 617389 |
| SYT14 | 100.0% | 100.0% | 100.0% | 99.4% | ?Spinocerebellar ataxia, autosomal recessive 11, 614229 |
| SZT2 | 100.0% | 100.0% | 100.0% | 99.7% | Developmental and epileptic encephalopathy 18, 615476 |
| TAC3 | 100.0% | 100.0% | 100.0% | 99.9% | Hypogonadotropic hypogonadism 10 w/wo anosmia, 614839 |
| TACO1 | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial complex IV deficiency, nuclear type 8, 619052 |
| TACR3 | 100.0% | 99.8% | 100.0% | 99.3% | Hypogonadotropic hypogonadism 11 w/wo anosmia, 614840 |
| TACSTD2 | 100.0% | 100.0% | 100.0% | 99.8% | Corneal dystrophy, gelatinous drop-like, 204870 |
| TAF13 | 100.0% | 100.0% | 100.0% | 99.1% | Intellectual developmental disorder, autosomal recessive 60, 617432 |
| TAF1C | 100.0% | 100.0% | 100.0% | 99.9% | No OMIM disease ID |
| TAF2 | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 40, 615599 |
| TAF6 | 100.0% | 100.0% | 100.0% | 99.7% | Alazami-Yuan syndrome, 617126 |
| TALDO1 | 100.0% | 100.0% | 100.0% | 99.4% | Transaldolase deficiency, 606003 |
| TANGO2 | 100.0% | 100.0% | 100.0% | 99.4% | Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 |
| TAP1 | 100.0% | 100.0% | 100.0% | 99.4% | Bare lymphocyte syndrome, type I, 604571 |
| TAP2 | 100.0% | 100.0% | 100.0% | 98.7% | Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 |
| TAPBP | 95.9% | 95.9% | 100.0% | 99.3% | Bare lymphocyte syndrome, type I, 604571 |
| TAPT1 | 100.0% | 100.0% | 100.0% | 98.9% | Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinc type, 616897 |
| TARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Combined oxidative phosphorylation deficiency 21, 615918 |
| TAT | 100.0% | 100.0% | 100.0% | 99.8% | Tyrosinemia, type II, 276600 |
| TBC1D20 | 100.0% | 100.0% | 100.0% | 99.2% | Warburg micro syndrome 4, 615663 |
| TBC1D23 | 100.0% | 100.0% | 100.0% | 99.3% | Pontocerebellar hypoplasia, type 11, 617695 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| | | | | | Deafness, autosomal recessive 86, 614617 Epilepsy, rolandic, with paroxysmal exercise-induce dystonia and writer's cramp, 608105 Myoclonic epilepsy, infantile, familial, 605021 Deafness, autosomal dominant 65, 616044 Developmental and epileptic encephalopathy 16, 615338 DOORS syndrome, 220500 |
| TBC1D24 | 100.0% | 100.0% | 100.0% | 100.0% | |
| TBC1D7 | 100.0% | 100.0% | 100.0% | 99.3% | Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 |
| TBCD | 100.0% | 100.0% | 100.0% | 99.8% | Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum, 617193 |
| | | | | | Kenny-Caffey syndrome, type 1, 244460 Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 Encephalopathy, progressive, with amyotrophy and optic atrophy, 617207 |
| TBCE | 100.0% | 100.0% | 100.0% | 99.5% | |
| TBCK | 100.0% | 100.0% | 100.0% | 99.5% | Hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900 |
| TBX15 | 100.0% | 99.4% | 100.0% | 99.3% | Cousin syndrome, 260660 |
| TBX19 | 100.0% | 100.0% | 100.0% | 99.7% | Adrenocorticotrophic hormone deficiency, 201400 |
| TBX6 | 100.0% | 100.0% | 100.0% | 99.8% | Spondylocostal dysostosis 5, 122600 |
| TBXAS1 | 100.0% | 100.0% | 100.0% | 99.4% | Ghosal hematodiaphyseal syndrome, 231095 |
| TBXT | 100.0% | 100.0% | 100.0% | 99.6% | Sacral agenesis with vertebral anomalies, 615709 |
| | | | | | Cardiomyopathy, hypertrophic, 25, 607487 Muscular dystrophy, limb-girdle, autosomal recessive 7, 601954 |
| TCAP | 100.0% | 100.0% | 100.0% | 100.0% | |
| TCIRG1 | 100.0% | 100.0% | 100.0% | 100.0% | Osteopetrosis, autosomal recessive 1, 259700 |
| TCN2 | 100.0% | 100.0% | 100.0% | 99.7% | Transcobalamin II deficiency, 275350 |
| TCTEX1D2 | 100.0% | 100.0% | 100.0% | 98.2% | Short-rib thoracic dysplasia 17 w/wo polydactyly, 617405 |
| TCTN1 | 95.4% | 94.0% | 99.9% | 99.0% | Joubert syndrome 13, 614173 |
| | | | | | Joubert syndrome 24, 616654 ?Meckel syndrome 8, 613885 |
| TCTN2 | 100.0% | 100.0% | 100.0% | 99.6% | |
| | | | | | Joubert syndrome 18, 614815 Orofaciodigital syndrome IV, 258860 |
| TCTN3 | 100.0% | 100.0% | 100.0% | 99.4% | |
| TDP1 | 100.0% | 100.0% | 100.0% | 99.6% | ?Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1, 607250 |
| TDP2 | 100.0% | 100.0% | 100.0% | 99.6% | Spinocerebellar ataxia, autosomal recessive 23, 616949 |
| TDRD7 | 100.0% | 100.0% | 100.0% | 99.6% | Cataract 36, 613887 |
| TECPR2 | 100.0% | 100.0% | 100.0% | 99.6% | Neuropathy, hereditary sensory and autonomic, type IX, with developmental delay, 615031 |
| TECR | 100.0% | 100.0% | 100.0% | 99.9% | Intellectual developmental disorder, autosomal recessive 14, 614020 |
| TECRL | 100.0% | 100.0% | 100.0% | 99.4% | Ventricular tachycardia, catecholaminergic polymorphic, 3, 614021 |
| | | | | | Deafness, autosomal dominant 8/12, 601543 Deafness, autosomal recessive 21, 603629 |
| TECTA | 100.0% | 100.0% | 100.0% | 99.7% | |

| | | | | | |
|---------|--------|--------|--------|-------|--|
| TELO2 | 100.0% | 100.0% | 100.0% | 99.9% | You-Hoover-Fong syndrome, 616954 |
| TENM3 | 100.0% | 100.0% | 100.0% | 99.8% | Microphthalmia, syndromic 15, 615145 ?Microphthalmia, isolated, with coloboma 9, 615145 |
| TENT5A | 100.0% | 100.0% | 100.0% | 98.9% | Osteogenesis imperfecta, type XVIII, 617952 |
| TF | 100.0% | 100.0% | 100.0% | 99.7% | Atransferrinemia, 209300 |
| TFAM | 100.0% | 100.0% | 100.0% | 99.4% | ?Mitochondrial DNA depletion syndrome 15 (hepatocerebral type), 617156 |
| TFG | 100.0% | 100.0% | 100.0% | 99.2% | ?Spastic paraplegia 57, autosomal recessive, 615658 Hereditary motor and sensory neuropathy, Okinawa type, 604484 |
| TFR2 | 100.0% | 100.0% | 100.0% | 99.4% | Hemochromatosis, type 3, 604250 |
| TFRC | 100.0% | 100.0% | 99.9% | 98.9% | Immunodeficiency 46, 616740 |
| TG | 100.0% | 100.0% | 100.0% | 99.6% | Thyroid dysmorphogenesis 3, 274700 |
| TGDS | 100.0% | 100.0% | 100.0% | 99.0% | Catel-Manzke syndrome, 616145 |
| TGFB1 | 100.0% | 100.0% | 100.0% | 99.9% | Inflammatory bowel disease, immunodeficiency, and encephalopathy, 618213 Camurati-Engelmann disease, 131300 |
| TGM1 | 100.0% | 100.0% | 100.0% | 99.6% | Ichthyosis, congenital, autosomal recessive 1, 242300 |
| TGM5 | 100.0% | 100.0% | 100.0% | 99.4% | Peeling skin syndrome 2, 609796 |
| TH | 100.0% | 100.0% | 100.0% | 99.7% | Segawa syndrome, recessive, 605407 |
| THOC6 | 100.0% | 100.0% | 100.0% | 99.9% | Beaulieu-Boycott-Innes syndrome, 613680 |
| THRB | 100.0% | 100.0% | 100.0% | 99.4% | Thyroid hormone resistance, autosomal recessive, 274300 Thyroid hormone resistance, 188570 Thyroid hormone resistance, selective pituitary, 145650 |
| THUMPD1 | 100.0% | 99.9% | 100.0% | 98.4% | Neurodevelopmental disorder with speech delay and variable ocular anomalies, 619989 |
| TIMM50 | 100.0% | 100.0% | 100.0% | 99.8% | 3-methylglutaconic aciduria, type IX, 617698 |
| TIMMDC1 | 100.0% | 100.0% | 100.0% | 99.0% | Mitochondrial complex I deficiency, nuclear type 31, 618251 |
| TJP2 | 100.0% | 100.0% | 100.0% | 99.1% | Hypercholanemia, familial 1, 607748 Cholestasis, progressive familial intrahepatic 4, 615878 |
| TK2 | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 ?Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3, 617069 |
| TKT | 98.1% | 98.1% | 100.0% | 99.8% | Short stature, developmental delay, and congenital heart defects, 617044 |
| TLE6 | 100.0% | 100.0% | 100.0% | 99.8% | Oocyte/zygote/embryo maturation arrest 15, 616814 |
| TMC1 | 100.0% | 100.0% | 100.0% | 98.6% | Deafness, autosomal dominant 36, 606705 Deafness, autosomal recessive 7, 600974 |
| TMC6 | 100.0% | 100.0% | 100.0% | 99.8% | Epidermodysplasia verruciformis, 226400 |
| TMC8 | 100.0% | 100.0% | 100.0% | 99.8% | Epidermodysplasia verruciformis 2, 618231 |

| | | | | | |
|-----------|--------|--------|--------|-------|---|
| TMCO1 | 88.0% | 87.7% | 100.0% | 98.8% | Craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development 1, 213980 |
| | | | | | Orofaciodigital syndrome XVI, 617563 |
| | | | | | Meckel syndrome 13, 617562 |
| TMEM107 | 100.0% | 100.0% | 100.0% | 99.6% | ?Joubert syndrome 29, 617562 |
| TMEM126A | 100.0% | 100.0% | 100.0% | 99.3% | Optic atrophy 7, 612989 |
| TMEM126B | 100.0% | 100.0% | 100.0% | 99.0% | Mitochondrial complex I deficiency, nuclear type 29, 618250 |
| TMEM132E | 100.0% | 100.0% | 100.0% | 99.7% | Deafness, autosomal recessive 99, 618481 |
| TMEM138 | 100.0% | 100.0% | 100.0% | 99.9% | Joubert syndrome 16, 614465 |
| TMEM165 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital disorder of glycosylation, type IIk, 614727 |
| TMEM199 | 100.0% | 100.0% | 100.0% | 99.6% | Congenital disorder of glycosylation, type IIp, 616829 |
| | | | | | Joubert syndrome 2, 608091 |
| TMEM216 | 100.0% | 100.0% | 100.0% | 99.5% | Meckel syndrome 2, 603194 |
| | | | | | Joubert syndrome 20, 614970 |
| TMEM231 | 100.0% | 100.0% | 100.0% | 99.7% | Meckel syndrome 11, 615397 |
| TMEM237 | 100.0% | 100.0% | 100.0% | 99.1% | Joubert syndrome 14, 614424 |
| TMEM260 | 100.0% | 100.0% | 100.0% | 99.1% | Structural heart defects and renal anomalies syndrome, 617478 |
| TMEM38B | 100.0% | 100.0% | 100.0% | 99.5% | Osteogenesis imperfecta, type XIV, 615066 |
| | | | | | Nephronophthisis 11, 613550 |
| | | | | | Joubert syndrome 6, 610688 |
| | | | | | Meckel syndrome 3, 607361 |
| | | | | | ?RHYS syndrome, 602152 |
| TMEM67 | 99.5% | 97.5% | 100.0% | 97.9% | COACH syndrome 1, 216360 |
| TMEM70 | 100.0% | 100.0% | 100.0% | 98.9% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 |
| TMEM94 | 100.0% | 100.0% | 100.0% | 99.8% | Intellectual developmental disorder with cardiac defects and dysmorphic facies, 618316 |
| TMIE | 100.0% | 100.0% | 100.0% | 99.9% | Deafness, autosomal recessive 6, 600971 |
| TMPRSS15 | 100.0% | 100.0% | 100.0% | 98.9% | Enterokinase deficiency, 226200 |
| TMPRSS3 | 100.0% | 100.0% | 100.0% | 99.5% | Deafness, autosomal recessive 8/10, 601072 |
| TMPRSS6 | 100.0% | 100.0% | 100.0% | 99.4% | Iron-refractory iron deficiency anemia, 206200 |
| TMTC3 | 100.0% | 99.5% | 100.0% | 99.0% | Lissencephaly 8, 617255 |
| | | | | | Osteopetrosis, autosomal recessive 7, 612301 |
| TNFRSF11A | 100.0% | 99.6% | 100.0% | 99.4% | Osteolysis, familial expansile, 174810 |
| TNFRSF11B | 100.0% | 100.0% | 100.0% | 99.7% | Paget disease of bone 5, juvenile-onset, 239000 |
| | | | | | Immunodeficiency, common variable, 2, 240500 |
| TNFRSF13B | 100.0% | 100.0% | 100.0% | 99.9% | Immunoglobulin A deficiency 2, 609529 |
| TNFRSF13C | 100.0% | 100.0% | 100.0% | 99.0% | Immunodeficiency, common variable, 4, 613494 |

| | | | | | |
|----------|--------|--------|--------|-------|---|
| TNFRSF4 | 100.0% | 100.0% | 100.0% | 99.5% | ?Immunodeficiency 16, 615593 |
| TNFSF11 | 100.0% | 100.0% | 100.0% | 99.6% | Osteopetrosis, autosomal recessive 2, 259710 |
| TNIK | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 54, 617028 |
| TNNI3 | 100.0% | 100.0% | 100.0% | 99.1% | ?Cardiomyopathy, dilated, 2A, 611880 Cardiomyopathy, hypertrophic, 7, 613690 Cardiomyopathy, familial restrictive, 1, 115210 Cardiomyopathy, dilated, 1FF, 613286 |
| TNNT1 | 100.0% | 100.0% | 100.0% | 98.3% | Nemaline myopathy 5C, autosomal dominant, 620389 Nemaline myopathy 5A, autosomal recessive, severe infantile, 605355 Nemaline myopathy 5B, autosomal recessive, childhood-onset, 620386 |
| TNXB | 100.0% | 100.0% | 100.0% | 99.6% | Ehlers-Danlos syndrome, classic-like, 1, 606408 Vesicoureteral reflux 8, 615963 |
| TOE1 | 100.0% | 100.0% | 100.0% | 99.5% | Pontocerebellar hypoplasia, type 7, 614969 |
| TONSL | 100.0% | 100.0% | 100.0% | 99.9% | Spondyloepimetaphyseal dysplasia, sponastrime type, 271510 |
| TOP3A | 100.0% | 100.0% | 100.0% | 99.5% | ?Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 5, 618098 Microcephaly, growth restriction, and increased sister chromatid exchange 2, 618097 |
| TOR1AIP1 | 100.0% | 100.0% | 100.0% | 99.2% | ?Muscular dystrophy, autosomal recessive, with rigid spine and distal joint contractures, 617072 |
| TP53RK | 100.0% | 100.0% | 100.0% | 99.5% | Galloway-Mowat syndrome 4, 617730 |
| TP73 | 100.0% | 100.0% | 100.0% | 99.9% | Ciliary dyskinesia, primary, 47, and lissencephaly, 619466 |
| TPI1 | 100.0% | 100.0% | 100.0% | 99.7% | Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 |
| TPK1 | 100.0% | 100.0% | 100.0% | 99.4% | Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 |
| TPM3 | 100.0% | 100.0% | 100.0% | 99.5% | Congenital myopathy 4A, autosomal dominant, 255310 Congenital myopathy 4B, autosomal recessive, 609284 |
| TPO | 100.0% | 100.0% | 100.0% | 99.7% | Thyroid dyshormonogenesis 2A, 274500 |
| TPP1 | 100.0% | 100.0% | 100.0% | 99.8% | Ceroid lipofuscinosis, neuronal, 2, 204500 Spinocerebellar ataxia, autosomal recessive 7, 609270 |
| TPRKB | 82.0% | 81.2% | 100.0% | 99.6% | Galloway-Mowat syndrome 5, 617731 |
| TPRN | 97.1% | 95.4% | 99.9% | 94.1% | Deafness, autosomal recessive 79, 613307 |
| TRAC | 100.0% | 100.0% | 100.0% | 99.6% | Immunodeficiency 7, TCR-alpha/beta deficient, 615387 |
| TRAF3IP1 | 100.0% | 100.0% | 100.0% | 98.9% | Senior-Loken syndrome 9, 616629 |
| TRAIP | 100.0% | 100.0% | 100.0% | 99.7% | Seckel syndrome 9, 616777 |
| TRAK1 | 100.0% | 100.0% | 100.0% | 99.7% | Developmental and epileptic encephalopathy 68, 618201 |
| TRAPPC11 | 100.0% | 100.0% | 100.0% | 99.3% | Muscular dystrophy, limb-girdle, autosomal recessive 18, 615356 |
| TRAPPC12 | 100.0% | 100.0% | 100.0% | 99.9% | Encephalopathy, progressive, early-onset, with brain atrophy and spasticity, 617669 |

| | | | | | |
|----------|--------|--------|--------|--------|---|
| TRAPPC2L | 100.0% | 100.0% | 100.0% | 100.0% | Encephalopathy, progressive, early-onset, with episodic rhabdomyolysis, 618331 |
| TRAPPC6B | 100.0% | 100.0% | 100.0% | 98.0% | Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, 617862 |
| TRAPPC9 | 100.0% | 100.0% | 100.0% | 99.4% | Intellectual developmental disorder, autosomal recessive 13, 613192 |
| TRDN | 99.9% | 99.6% | 100.0% | 98.4% | Cardiac arrhythmia syndrome, w/wo skeletal muscle weakness, 615441 |
| TREM2 | 100.0% | 100.0% | 100.0% | 100.0% | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2, 618193 |
| | | | | | Vasculopathy, retinal, with cerebral leukoencephalopathy and systemic manifestations, 192315 |
| | | | | | Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 |
| TREX1 | 100.0% | 100.0% | 100.0% | 100.0% | Chilblain lupus, 610448 |
| TRH | 100.0% | 100.0% | 100.0% | 99.0% | No OMIM disease ID |
| TRIM2 | 93.8% | 93.8% | 100.0% | 99.3% | Charcot-Marie-Tooth disease, type 2R, 615490 |
| | | | | | ?Bardet-Biedl syndrome 11, 615988 |
| TRIM32 | 100.0% | 100.0% | 100.0% | 100.0% | Muscular dystrophy, limb-girdle, autosomal recessive 8, 254110 |
| TRIM37 | 98.3% | 98.3% | 100.0% | 99.4% | Mulibrey nanism, 253250 |
| TRIOBP | 100.0% | 100.0% | 100.0% | 99.1% | Deafness, autosomal recessive 28, 609823 |
| | | | | | Odontochondrodysplasia 1, 184260 |
| TRIP11 | 100.0% | 100.0% | 100.0% | 98.3% | Achondrogenesis, type IA, 200600 |
| | | | | | Oocyte/zygote/embryo maturation arrest 9, 619011 |
| TRIP13 | 100.0% | 100.0% | 100.0% | 99.6% | Mosaic variegated aneuploidy syndrome 3, 617598 |
| | | | | | ?Muscular dystrophy, congenital, Davignon-Chauveau type, 617066 |
| TRIP4 | 100.0% | 100.0% | 100.0% | 99.2% | Spinal muscular atrophy with congenital bone fractures 1, 616866 |
| TRIT1 | 100.0% | 100.0% | 100.0% | 99.7% | Combined oxidative phosphorylation deficiency 35, 617873 |
| TRMT1 | 100.0% | 100.0% | 100.0% | 99.5% | Intellectual developmental disorder, autosomal recessive 68, 618302 |
| TRMT10A | 100.0% | 100.0% | 100.0% | 99.2% | Microcephaly, short stature, and impaired glucose metabolism 1, 616033 |
| TRMT10C | 100.0% | 100.0% | 100.0% | 98.7% | Combined oxidative phosphorylation deficiency 30, 616974 |
| TRMT5 | 100.0% | 100.0% | 100.0% | 99.6% | Peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay, 616539 |
| TRMU | 100.0% | 100.0% | 100.0% | 99.4% | Liver failure, transient infantile, 613070 |
| | | | | | Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 |
| TRNT1 | 100.0% | 100.0% | 100.0% | 99.2% | Retinitis pigmentosa and erythrocytic microcytosis, 616959 |
| TRPM1 | 100.0% | 100.0% | 99.8% | 97.8% | Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 |
| TRPM6 | 100.0% | 100.0% | 100.0% | 99.4% | Hypomagnesemia 1, intestinal, 602014 |
| TSEN15 | 100.0% | 100.0% | 100.0% | 99.7% | Pontocerebellar hypoplasia, type 2F, 617026 |
| TSEN2 | 100.0% | 100.0% | 100.0% | 99.1% | Pontocerebellar hypoplasia type 2B, 612389 |
| TSEN34 | 100.0% | 100.0% | 100.0% | 99.6% | ?Pontocerebellar hypoplasia type 2C, 612390 |

| | | | | | |
|---------|--------|--------|--------|--------|---|
| | | | | | Pontocerebellar hypoplasia type 2A, 277470 Pontocerebellar hypoplasia type 4, 225753 ?Pontocerebellar hypoplasia type 5, 610204 |
| TSEN54 | 100.0% | 100.0% | 100.0% | 99.8% | |
| TSFM | 94.3% | 94.3% | 100.0% | 99.8% | Combined oxidative phosphorylation deficiency 3, 610505 |
| TSHB | 100.0% | 100.0% | 100.0% | 100.0% | Hypothyroidism, congenital, nongoitrous 4, 275100 |
| | | | | | Hyperthyroidism, familial gestational, 603373 Hyperthyroidism, nonautoimmune, 609152 Hypothyroidism, congenital, nongoitrous, 1, 275200 Thyroid adenoma, hyperfunctioning, somatic, Thyroid carcinoma with thyrotoxicosis, somatic, |
| TSHR | 100.0% | 100.0% | 100.0% | 99.5% | |
| TSPAN12 | 100.0% | 100.0% | 100.0% | 99.7% | Exudative vitreoretinopathy 5, 613310 |
| | | | | | Tooth agenesis, selective, 10, 620173 ?Deafness, autosomal recessive 98, 614861 |
| TSPEAR | 100.0% | 100.0% | 100.0% | 99.6% | Ectodermal dysplasia 14, hair/tooth type w/wo hypohidrosis, 618180 |
| TSPYL1 | 100.0% | 100.0% | 100.0% | 99.7% | Sudden infant death with dysgenesis of the testes syndrome, 608800 |
| TTC19 | 100.0% | 100.0% | 100.0% | 99.5% | Mitochondrial complex III deficiency, nuclear type 2, 615157 |
| | | | | | Short-rib thoracic dysplasia 4 w/wo polydactyly, 613819 Nephronophthisis 12, 613820 |
| TTC21B | 100.0% | 99.8% | 100.0% | 99.0% | |
| TTC25 | 100.0% | 100.0% | 100.0% | 99.1% | Ciliary dyskinesia, primary, 35, 617092 |
| TTC37 | 100.0% | 100.0% | 100.0% | 99.3% | Trichohepatoenteric syndrome 1, 222470 |
| TTC7A | 100.0% | 100.0% | 100.0% | 99.7% | Gastrointestinal defects and immunodeficiency syndrome, 243150 |
| | | | | | Bardet-Biedl syndrome 8, 615985 ?Retinitis pigmentosa 51, 613464 |
| TTC8 | 100.0% | 99.9% | 100.0% | 99.5% | |
| TTI2 | 100.0% | 100.0% | 100.0% | 99.1% | Intellectual developmental disorder, autosomal recessive 39, 615541 |
| TTLL5 | 100.0% | 100.0% | 100.0% | 99.3% | Cone-rod dystrophy 19, 615860 |
| TTPA | 100.0% | 100.0% | 100.0% | 99.6% | Ataxia with isolated vitamin E deficiency, 277460 |
| TUB | 100.0% | 100.0% | 100.0% | 99.8% | ?Retinal dystrophy and obesity, 616188 |
| TUBA8 | 100.0% | 100.0% | 100.0% | 99.7% | Macrothrombocytopenia, isolated, 2, autosomal dominant, 619840 |
| TUBGCP2 | 96.7% | 96.7% | 100.0% | 99.8% | Pachygyria, microcephaly, developmental delay, and dysmorphic facies, w/wo seizures, 618737 |
| TUBGCP4 | 100.0% | 100.0% | 100.0% | 99.3% | Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335 |
| TUBGCP6 | 100.0% | 100.0% | 100.0% | 99.9% | Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270 |
| TUFM | 100.0% | 100.0% | 100.0% | 99.7% | Combined oxidative phosphorylation deficiency 4, 610678 |
| | | | | | Leber congenital amaurosis 15, 613843 Retinitis pigmentosa 14, 600132 |
| TULP1 | 100.0% | 100.0% | 100.0% | 99.5% | |
| TUSC3 | 100.0% | 100.0% | 100.0% | 99.7% | Intellectual developmental disorder, autosomal recessive 7, 611093 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| TWIST2 | 100.0% | 100.0% | 100.0% | 99.7% | Ablepharon-macrostomia syndrome, 200110 Barber-Say syndrome, 209885 Focal facial dermal dysplasia 3, Setleis type, 227260 |
| TWNK | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286 Perrault syndrome 5, 616138 |
| TXNL4A | 100.0% | 100.0% | 100.0% | 99.8% | Burn-McKeown syndrome, 608572 |
| TYK2 | 100.0% | 100.0% | 100.0% | 99.8% | Immunodeficiency 35, 611521 |
| TYMP | 100.0% | 100.0% | 100.0% | 100.0% | Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 |
| TYR | 100.0% | 99.9% | 100.0% | 99.7% | Albinism, oculocutaneous, type IB, 606952 Albinism, oculocutaneous, type IA, 203100 |
| TYROBP | 100.0% | 100.0% | 100.0% | 99.1% | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1, 221770 |
| TYRP1 | 100.0% | 100.0% | 100.0% | 99.7% | Albinism, oculocutaneous, type III, 203290 |
| UBA5 | 100.0% | 100.0% | 100.0% | 98.9% | ?Spinocerebellar ataxia, autosomal recessive 24, 617133 Developmental and epileptic encephalopathy 44, 617132 |
| UBE2T | 100.0% | 100.0% | 100.0% | 99.9% | Fanconi anemia, complementation group T, 616435 |
| UBE3B | 100.0% | 100.0% | 100.0% | 99.4% | Kaufman oculocerebrofacial syndrome, 244450 |
| UBR1 | 98.0% | 98.0% | 100.0% | 99.0% | Johanson-Blizzard syndrome, 243800 |
| UCHL1 | 100.0% | 100.0% | 100.0% | 99.0% | Spastic paraplegia 79A, autosomal dominant, 620221 Spastic paraplegia 79B, autosomal recessive, 615491 |
| UFC1 | 100.0% | 100.0% | 100.0% | 99.3% | Neurodevelopmental disorder with spasticity and poor growth, 618076 |
| UFM1 | 100.0% | 100.0% | 100.0% | 99.8% | Leukodystrophy, hypomyelinating, 14, 617899 |
| UGDH | 100.0% | 100.0% | 100.0% | 99.4% | Developmental and epileptic encephalopathy 84, 618792 |
| UGT1A1 | 100.0% | 100.0% | 100.0% | 99.8% | Crigler-Najjar syndrome, type I, 218800 Hyperbilirubinemia, familial transient neonatal, 237900 Crigler-Najjar syndrome, type II, 606785 |
| UMPS | 100.0% | 100.0% | 100.0% | 99.8% | Orotic aciduria, 258900 |
| UNC13D | 100.0% | 100.0% | 100.0% | 99.7% | Hemophagocytic lymphohistiocytosis, familial, 3, 608898 |
| UNC80 | 100.0% | 100.0% | 100.0% | 99.4% | Hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801 |
| UNG | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency with hyper IgM, type 5, 608106 |
| UPB1 | 100.0% | 100.0% | 100.0% | 99.4% | Beta-ureidopropionase deficiency, 613161 |
| UQCC2 | 100.0% | 100.0% | 100.0% | 99.6% | Mitochondrial complex III deficiency, nuclear type 7, 615824 |
| UQCC3 | 100.0% | 100.0% | 100.0% | 99.4% | ?Mitochondrial complex III deficiency, nuclear type 9, 616111 |
| UQCRB | 100.0% | 100.0% | 100.0% | 99.7% | Mitochondrial complex III deficiency, nuclear type 3, 615158 |

| | | | | | |
|---------|--------|--------|--------|--------|--|
| UQCRC2 | 100.0% | 100.0% | 100.0% | 99.4% | Mitochondrial complex III deficiency, nuclear type 5, 615160 |
| UQCRFS1 | 100.0% | 100.0% | 100.0% | 100.0% | Mitochondrial complex III deficiency, nuclear type 10, 618775 |
| UQCRCQ | 100.0% | 100.0% | 100.0% | 98.8% | Mitochondrial complex III deficiency, nuclear type 4, 615159 |
| UROCI | 100.0% | 100.0% | 100.0% | 99.9% | ?Urocanase deficiency, 276880 |
| UROD | 100.0% | 100.0% | 100.0% | 99.7% | Porphyria, hepatoerythropoietic, 176100 Porphyria cutanea tarda, 176100 |
| UROS | 100.0% | 100.0% | 100.0% | 98.9% | Porphyria, congenital erythropoietic, 263700 |
| USB1 | 100.0% | 100.0% | 100.0% | 98.7% | Poikiloderma with neutropenia, 604173 |
| USH1C | 100.0% | 100.0% | 100.0% | 98.1% | Usher syndrome, type 1C, 276904 Deafness, autosomal recessive 18A, 602092 |
| USH1G | 100.0% | 100.0% | 100.0% | 99.9% | Usher syndrome, type 1G, 606943 |
| USH2A | 99.9% | 99.6% | 100.0% | 99.7% | Usher syndrome, type 2A, 276901 Retinitis pigmentosa 39, 613809 |
| USP18 | 100.0% | 100.0% | 100.0% | 99.6% | Pseudo-TORCH syndrome 2, 617397 |
| USP45 | 100.0% | 100.0% | 100.0% | 99.2% | ?Leber congenital amaurosis 19, 618513 |
| UVSSA | 100.0% | 100.0% | 100.0% | 99.8% | UV-sensitive syndrome 3, 614640 |
| VAC14 | 100.0% | 100.0% | 100.0% | 99.8% | Striatonigral degeneration, childhood-onset, 617054 |
| VAMP1 | 100.0% | 100.0% | 100.0% | 99.5% | Myasthenic syndrome, congenital, 25, 618323 Spastic ataxia 1, autosomal dominant, 108600 |
| VARS1 | 100.0% | 100.0% | 100.0% | 99.6% | Neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802 |
| VARS2 | 100.0% | 100.0% | 100.0% | 99.5% | Combined oxidative phosphorylation deficiency 20, 615917 |
| VAX1 | 99.9% | 99.1% | 100.0% | 96.2% | ?Microphthalmia, syndromic 11, 614402 |
| VDR | 100.0% | 100.0% | 100.0% | 99.1% | Rickets, vitamin D-resistant, type IIA, 277440 |
| VHL | 100.0% | 100.0% | 100.0% | 99.8% | Erythrocytosis, familial, 2, 263400 von Hippel-Lindau syndrome, 193300 Renal cell carcinoma, somatic, 144700 Pheochromocytoma, 171300 Hemangioblastoma, cerebellar, somatic, |
| VIPAS39 | 100.0% | 100.0% | 100.0% | 99.5% | Arthrogyriposis, renal dysfunction, and cholestasis 2, 613404 |
| VKORC1 | 97.8% | 92.7% | 100.0% | 99.6% | Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 Warfarin resistance, 122700 |
| VLDLR | 100.0% | 100.0% | 100.0% | 99.5% | Cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1, 224050 |
| VPS11 | 100.0% | 100.0% | 100.0% | 99.8% | ?Dystonia 32, 619637 Leukodystrophy, hypomyelinating, 12, 616683 |
| VPS13A | 100.0% | 100.0% | 100.0% | 98.9% | Choreoacanthocytosis, 200150 |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| VPS13B | 99.6% | 99.2% | 100.0% | 99.4% | Cohen syndrome, 216550 |
| VPS13C | 100.0% | 100.0% | 100.0% | 99.3% | Parkinson disease 23, autosomal recessive, early onset, 616840 |
| VPS13D | 100.0% | 100.0% | 100.0% | 99.3% | Spinocerebellar ataxia, autosomal recessive 4, 607317 |
| VPS33A | 89.5% | 89.5% | 100.0% | 98.8% | Mucopolysaccharidosis-plus syndrome, 617303 |
| VPS33B | 100.0% | 100.0% | 100.0% | 99.5% | Keratoderma-ichthyosis-deafness syndrome, autosomal recessive, 620009 Cholestasis, progressive familial intrahepatic, 12, 620010 Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 |
| VPS37A | 100.0% | 100.0% | 99.9% | 96.6% | Spastic paraplegia 53, autosomal recessive, 614898 |
| VPS45 | 95.1% | 95.1% | 100.0% | 99.4% | Neutropenia, severe congenital, 5, autosomal recessive, 615285 |
| VPS51 | 100.0% | 100.0% | 100.0% | 99.5% | Pontocerebellar hypoplasia, type 13, 618606 |
| VPS53 | 100.0% | 100.0% | 100.0% | 99.7% | Pontocerebellar hypoplasia, type 2E, 615851 |
| VRK1 | 100.0% | 99.8% | 100.0% | 98.9% | Pontocerebellar hypoplasia type 1A, 607596 |
| VSX2 | 100.0% | 100.0% | 100.0% | 99.8% | Microphthalmia, isolated 2, 610093 Microphthalmia with coloboma 3, 610092 |
| VWA1 | 100.0% | 100.0% | 100.0% | 99.9% | Neuropathy, hereditary motor, with myopathic features, 619216 |
| VWA3B | 100.0% | 100.0% | 100.0% | 99.1% | ?Spinocerebellar ataxia, autosomal recessive 22, 616948 |
| VWF | 100.0% | 100.0% | 100.0% | 99.7% | von Willebrand disease, type 1, 193400 von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 von Willebrand disease, type 3, 277480 |
| WARS2 | 100.0% | 100.0% | 100.0% | 99.1% | Parkinsonism-dystonia 3, childhood-onset, 619738 Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, w/wo seizures, 617710 |
| WASHC4 | 100.0% | 100.0% | 100.0% | 99.2% | Intellectual developmental disorder, autosomal recessive 43, 615817 |
| WASHC5 | 100.0% | 100.0% | 100.0% | 99.2% | Ritscher-Schinzel syndrome 1, 220210 Spastic paraplegia 8, autosomal dominant, 603563 |
| WBP2 | 100.0% | 100.0% | 100.0% | 99.2% | Deafness, autosomal recessive 107, 617639 |
| WDPCP | 97.5% | 97.3% | 100.0% | 99.6% | ?Bardet-Biedl syndrome 15, 615992 Congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085 |
| WDR19 | 100.0% | 100.0% | 100.0% | 98.9% | Nephronophthisis 13, 614377 Cranioectodermal dysplasia 4, 614378 Senior-Loken syndrome 8, 616307 Short-rib thoracic dysplasia 5 w/wo polydactyly, 614376 ?Spermatogenic failure 72, 619867 |
| WDR34 | 100.0% | 100.0% | 100.0% | 100.0% | Short-rib thoracic dysplasia 11 w/wo polydactyly, 615633 |

| | | | | | |
|--------|--------|--------|--------|-------|--|
| WDR35 | 100.0% | 100.0% | 100.0% | 99.7% | Short-rib thoracic dysplasia 7 w/wo polydactyly, 614091 Cranioectodermal dysplasia 2, 613610 |
| WDR4 | 100.0% | 100.0% | 100.0% | 99.4% | Galloway-Mowat syndrome 6, 618347 Microcephaly, growth deficiency, seizures, and brain malformations, 618346 |
| WDR45B | 100.0% | 100.0% | 100.0% | 98.6% | Neurodevelopmental disorder with spastic quadriplegia and brain abnormalities w/wo seizures, 617977 |
| WDR60 | 100.0% | 100.0% | 100.0% | 99.2% | Short-rib thoracic dysplasia 8 w/wo polydactyly, 615503 |
| WDR62 | 100.0% | 100.0% | 100.0% | 99.8% | Microcephaly 2, primary, autosomal recessive, w/wo cortical malformations, 604317 |
| WDR72 | 96.8% | 96.8% | 100.0% | 99.4% | Amelogenesis imperfecta, type IIA3, 613211 |
| WDR73 | 100.0% | 100.0% | 100.0% | 99.8% | Galloway-Mowat syndrome 1, 251300 |
| WDR81 | 100.0% | 100.0% | 100.0% | 99.9% | Cerebellar ataxia, impaired intellectual development, and dysquilibrium syndrome 2, 610185 Hydrocephalus, congenital, 3, with brain anomalies, 617967 |
| WEE2 | 100.0% | 100.0% | 100.0% | 99.5% | Oocyte/zygote/embryo maturation arrest 5, 617996 |
| WFS1 | 100.0% | 100.0% | 100.0% | 99.9% | Deafness, autosomal dominant 6/14/38, 600965 ?Cataract 41, 116400 Wolfram-like syndrome, autosomal dominant, 614296 Wolfram syndrome 1, 222300 |
| WHRN | 100.0% | 100.0% | 100.0% | 99.8% | Deafness, autosomal recessive 31, 607084 Usher syndrome, type 2D, 611383 |
| WIPF1 | 100.0% | 100.0% | 100.0% | 99.2% | Wiskott-Aldrich syndrome 2, 614493 |
| WIPI2 | 100.0% | 100.0% | 100.0% | 99.3% | ?Intellectual developmental disorder with short stature and variable skeletal anomalies, 618453 |
| WNK1 | 100.0% | 100.0% | 100.0% | 99.4% | Neuropathy, hereditary sensory and autonomic, type II, 201300 Pseudohypoaldosteronism, type IIC, 614492 |
| WNT1 | 100.0% | 100.0% | 100.0% | 99.8% | Osteogenesis imperfecta, type XV, 615220 |
| WNT10A | 100.0% | 100.0% | 100.0% | 99.7% | Schopf-Schulz-Passarge syndrome, 224750 Tooth agenesis, selective, 4, 150400 Ectodermal dysplasia 16 (odontoonychodermal dysplasia), 257980 |
| WNT10B | 100.0% | 100.0% | 100.0% | 99.9% | Tooth agenesis, selective, 8, 617073 Split-hand/foot malformation 6, 225300 |
| WNT3 | 100.0% | 100.0% | 99.9% | 98.2% | ?Tetra-amelia syndrome 1, 273395 |
| WNT4 | 100.0% | 99.8% | 100.0% | 99.4% | ?SERKAL syndrome, 611812 Mullerian aplasia and hyperandrogenism, 158330 |
| WNT7A | 100.0% | 100.0% | 100.0% | 99.9% | Fuhrmann syndrome, 228930 Ulna and fibula, absence of, with severe limb deficiency, 276820 |
| WRAP53 | 100.0% | 100.0% | 100.0% | 99.6% | Dyskeratosis congenita, autosomal recessive 3, 613988 |
| WRN | 100.0% | 100.0% | 100.0% | 98.9% | Werner syndrome, 277700 |

| | | | | | |
|----------|--------|--------|--------|--------|--|
| | | | | | Esophageal squamous cell carcinoma, somatic, 133239 Developmental and epileptic encephalopathy 28, 616211 Spinocerebellar ataxia, autosomal recessive 12, 614322 |
| WVOX | 100.0% | 100.0% | 100.0% | 99.7% | |
| XDH | 100.0% | 100.0% | 100.0% | 99.5% | Xanthinuria, type I, 278300 |
| XPA | 100.0% | 100.0% | 100.0% | 99.4% | Xeroderma pigmentosum, group A, 278700 |
| XPC | 100.0% | 100.0% | 100.0% | 97.7% | Xeroderma pigmentosum, group C, 278720 |
| XPNPEP3 | 100.0% | 100.0% | 100.0% | 99.8% | Nephronophthisis-like nephropathy 1, 613159 |
| XRCC1 | 100.0% | 100.0% | 100.0% | 99.3% | ?Spinocerebellar ataxia, autosomal recessive 26, 617633 |
| | | | | | Spermatogenic failure 50, 619145 ?Premature ovarian failure 17, 619146 ?Fanconi anemia, complementation group U, 617247 |
| XRCC2 | 100.0% | 100.0% | 100.0% | 99.5% | |
| XRCC4 | 100.0% | 100.0% | 100.0% | 98.4% | Short stature, microcephaly, and endocrine dysfunction, 616541 |
| XYLT1 | 100.0% | 99.8% | 100.0% | 98.6% | Desbuquois dysplasia 2, 615777 |
| XYLT2 | 99.9% | 99.2% | 100.0% | 99.7% | Spondyloocular syndrome, 605822 |
| YARS2 | 100.0% | 100.0% | 100.0% | 99.6% | Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 |
| YIF1B | 90.0% | 90.0% | 100.0% | 99.4% | Kaya-Barakat-Masson syndrome, 619125 |
| YME1L1 | 100.0% | 100.0% | 100.0% | 99.0% | ?Optic atrophy 11, 617302 |
| YY1AP1 | 100.0% | 100.0% | 100.0% | 99.5% | Grange syndrome, 602531 |
| | | | | | Immunodeficiency 48, 269840 Autoimmune disease, multisystem, infantile-onset, 2, 617006 |
| ZAP70 | 100.0% | 100.0% | 100.0% | 99.9% | |
| ZBTB11 | 100.0% | 100.0% | 100.0% | 99.7% | Intellectual developmental disorder, autosomal recessive 69, 618383 |
| ZBTB16 | 100.0% | 100.0% | 100.0% | 99.9% | Leukemia, acute promyelocytic, PL2F/RARA type, |
| ZBTB24 | 100.0% | 100.0% | 100.0% | 99.7% | Immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069 |
| ZBTB42 | 100.0% | 100.0% | 100.0% | 100.0% | ?Lethal congenital contracture syndrome 6, 616248 |
| ZC3H14 | 100.0% | 100.0% | 100.0% | 99.1% | Intellectual developmental disorder, autosomal recessive 56, 617125 |
| ZFYVE26 | 100.0% | 100.0% | 100.0% | 99.7% | Spastic paraplegia 15, autosomal recessive, 270700 |
| | | | | | Mandibuloacral dysplasia with type B lipodystrophy, 608612 Restrictive dermopathy 1, 275210 |
| ZMPSTE24 | 100.0% | 100.0% | 100.0% | 99.6% | |
| ZMYND10 | 100.0% | 100.0% | 100.0% | 99.9% | Ciliary dyskinesia, primary, 22, 615444 |
| ZNF142 | 100.0% | 100.0% | 100.0% | 99.9% | Neurodevelopmental disorder with impaired speech and hyperkinetic movements, 618425 |
| ZNF335 | 100.0% | 100.0% | 100.0% | 99.8% | Microcephaly 10, primary, autosomal recessive, 615095 |
| ZNF341 | 100.0% | 100.0% | 100.0% | 99.6% | Hyper-IgE recurrent infection syndrome 3, autosomal recessive, 618282 |
| | | | | | Retinitis pigmentosa 72, 616469 ?Exudative vitreoretinopathy 6, 616468 |
| ZNF408 | 100.0% | 100.0% | 100.0% | 99.7% | |

| | | | | | |
|--------|--------|--------|--------|--------|--|
| ZNF423 | 100.0% | 100.0% | 100.0% | 99.9% | Nephronophthisis 14, 614844 Joubert syndrome 19, 614844 |
| ZNF469 | 100.0% | 100.0% | 100.0% | 99.7% | Brittle cornea syndrome 1, 229200 |
| ZNF513 | 100.0% | 100.0% | 100.0% | 99.3% | ?Retinitis pigmentosa 58, 613617 |
| ZNHIT3 | 78.2% | 76.2% | 100.0% | 98.8% | PEHO syndrome, 260565 |
| ZP1 | 100.0% | 100.0% | 100.0% | 100.0% | Oocyte/zygote/embryo maturation arrest 1, 615774 |

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 is the chemistry used for WES analysis.

Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.

Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.

Genes with coverage denoting NC are non-protein coding genes.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : March 17th, 2023

This list is accurate for panel version DG 3.7.0

Ad 1. "No OMIM Disease ID" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors